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CHAPTER-I 
INTRODUCTION 
COLLOIDAL DRUG DELIVERY SYSTEMS 
 
During the past decade, advanced drug delivery research and development has surged 
ahead of others in formulation research. The emergence of novel technology and the growing 
capabilities of proteomics, genomics and combinatorial chemistry have provided scientists with 
new technologies.  
Commonly accepted criteria of advanced drug delivery system include 
a) Maximal drug bioavailability  
b) Tissue targeting 
c) Controlled release kinetics  
d) Minimal immune response  
e) Ease of administration for better patient compliance  
f) Ability to deliver different drugs such as lipophilic, amphiphiles and biomolecules.   
g) Enhanced permeability of poorly permeable drugs. 
h) Avoidance of side effects by reducing the dose and frequency of drug intake (Chein et al, 
2005). 
Therapeutic efficacy of drug depends on four fundamental pathways of drug transport 
and modification within the body 
Absorption into the plasma from the administration site. 
Distribution between plasma and tissues. 
Metabolism within the tissues. 
Elimination from the body. 
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 Absorption rate depends on many factors such as hydrophobicity, chemical environment, 
particle size, crystallinity, blood flow, absorptive surface area and residence time at absorptive 
surface (Delie et al, 2005).  
Drug distribution largely depends on blood flow, capillary permeability such as in BBB, 
ligand binding and hydrophobicity. 
Drug metabolism and elimination also depend on above mentioned properties. The drug 
delivery system can greatly impact each pathway, and, therefore, the delivery system is a critical 
design component in pharmaceutical sciences. 
Lipophiles (or) poorly water soluble drug, perform pivotal roles in numerous biological 
processes. Many leading small molecules of drugs are lipophilic. Anticancer drug including 
piposulfan, etoposide, camptothecin and paclitaxel are lipophilic. Antifungal drugs such as 
amphotericin-B, fluconazoloe, itraconazole are lipophilic. Key antioxidants such as vitamin A, 
vitamin E, retinol, lycophene and   β-carotene also are lipophilic. These lipophiles must be 
formulated and delivered in a safe, efficacious and cost effective manner. Lipophile delivery has 
long been a challenge in pharmaceutical sciences.  
Main reasons for failure in therapy include 
• Insufficient drug concentration at the site of action due to poor absorption, rapid 
metabolism, and elimination of drug distribution to other tissues combined with high 
drug toxicity. 
• Poor drug solubility which excludes I.V. injection of aqueous drug solution. 
• High fluctuation of plasma levels due to unpredictable bioavailability after per oral 
administration, including the influence of food on plasma levels. 
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A promising strategy to overcome these problems involves the development of suitable 
drug colloidal carrier system (Hussain et al, 1999). 
Need of colloidal carrier systems  
Colloidal carriers are promising systems to fulfill the requirements of a poorly aqueous 
soluble drug. Nanosized carriers are treated as hopeful means to increase the solubility and the 
bioavailability of poorly water soluble – active ingredients belonging to the classes II and IV in 
the biopharmaceutical classification system [BCS], (Martins et al, 2007, Sachan et al, 2006). 
The common characteristic of all colloidal carriers is the sub-micron particle size. 
Corresponding to the broad diversity of colloidal carriers, the possible administration routes vary 
as follows 
• Dermal 
• Peroral 
• Parenteral 
• Ocular 
• Pulmonary 
For I.V. administration, to avoid embolism in blood vessels, no particles above 5 µm and 
only few particles between one to five micrometers are accepted. Solid particulate systems are 
limited to either the subcutaneous or intramuscular routes of administration; intravenous 
administration may result in vaso occlusion.      
 
Focusing on the biofate of lipid – containing drug carriers after per oral administration, 
short chain and medium chain liquid lipids are known to be easily hydrolyzed and to be readily 
absorbed in the gastrointestinal tract [GIT]. Crystalline lipids are poorly attacked by lipases and 
very long chains (From C18 up) in solid state are poorly absorbed (Basu et al, 2003).   
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Nanosizing of the bulk material may lead to dramatic changes of the physical properties 
of the substance. There may be depression of the melting point which results in the existence of 
super cooled melts. Nanometric systems have to fulfill the requirements of drug delivery systems 
mentioned above. They should be free from aggregation/ coalescence tendency. Incorporation of 
sensitive drug molecule in some carrier matrices is claimed as a protection against enzymatic 
degradation, hydrolysis or photolysis. Despite their small size, colloidal carriers can provide 
controlled drug release. 
Colloidal drug carrier systems  
1.1Liposomes  
Liposomes consist of one or more lipid bilayers of amphiphilic lipids                          
(phospholipids, cholesterol, glycolipids). The lipophilic moieties of the bilayer face each other 
and create an inner hydrophobic environment in the membrane. Lipophilic or amphiphilic drugs 
can be associated with non polar parts of lipid bilayers if they fit in size and geometry. The 
hydrophilic molecular head groups face the outer water phase and the inner aqueous core of the 
vesicles. Water soluble compounds can be included within the aqueous compartments (Bawarski 
et al, 2008, Biju et al, 2006). 
Liposomes are classified as large multilamellar liposomes (MLV), large unilameller 
vesicles(LUV), small unilameller vesicles (SUV), oligolameller vesicles (OLV) and 
multivesicular (MVU) systems, depending on the their size, the number of bilayers and the 
existence of inner vesicles in a vesicle. The size of liposomes varies from 20nm to few 
micrometers with lipid membranes approximately 5nm. 
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Some of the marketed products are 
•
 Ambisome 
TM
 -parenteral 
 
• Daunoxome 
TM
-parenteral 
• Prvaryl 
TM
- Lipogel- Topical administration. 
1.2 Niosomes 
Niosomes are novel drug delivery systems, in which the medication is encapsulated in a 
vesicle. The vesicle is composed of a bilayer of non-ionic surface active agent and hence the 
name niosomes. The niosomes are very small rather microscopic in size. Their size lies in the 
nano metric scale. Although structurally similar to liposomes, they offer several advantages over 
them. Niosomes can greatly increase transdermal drug delivery and also can be used in targeted 
drug delivery, and thus increased study in these structures can provide new methods for drug 
delivery.  
1.3 Nanocapsules  
Oil containing nanocapsules differ from nanoemulsions in providing a barrier made from 
polymer between the core and the surrounding environment. Reports on nanoparticles with 
aqueous cores in an aqueous outer phase are published. For the preparation of nanocapsules the 
way the solvent displacement and interfacial polymerization are achieved are individualized 
(Kreuter et al, 2007, Magalhaes et al, 1995). 
 According to the liphophilicity of the capsule content, hydrophilic and lipophilic drugs 
can be dissolved additionally. The polymeric particle surface may serve as compartment.  
Encapsulation may decrease the toxicity of drugs after peroral or parenteral application. 
Encapsulation saves sensitive drugs from rapid degradation, reduce the interactions with 
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reticuloendothetial system (RES) and alter body distribution the surface of nanocapsules can be 
modified by materials such as surfactants. 
1.4 Nanosuspensions    
Nanosuspensions are saturated solutions. They represent the simplest colloidal carriers 
with respect to composition. The drug payload amounts to nearly 100%. In an aqueous 
environment, the drug is pearl milled, precipitated or high pressure homogenized to a particle 
distribution mostly below one micrometer. Despite the use of tensides, particle growth up to 
micrometric crystals may occur when the drug molecules of small particles dissolve in the outer 
environment and precipitate later on the surface of larger particles (Patravale et al, 2004, 
Constartinides et al, 2008). 
Due to tremendous interface area between drug and environment, solubilization velocity 
of the drug is increased according to the Noyes Whitney equation. Attention has to be paid on 
drugs with small safety margins where burst release has to be avoided. But controlled release and 
reproducible blood levels are not easily achievable because as a release controlling barrier only 
the tenside layer may serve in the nanosuspension. Suspensions of crystals in the µm range are 
already established in the market (eg: Predigaleu 
TM
). The only two registered Nanosuspensions 
are Repamune TM and Emend TM for immediate delivery. 
1.5 Mixed micelles 
As long – chain phospholipids are known to form bilayers when dispersed in water, the 
preferred phase of short-chain analogues is the micellar phase. In general ampholytic molecules, 
which are able to decrease the surface tension of a solvent, arrange in micelles, as Tween 
TM 
or 
sodium dodecyl sulfate. A micellar solution is a thermodynamically stable system formed 
spontaneously in water or in organic solvents. The small colloidal aggregates (micelles) are in 
7 
 
rapid thermodynamic equilibrium with a measurable concentration of monomer in micellar 
solutions. The micelle solubilizes large molecules in any zone of the micelle volume, but the 
penetration into the micelle depends on the inner space of the micelle, on the hydrophobicity of 
the drug and on the charge of the incorporated molecule. The interaction between micelles and 
lipophilic drugs leads to the formation of mixed micelles (MM), often called as swollen micelles. 
The addition of salt or alcohol can vary the degree of penetration into the micelle. In mixed 
micelles, the mobility of the micellar phase was found to decrease due to incorporated molecules. 
Considerably swollen micelles are larger than the analogous “free micelles” because 
solubilization may result mostly from the increase in micellar site (Bawarski et al, 2005, 
Torchilin et al, 2006).   
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CHAPTER-II 
A REVIEW ON VESICULAR SYSTEM 
INTRODUCTION 
Many drugs, particularly chemotherapeutic agents, have narrow therapeutic window. 
Their clinical use is limited and compromised by dose limiting toxic effect. The therapeutic 
effectiveness of the existing drugs is improved by formulating them in an advantageous way. In 
the past few decades, considerable attention has been focused on the development of new drug 
delivery systems (NDDS). The NDDS should deliver the drug at a rate directed by the needs of 
the body, over a predetermined period of treatment and it should channel the active entity to the 
site of action. Conventional dosage forms and prolonged release dosage forms are unable to meet 
these requirements. 
  In recent years, vesicles have become the carriers of choice in drug delivery. Lipid 
vesicles were found to be of value in immunology, membrane biology, diagnostic techniques and 
genetic engineering. 
Vesicles can play a major role in modeling biological membranes and in the transport and 
targeting of active agents (Umeda et al, 1997).  
Conventional chemotherapy for the treatment of intracellular infections is not effective, 
due to limited permeation of drugs into cells. This can be overcome by use of vesicular drug 
delivery systems. Encapsulation of a drug in vesicular structures can prolong the existence of the 
drug in systemic circulation, and perhaps, reduces the toxicity if selective uptake can be achieved 
(Todd et al, 1982). 
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The phagocytic uptake of the systemic delivery of the drug-loaded vesicular delivery 
system provides an efficient method for delivery of drug directly to the site of infection, leading 
to reduction of drug toxicity with no adverse effects.  
Vesicular drug delivery reduces the cost of therapy by improved bioavailability of 
medication, especially in case of poorly soluble drugs. Vesicles can incorporate both hydrophilic 
and lipophilic drugs. 
Vesicular drug delivery systems delay drug elimination of rapidly metabolizable drugs, 
and function as sustained release systems. This system solves the problems of drug insolubility, 
instability, and rapid degradation. 
Advantages of vesicular systems: 
 
 
• Efficient method for delivery of drug directly to the site of infection. 
• Reduction of drug toxicity with no adverse effects. 
• Reduces the cost of the therapy by improved bioavailability of the medication, 
• Incorporate both hydrophilic and lipophilic drugs. 
• Delay drug elimination of rapidly meatbolizable drugs 
• Function as sustained release systems. 
• Solves the problems of drug insolubility, instability, and rapid degradation. 
2.1 TYPES OF VESICULAR SYSTEMS 
 Various types of vesicular systems are as follows 
• Liposomes 
• Niosomes 
• Transferosomes 
• Pharmacosomes 
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• Enzymosomes 
• Virosomes 
• Ufasomes 
• Cryptosomes 
• Emulsomes 
• Discomes 
• Aquasomes 
• Ethosomes 
• Genosomes 
• Photosomes 
• Erythrosomes 
• Hemosomes 
• Proteosomes 
• Vesosomes 
• Archaeosomes 
• Apsasomes 
• Colloidosomes 
• Cubasomes 
2.2 LIPOSOMES 
Liposomes are simple microscopic vesicles in which lipid bilayer structures are present 
with an aqueous volume entirely enclosed by a membrane composed of lipid molecule. There are 
a number of components present in liposomes, with phospholipid and cholesterol being the main 
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ingredients. The type of phospholipids includes phosphoglycerides and sphingolipids together 
with their hydrolysis products. 
2.2.1Liposomes Preparation Methods 
A) Multilamellar Liposomes (MLV) 
i) Lipid Hydration Method 
(a) This is the most widely used method for the preparation of MLV. The method involves 
drying a solution of lipids so that a thin film is formed at the bottom of round bottom flask 
and then hydrating the film by adding aqueous buffer and vortexing the dispersion for some 
time. The hydration step is done at a temperature above the gel-liquid crystalline transition 
temperature Tc of the lipid or above the Tc of the highest melting component in the lipid 
mixture. The compounds to be encapsulated are added either to aqueous buffer or to organic 
solvent containing lipids depending upon their solubilities.  MLV are simple to prepare by 
this method and a variety of substances can be encapsulated in these liposomes. The 
drawbacks of the method are low internal volume, low encapsulation efficiency and the size 
distribution is not normal (Bengham    et al, 1974). 
(b) MLVs with high encapsulation efficiency can be prepared by hydrating the lipids in the 
presence of an immiscible organic solvent (petroleum ether, diethyl ether). The contents are 
emulsified by vigorous vortexing or sonication. The organic solvent is removed by passing a 
stream of nitrogen gas over the mixture. MLVs are formed immediately in the aqueous phase 
after the removal of organic solvent. The main drawback of this method is the exposure of 
the materials to be encapsulated to organic solvent and to sonication (Papahadjopoulos et al, 
1978). 
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ii) Solvent Spherule Method 
A method for the preparation of MLVs of homogeneous size distribution was proposed 
by Kim et al, 1985. The process involved dispersing in aqueous solution the small spherules of 
volatile hydrophobic solvent in which lipids had been dissolved. MLVs were formed when 
controlled evaporation of organic solvent occurred in a water bath (Kim et al, 1985). 
B) Small Unilamellar Liposomes (SUV) 
i) Sonication Method 
Here MLVs are sonicated either with a bath type sonicator or a probe sonicator under an 
inert atmosphere. The main drawbacks of this method are very low internal 
volume/encapsulation efficiency, possibly degradation of phospholipids and compounds to be 
encapsulated, exclusion of large molecules, metal contamination from probe tip and presence of 
MLV along with SUV (Oezden et al, 1991).  
(ii) French Pressure Cell Method 
The method involves the extrusion of MLV at 20,000 psi at 4°C through a small orifice. 
The method has several advantages over sonication method. The method is simple rapid, 
reproducible and involves gentle handling of unstable materials. The resulting liposomes are 
somewhat larger than sonicated SUVs. The drawbacks of the method are that the temperature is 
difficult to achieve and the working volumes are relatively small (about 50mL maximum), 
(Hamilton et al, 1984). 
C) Large Unilamellar Liposomes (LUV) 
They have high internal volume/encapsulation efficiency and are now days being used for 
the encapsulation of drugs and macromolecules. 
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I. SOLVENT INJECTION METHODS 
a) Ether Infusion Method 
A solution of lipids dissolved in diethyl ether or ether-methanol mixture is slowly 
injected in to an aqueous solution of the material to be encapsulated at 55-65°C or under reduced 
pressure. The subsequent removal of ether under vacuum leads to the formation of  liposomes. 
The main drawbacks of the method are that the population is heterogeneous (70-190 nm) and the 
exposure of compounds to be encapsulated to organic solvents or high temperature (Sehieren et 
al, 1978). 
b) Ethanol Injection Method 
A lipid solution of ethanol is rapidly injected in to a vast excess of buffer. The MLVs are 
immediately formed. The drawbacks of the method are that the population is heterogeneous          
(30-110 nm), liposomes are very dilute, it is difficult to remove all ethanol because it forms 
azeotrope with water and the possibility of interaction of various biologically active 
macromolecules  in  presence of even low amounts of ethanol (Batzri et al, 1973). 
II. DETERGENT REMOVAL METHODS 
The detergents at their critical micellar concentration have been used to solubilise lipids. 
As the detergent is removed the micelles become progressively richer in phospholipid and finally 
combine to form LUVs. The detergents were removed by dialysis. The advantages of detergent 
dialysis method are excellent reproducibility and production of liposome populations which are 
homogenous in size. The main drawback of the method is the retention of traces of detergent(s) 
within the liposomes. A commercial device called LIPOPREP which is a version of dialysis 
system is available for the removal of detergents. Other techniques have been used for the 
removal of detergents: (a) by using Gel Chromatography involving a column of Sephadex G-25,  
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(b) by adsorption or binding of Triton X-100 (a detergent) to Bio-Beads SM-2. (c) By binding of 
octyl glucoside (a detergent) to Amberlite XAD-2 beads (Philippot et al, 1985). 
iii. Reverse Phase Evaporation Method 
First water in oil emulsion is formed by brief sonication of a two phase system containing 
phospholipids in organic solvent (diethylether or isopropylether or mixture of isopropyl ether and 
chloroform) and aqueous buffer. The organic solvents are removed under reduced pressure, 
resulting in the formation of a viscous gel. The liposomes are formed when residual solvent is 
removed by continued rotary evaporation under reduced pressure. (Handa et al, 1984).   
iv. Calcium Induced Fusion Method  
 This method is used to prepare LUV from acidic phospholipids; calcium addition to SUV 
induces fusion and results in the formation of multilamellar structures in spiral configuration 
(Cochleate cylinders). The addition of EDTA to these preparations results in the formation of 
LUVs. Here macromolecules can be encapsulated under gentle conditions and the chief 
disadvantage of this method is that LUVs can only be obtained from acidic phospholipids 
(Mayhew et al, 1984). 
D. Giant Liposomes 
The procedure for the formation of giant liposomes involves the dialysis, of a methanol is 
solution of phosphatidylcholine in the presence of methylglucoside detergent against an aqueous 
solution containing up to 1 M NaCl. The liposomes range in diameter from 10 to 100 mm            
(Oku et al, 1983).  
E. Multivesicular Liposomes 
The water in oil emulsion was converted to organic solvent spherules by the addition of 
the emulsion to solution. The evaporation of organic solvent resulted in the formation of 
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multivesicular product. The diameter of liposomes ranges from 5.6 to 29 pm. The materials 
which can be encapsulated include glucose, EDTA, human DNA. These liposomes have very 
high encapsulation efficiency (up to 89%), (Kim et al, 1983). 
Advantages and Disadvantages 
• Liposomes as a potential delivery system for the oral administration of insulin have been 
extensively studied (Patel et al, 1982, Hashimoto et al, 1979, Derycke et al, 2004, Allen           
et al, 1978).   
• The liposomes have protective effects against proteolytic digestive enzymes like pepsin and 
pancreatin and they can increase the intestinal uptake of macromolecules.  
• Long-circulating and actively targeting liposomes, stand a better chance as truly tumor tropic 
carriers of photosensitizers. 
• Liposomal drug delivery systems provide protection of the drug, controlled release of the 
active moiety along with the targeted delivery, and cellular uptake via endocytosis.  
• Liposomes also pose certain problems like degradation by hydrolysis, oxidation, 
sedimentation, leaching of drug and aggregation or fusion during storage. 
• Liposome stability is increased by efficient formulation and lyophilization.  
• Formulation involves the selection of the appropriate lipid composition and concentration of 
the bilayer, in addition to the aqueous phase ingredients, such as buffer, antioxidants, metal, 
chelators, and cryoprotectant. Charge-inducing lipids, such as phosphatidylglyceride are 
incorporated into the liposome bilayer to decrease fusion, while cholesterol and 
sphingomyelin can be incorporated in formulations, in order to decrease the permeability and 
leakage of encapsulated drugs. Buffers decrease hydrolysis.  
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• Addition of antioxidants can decrease the oxidation. Freeze-dried liposome formulations 
should incorporate a lipo protectant-like non-reducing disaccharide such as trehalose or 
sucrose. Difficulties are experienced in sterilization and large-scale production of liposomes.  
• The cost and purity of phospholipid is another limiting factor. They are suitable for 
parenteral administration but oral administration is not possible because of inability of 
liposomes to survive to the action of bile salts and phospholipids. 
2.3 NIOSOMES 
Niosomes are novel drug delivery systems in which the medication is encapsulated in a 
vesicle. The vesicle is composed of a bilayer of non-ionic surface active agent and hence the 
name niosomes. The niosomes are very small, and microscopic in size. Their size lies in the nano 
metric scale. Although structurally similar to liposomes, they offer several advantages over them. 
Niosomes have been shown to greatly increase transdermal drug delivery and also can be used in 
targeted drug delivery. These structures can provide new methods for drug delivery.   
2.4 TRANSFEROSOMES 
• Liposomes and niosomes are the vesicular carrier systems of drug delivery (Arun et al, 2005, 
Jain et al, 1998).  
• For transdermal delivery a new type of carrier system called “transfersomes” was introduced 
for the delivery of number of low and high molecular weight drugs. It consists of both 
hydrophilic and hydrophobic properties with high deformability gives  better penetration of 
intact vesicles.  
• Transfersomes may be described as lipid droplets of such deformability that permits its easy 
penetration through the pores much smaller than the droplets size. They protect the 
encapsulated drug from metabolic degradation.  
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• In thermodynamic terms this typically corresponds to an aggregate in the    quasi-metastable 
state, which facilitates the formation of highly curved bilayers. From the composition point 
of view, transfersomes are a self adaptable and optimized mixed lipid aggregate. They act as 
depot, releasing their content slowly and gradually.  
• Transfersomes have been developed in order to take advantage of phospholipid vesicles as 
transdermal drug carrier. These self optimized aggregates, with ultra flexible membrane, are 
able to deliver the drug reproducibly either into or through the skin, depending on the choice 
of administration or application, with high efficiency.  
• These vesicular transfersomes are several orders of magnitude more elastic than the standard 
liposomes and thus well suited for the skin penetration. Transfersomes overcome the skin 
penetration difficulty by squeezing themselves along the intracellular sealing lipids of 
stratum corneum. There is provision for this, because of the high vesicles deformability, 
which permits the entry due to mechanical stress of surroundings in a self adapting manner.  
• Flexibility of transfersome membrane is achieved by mixing suitable surface active agents in 
proper ratios. The resulting flexibility of transfersomes membrane minimize the risk of  
vesicle rupture in the skin and allow transfersomes to follow the natural water gradient across 
the epidermis when applied under non occlusive condition.  
• Transfersomes can penetrate the intact stratum corneum spontaneously either through 
intracellular route or transcellular route. The high and self-optimizing deformability of 
typical composite transferosmes membrane, which are adaptable to ambient stress allow the 
ultra deformable transfersomes to change its membrane composition locally and reversibly, 
when it is pressed against and attracted into narrow pore. Some of the limitations which have 
been encountered is that transferosmes are chemically unstable because of their 
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predisposition to oxidative degradation as well as purity of natural phospholipid is another 
criteria militating against adoption of transfersomes as drug delivery vehicles. 
Application 
• Transfersomes have been widely used as carrier for the transport of proteins and peptides. 
• Delivery of insulin by transfersomes is the successful means of non invasive therapeutic 
use of such large molecular weight drugs on the skin. 
• Transfersomes have also been used as a carrier for interferons. 
• Transfersomes as drug delivery systems have the potential for providing controlled 
release of the administred drug and increasing the stability of labile drugs. 
• Another most important application of transfersomes is transdermal immunization using 
transfersomes loaded with soluble protein like integral membrane protein, human serum 
albumin, and gap junction protein. This approach offers at least two advantages, first they 
are applicable without injection and second, they give rise to rather high titer and 
possibly, to relatively high IgG A levels. 
• Transfersomes have also been used for the delivery of corticosteroids. Transfersomes 
improve the site specificity and overall drug safety of corticosteroid delivery into skin by 
optimizing the epicutaneously administered drug dose. Transfersomes based 
corticosteroids are biologically active at dose several times lower than the currently used 
formulation for the treatment of skin diseases. 
• Application of anesthetics in the suspension of highly deformable vesicles, transfersomes, 
induces a topical anesthesia, under appropriate conditions, with less than 10 min. 
Maximum resulting pain insensitivity is nearly as strong (80%) as that of a comparable 
subcutaneous bolus injection, but the effect of transferosomal anesthetics last longer.  
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• Transferosmes have also been used for the topical analgesics, anaesthetics, NSAIDS and 
anti-cancer agents. 
Limitations 
1. Transfersomes are chemically unstable because of their predisposition to oxidative 
degradation, 
2. Lack of purity of the natural phospholipids comes in the way of adoption of transfersomes as 
drug delivery vehicles. 
3. Transfersome formulations are expensive. 
2.5 PHARMACOSOMES 
• The limitations of transfersomes can be overcome by the "pharmacosome" approach. The 
prodrug conjoins hydrophilic and lipophilic properties, and therefore acquires amphiphilic 
characters, and similar to other vesicle forming components, was found to reduce interfacial 
tension, and at higher concentrations exhibits mesomorphic behavior (Goymann et al, 1991).  
• These are defined as colloidal dispersions of drugs covalently bound to lipids, and may exist 
as ultrafine vesicular, micellar or hexagonal aggregates. Problems of drug incorporation, 
leakage from the carrier or insufficient shelf life can be avoided by the pharmacosome 
approach (Zhang et al, 2001).  
• The idea for the development of the vesicular pharmacosome is based on surface and             
bulk interactions of lipids with drug. Any drug possessing an active hydrogen atom (-COOH, 
-OH, -NH2, etc.) can be esterified to the lipid, with or without spacer chain. Synthesis of 
such a compound may be guided in such a way that strongly result in an amphiphilic 
compound, which will facilitate membrane, tissue, or cell wall transfer, in the organism 
(Vaizoglu et al, 1986).  
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The salient features of Pharmacosomes are 
• Entrapment efficiency is not only high and predetermined, because drug itself in 
conjugation with lipids forms vesicles. 
• Unlike liposomes, there is no need of following the tedious, time-consuming step for 
removing the free, unentrapped drug from the formulation. 
• Since the drug is covalently linked, loss due to leakage of drug, does not take place. 
However, loss may occur by hydrolysis. 
• Encaptured volume and drug-bilayer interactions do not influence entrapment efficiency. 
 
• In pharmacosomes membrane fluidity depends upon the phase transition temperature of 
the drug lipid complex, but it does not affect release rate since the drug is covalently 
bound (Volkering et al, 1995).  
• The drug is released from pharmacosome by hydrolysis (including enzymatic). 
• Phospholipid transfer/exchange is reduced, and solubilization by HDL is low. 
• The physicochemical stability of the pharmacosome depends upon the physicochemical 
properties of the drug lipid complex. 
• Due to their amphiphilic behavior, such systems allow, after medication, a multiple 
transfer through the lipophilic membrane system or tissue, through cellular walls 
piggyback endocytosis and exocytosis. 
• Following absorption, their degradation velocity into active drug molecule depends to a 
great extent on the size and functional groups of drug molecule, the chain length of the 
lipids, and the spacer. These can be varied relatively precisely for optimized in vivo 
pharmacokinetics. 
• They can be given orally, topically, extra or intravascularly. 
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Method of Preparation 
In general two methods have been employed to prepare pharmacosomes. They are 
1. Hand-shaking method 
2. Ether-injection method 
Hand-shaking method 
In the hand-shaking method, the dried film of the drug– lipid complex (with or without 
egg lecithin) is deposited in a round-bottom flask and upon hydration with aqueous medium, 
readily gives a vesicular suspension. 
The ether injection method 
An organic solution of the drug– lipid complex is injected slowly into the hot aqueous 
medium wherein the vesicles are readily formed. At low concentration the amphiphiles exists in 
the monomer state. Further increase in monomers may lead to variety of structures i.e., micelles 
of spherical or rod like or disc shaped type or cubic or hexagonal shape. Compared the effect of 
diglyceride prodrug on interfacial tension, with the effect produced by a standard detergent 
dodecylamine hydrochloride, and found similar effect on lowering of surface tension. Above the 
critical micelle concentration (CMC), the prodrug exhibits mesomorphic lyotropic behavior, and 
assembles in supramolecular structures (Steve et al, 1996, Taskintune et al, 1997). 
2.6 COLLOIDSOMES 
Colloidsomes are a novel class of microcapsules whose shell consists of coagulated or 
fused colloid particles at interface of emulsion droplets. The particles self assemble on the 
surface of droplets in order to minimize the total interfacial energy forming colloidsomes. Such 
structures were produced for first time by templating latex particles adsorbed on the surface of 
octanol-in-water emulsion drops and subsequent removal of oil fusing the particle monolayers. 
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POTENTIAL BENEFITS OF COLLOIDOSOMES 
• Efficient encapsulation; size, permeability, mechanical strength and compatibility can be 
easily controlled. 
• Control of the size allows flexibility in applications and choice of encapsulated materials.  
• Control of compatibility allows encapsulation of sensitive ingredients, such as 
biomolecules and cells.  
LIMITATIONS 
A major problem in the colloidosome manufacture is the poor yield of particles. If the 
shell locking is inefficient then the colloidosomes simply coalesce and fall apart on transfer into 
water.  
2.7 ETHOSOMES  
 Ethosomes are novel lipid carriers. Ethosomal systems are novel permeation enhancing 
lipid carriers embodying ethanol containing lipid vesicles with inter digitated fluid bilayers. 
Ethosomes have high encapsulation efficiency, skin deposition ability and depth of skin 
penetration for a wide range of molecules including lipophilic drugs. Whether for pharmaceutical 
purposes, gene therapy, vaccination or cellular transformations in biomedical research the 
delivery of molecules through the biological membrane has become a major focus of research in 
recent years for which ethosomes are well suited.  
2.8 ENZYMOSOMES  
Liposomal construct engineered to provide a mini bio environment in which enzymes are 
covalently immobilized or coupled to the surface of the liposomes. They are used for targeted 
delivery to tumor cells.  
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2.9 VIROSOMES 
Liposomes spiked with virus glycoprotein, incorporated into the liposomal bilayers based 
on retro virus derived lipids. They are used for immunological adjuvants. 
2.10 UFASOMES 
Vesicles enclosed by fatty acids obtained from long chain fatty acids (oleic acid, linoleic 
acid) by mechanical agitation of evaporated films in the presence of buffer solutions. They are 
used for ligand mediated drug targeting. 
2.11 CRYPTOSOMES 
Lipid vesicles with a surface coat composed of PC and of suitable polyoxyethylene 
derivative of phosphatidylethanolamine. They are used for ligand mediated drug targeting. 
2.12 EMULSOMES 
Nanosize lipid particles (bioadhesive nano emulsion) consisted of microscopic lipid 
assembly with a polar core which contains water insoluble drugs in the solution form without 
requiring any surface active agent or co solvent. These fat cored lipid paticles are dispersed in an 
aqueous phase. Emulsome represents lipid based drug delivery of systems with wide range of 
therapeutic applications especially for parenteral delivery of poorly water soluble drugs. 
                                  
   Figure 1. Diagrammatic structure of emulsome 
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2.13 DISCOMES 
 These are niosomes solubilized with non-ionic surfactant (Polyoxyethylene cetyl ether 
class, Solulan C24). Discomes are large (12-60µm) structures and are capable of entrapping 
water-soluble solutes. They are used for ligand mediated drug targeting. 
2.14 AQUASOMES 
They are three layered self-assembly compositions with ceramic carbon nanocrystalline 
particulate core coated with glassy cellobiose.  They are used for specific targeting, molecular 
shielding. 
2.15 GENOSOMES 
They are macromolecular complexes for functional gene transfer. They are used for cell 
specific gene transfer. 
2.16 PHOTOSOMES 
They are photolyase encapsulated liposomes. Which release the contents by photo-
triggered charges in membrane permeability characteristics. They are used for photo dynamic 
therapy. 
2.17 ERYTHROSOMES 
Red blood cells offer a number of possibilities as drug carriers in controlled drug delivery 
systems. The release rate from erythrosomes, longevity and physical characteristics can be easily 
manipulated to alter the delivery mechanism. They are used in both site-directed and sustained-
release systems. Liposomal systems in which chemically cross linked human erythrocyte 
cytoskeletons are used as a support on which lipid bilayer is coated. They are used for effective 
targeting of macromolecular drugs.  Artificial red blood cells prepared by encapsulating 
hemoglobin by interfacial polymerization have been used as oxygen carriers.  
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2.18 HEMOSOMES 
Haemoglobin containing liposomes engineered by immobilizing haemoglobin with a 
polymerisable phospholipid are called hemosomes. They are used for high capacity oxygen 
carrying system. 
2.19 PROTEOSOMES 
  High molecular weight multi-subunit enzyme complexes with specific assembly pattern 
of enzymes are known as proteosomes. They are used for better catalytic activity turnover than 
non-associated enzymes. 
2.20 VESOSOMES 
 Nested bilayer compartments in vitro via the “interdigitated” bilayer phase formed by 
adding ethanol to a variety of saturated phospholipids are called vesosomes. Multiple 
compartments of the vesosome give better protection to the contents in serum. 
2.21 ARCHAEOSOMES 
Archaeosomes are vesicles composed of glycerolipids of archaea with potent adjuvant 
activity.  
2.22 APSASOMES  
 Ascorbyl palmitate vesicles are known as apasomes.  
 Ascorbyl palmitate (ASP) was explored as bilayer vesicle forming material. Vesicles 
prepared with amphiphiles having antioxidant property may have potential applications towards 
disorders implicated with reactive oxygen species. Ascorbic acid (vitamin-C) is a major 
antioxidant in human plasma as well as in and across cell membranes. It reduces α-tocopherol as 
well as peroxides and reactive oxygen species such as superoxide. 
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2.23 CUBOSOMES
 
 Cubosomes consist of honeycombed (cavernous) structures separating two internal 
aqueous channels and a large interfacial area. Self-assembled cubosomes as active drug delivery 
systems and they exhibit different internal cubic structure and composition with different drug-
loading modalities. Cubosomes are nanoparticles whose size ranges from 10-500nm in diameter 
they appear like dots square shaped, slightly spherical. 
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CHAPTER-III 
 REVIEW ON NIOSOMES  
 
Targeted delivery of anticancer and anti infective drugs is a challenging task with the use 
of novel drug delivery systems. Different novel approaches used for delivering drugs include 
liposomes, microspheres, nanotechnology, micro emulsions, antibody-loaded drug delivery, 
magnetic microcapsules, implantable pumps and niosomes. Niosomes are formations of vesicles 
by hydrating mixture of cholesterol and nonionic surfactants (Handjani et al, 1979). These 
vesicles are called niosomes. These are formed by self-assembly of non-ionic surfactants in 
aqueous media as spherical, unilamellar, multilamellar system and polyhedral structures in 
addition to inverse structures which appear only in non-aqueous solvent (Sternberg et al, 1995, 
Uchegbu and Florence 1995, Murdan et al, 1998). The process of vesicle formulation by self-
assembly of nonionic surfactants is rarely spontaneous and usually requires some input of energy 
through physical agitation, extrusion or heat (Lasic et al, 1990). 
Niosomes and liposomes are equiactive in drug delivery potential. Niosomes are 
preferred over liposomes because the former exhibit high chemical stability and economy 
(Hunter et al, 1988). Niosomes also exhibit special characteristics such as ease of handling and 
storage. Surfactant, forming niosomes are biodegradable, non-immunogenic and biocompatible. 
3.1 ADVANTAGES OF NIOSOMES 
• The niosomal drug delivery is a potential drug delivery method for controlled and 
targeted drug delivery. 
• Niosomal dispersion in an aqueous phase can be emulsified in a non-aqueous phase to 
regulate the delivery rate of drug and administer normal vesicle in external non aqueous 
phase (Pranshu et al, 2011). 
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• The vesicle suspension is water–based vehicle and offer patient convenience.  
• They are osmotically active and stable. 
• Handling and storage requires no special conditions. 
• They improve oral bioavailability of poorly absorbed drugs. They enhance skin 
penetration of drugs (Madhav et al, 2011). 
• They can be made to reach the site of action by oral, parenteral as well as topical routes. 
• The surfactants used are biodegradable, biocompatible and non-immunogenic. 
• They improve the therapeutic performance of the drug molecules by delayed clearance 
from the circulation, protecting the drug from biological environment and restricting 
effects to target cells (Attaullah et al, 2011). 
• Niosomes possess an infrastructure consisting of hydrophilic, amphiphilic and lipophilic 
moieties together and as a result can accommodate drug molecules with a wide range of 
solubilities (Kumar et al, 2011). 
• The characteristics of the vesicle formulation are variable and controllable. Altering 
vesicle composition, size, lamellarity, surface charge and concentration can control the 
vesicle characteristics. 
• The vesicles may act as a depot, releasing the drug in a controlled manner. 
3.2 FACTORS AFFECTING NIOSOME FORMULATION 
Drug 
Entrapment of drug in niosomes increases vesicle size, probably by interaction of solute 
with surfactant head groups, increasing the charge and mutual repulsion of the surfactant 
bilayers, thereby increasing vesicle size. In polyoxyethylene glycol (PEG) coated vesicles; some 
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drug is entrapped in the long PEG chains, thus reducing the tendency to increase the size. The 
Hydrophilic lipophilic balance of the drug affects degree of entrapment (Raja et al, 1994). 
Structure of surfactants 
         The geometry of vesicle is affected by structure of surfactant. On the basis of critical 
packing parameters of surfactants we can predicate geometry of vesicle to be formed. Critical 
packing parameters can be defined using following equation, 
CPP (Critical Packing Parameters) = 
oc a.
V
CPP
l
=  
 
Where V = hydrophobic group volume, 
             cl  = the critical hydrophobic group length, 
             ao= the area of hydrophilic head group. 
From the critical packing parameter value the type of miceller structure formed can be 
ascertained as given below, 
If CPP < ½ then spherical are micelles formed.  
If CPP < 1½ formation of bilayer micelles are formed. 
If CPP > 1 inverted micelles are formed. 
Amount and type of surfactant 
The mean size of niosomes increases proportionally with increase in the HLB of 
surfactants like Span 85 (HLB 1.8) to Span 20 (HLB 8.6), because the surface free energy 
decreases with an increase in hydrophobicity of surfactant. Bilayers of the vesicles are either in 
the so-called liquid state or in gel state, depending on the temperature, the type of lipid or 
surfactant and the presence of components such as cholesterol. In the gel state, alkyl chains are 
present in a     well-ordered structure, and in the liquid state, the structure of the bilayers is more 
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disordered. The surfactants and lipids are characterized by the gel-liquid phase transition 
temperature (TC).Phase transition temperature (TC) of surfactant also effects entrapment 
efficiency for e.g. Span 60 has higher TC than other surfactant and provides better entrapment.  
Cholesterol content and charge 
Inclusion of cholesterol in niosomes increases its hydrodynamic diameter and entrapment 
efficiency. The action of cholesterol is two fold on the one hand, cholesterol increases the chain 
order of liquid-state bilayers and on the other, cholesterol decreases the chain order of gel state 
bilayers. At a high cholesterol concentration, the gel state is transformed to a liquid ordered 
phase (Hunter et al, 1988). An increase in cholesterol content of the bilayers results in a decrease 
in the release rate of encapsulated material and therefore an increase of the rigidity of the 
bilayers obtained. Presence of charge tends to increase the inter lamellar distance between 
successive bilayers in multilamellar vesicle structure and leads to greater overall entrapped 
volume. 
Resistance to osmotic stress 
Addition of a hypertonic salt solution to a suspension of niosomes brings about reduction 
in diameter. In hypotonic salt solution, there is initial slow release with slight swelling of 
vesicles probably due to inhibition of eluting fluid from vesicles, followed by faster release, 
which may be due to mechanical loosening of vesicles structure under osmotic stress. 
Membrane Composition 
The stable niosomes can be prepared with addition of different additives along with 
surfactants and drugs. Niosomes formed have a number of morphologies and their permeability 
and stability properties can be altered by manipulating membrane characteristics by different 
additives. In case of polyhedral niosomes formed from C16G2, the shape of these polyhedral 
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niosome remains unaffected by adding low amount of solulan C24 (cholesteryl poly-24-
oxyethylene ether), which prevents aggregation due to development of stearic hindrance. In 
contrast spherical Niosomes are formed by C16G2: cholesterol: solulan (49:49:2). The mean size 
of niosomes is influenced by membrane composition such as polyhedral niosomes formed by 
C16G2: solulan C24 in ratio (91:9) having bigger size (8.0±0.03mm) than spherical/tubular 
niosomes formed by C16G2: cholesterol: solulan C24 in ratio (49:49:2) (6.6±0.2mm). Addition 
of cholesterol molecule to niosomal system provides rigidity to the membrane and reduces the 
leakage of drug from niosome. 
 
Figure 2a. Structure of niosome 
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Figure 2b . Struture of niosome 
COMPOSITION OF NIOSOMES
 
In addition to drug the niosome consists of 2 components.  The main components are non-
ionic surfactants.  Membrane additives  stabilize the niosomes (Biju et al, 2006, Jain et al, 2002).  
1. Main component : Non-ionic surfactant  
2. Membrane additives: Cholesterol,  Stabilizer- Charged inducer molecule 
3. Drug         
3.3  NON- IONIC SURFACTANTS 
 
The non-ionic surfactants are uncharged amphiphilic compounds. The non-ionic 
surfactants  orient in an aqueous medium as planar bilayer lattices wherein polar (or) hydrophilic 
heads align facing aqueous bulk while hydrocarbon segments are so aligned that their interaction 
with aqueous media is minimized (Biju et al, 2006). 
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          Every bilayer folds over itself to be a continuous membrane that forms vesicles so that 
hydrocarbon / water interface remains no more exposed. 
Examples of non-ionic surfactants forming vesicles are,  polyoxy ethylene fatty acid 
esters, polyoxy ethylene alkyl esters (including ethers of fatty alcohols) polyoxy ethylene 
sorbitan esters, polyoxy ethylene glyceryl mono and diesters, sucrose diester, propylene glycol 
stearate, long chain acyl amide, C12-C22 fatty alcohols etc., 
 BRIJ
TM
 (Polyoxy ethylene fatty acid esters), SPAN
TM 
(Sorbitan fatty acid esters) and 
TWEEN
TM
 (Polyoxy ethylene derivatives of sorbitan fatty acid esters.) are commercially 
available amphiphile surfactants.  
           The choice of non-ionic surfactant on vesicle formation depends on hydrophilic lipophilic 
balance (HLB), critical micellar concentration (CMC) and critical packing parameter of 
amphiphiles. 
HLB of surfactants 
 
 Hydrophilic lipophilic balance (HLB) is a good indicator of the vesicle forming ability of 
surfactants (Uchegbu et al, 1998). 
• With the sorbitan ester (span) surfactants, a HLB number of between      4 and 8 was 
found to be compatible with vesicles formation. 
• Tween 20 having HLB number 16.7 is too hydrophilic to form a bilayer membrane. 
However with an optimum level of cholesterol it forms niosomes. 
• Ether amphiphiles bearing a steroidal C14 alkyl (or) C16 alkyl groups form vesicles. 
• Polyoxy ethylene alkyl ether (Brij) forming vesicles increase six-fold bioavailability 
for intranasally administered insulin. 
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• Low phase transition temperature, increased leakage of low molecular weight drugs 
from the aqueous compartment and decreased stability of the niosomes was observed 
when hydrophilic surfactants are used. 
• High phase transition temperature, decreased leakage of low molecular weight drugs 
from the aqueous compartment and increased stability of the niosomes was observed 
with hydrophobic surfactants. 
CRITICAL PACKING PARAMETER 
 
The micelle-forming amphiphiles show relatively high solubility in water. The 
concentration corresponds to CMC. The prediction of vesicle formation characteristics is not just 
a matter of HLB numbers, CMC values, but involves several other factors Israelachvili et al, 
1991 suggested that parameters of self assemblages are governed by critical packing parameter 
(CPP). Their self-organization in water is mainly the result of the hydrophobic effect, as in the 
case of soap and detergent.It also depends on the relative proportions of hydrophobicity and 
hydrophilicity of the lipids as well as mesogen molecular geometry. The symmetry of the lipid 
self-assembly and liquid crystalline-phase formation show strong dependence on the molecular 
shape of the mesogen/amphiphiles. The different shapes and volumes constructing different 
phases are characterized by CPP, a dimensionless group (Ucheghu et al, 1998, Vyas et al, 2004).  
 The critical packing parameter (CPP) is defined as 
oc a.
V
CPP
l
=  
Where,  
  V=  Hydrophobic group volume 
  cl = The critical hydrophobic group length 
  ao = The area of hydrophilic head group 
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                  Figure 3.  Schematic representation of an amphiphile  
The vesicle forming ability of amphiphiles depends on the CPP value which is 
determined by using hydrophobic group volume and area of hydrophilic head group. 
 CPP = 0.5-1 -- Surfactant is likely to form vesicles. 
 CPP < 0.5   --  Large hydrophilic head group give spherical micelles. 
 CPP > 1.0  --  Large contribution from the hydrophobic group value  
   produces inverted   micelles (Biswal et al, 2008). 
The different structures formed by amphiphilic molecules are represented in figures as 
follows:  
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  Figure 4.  Structures formed by amphiphilic molecules                              
 CHOLESTEROL 
 
      Steroids are important components of cell membrane and bring bilayer fluidity and 
permeability. The most common additive found in niosomal systems is cholesterol which is 
known to abolish the gel to liquid phase transition of liposomal and niosomal systems, resulting 
in less leakiness of the vesicles. It may have effects on membrane permeability, encapsulation 
efficiency, bilayer rigidity, ease of rehydration of freeze dried niosomes and toxicity. A molar 
ratio of 1:1 between cholesterol and non-ionic surfactants is an optimal ratio for the formation of 
physically stable niosomal vesicles. Cholesterol can be incorporated in bilayers at significantly 
higher molar ratio, although by itself it does not form niosomal bilayer. Its -OH group orients 
towards aqueous phase while the rest of the molecule orients (aliphatic chains) parallel to the 
hydrocarbon chain of surfactants (Vyas et al, 2004, Biswal et al, 2008). 
 Cholesterol is known to have important modulatory effect on the bilayer membrane. 
Cholesterol acts as fluidity buffer. Below the phase transition it tend to make the membrane less 
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ordered while above the transition it tends  to make the membrane more ordered, thus 
suppressing the tilts and shift in membrane structure specifically at the phase transition. 
Role of cholesterol in bilayer formation 
• Acts as a fluidity buffer. 
• After intercalation with phospholipid molecules alters the freedom of motion of carbon 
molecules in the acyl chain. 
• Restricts the transformations of trans-to gauche-conformation. 
 DRUG 
 
              The drug is actively or passively entrapped in vesicles. In passive trapping, drug and 
lipids are co dispersed with fraction of drug being entrapped, according to hydrophobicity and 
electrostatic charge. If the drug is hydrophilic, it will be entrapped in the internal aqueous phase 
and the hydrophobic drug will be entrapped in lipid region. Active trapping can be achieved by 
ion gradients placed across the niosomal membranes. This allows drug entrapment after the 
niosomal carrier has been formed (Biswal et al, 2008).  
The physico-chemical properties of encapsulated drug influence charge and rigidity of 
the niosome bilayer. The drug interacts with surfactant head groups and develops the charge that 
creates mutual repulsion between surfactant bilayers and hence increases vesicle size. The 
aggregation of vesicles is prevented due to the charge development on bilayer. 
STABILIZER
  
           One of the methods used to stabilize niosomes is to add a charged inducing molecule to 
the bilayer. It is used for preventing aggregation of niosomes.   
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Examples of positive charge inducers 
 
Protamine, Polyamine, Polyvinyl pyridine, Poly oxethane, Poly amidoamines, Cetyl 
pyridinium chloride, Stearyl amine (STR), Triethanolamine etc. 
Examples of negative charge inducers 
 
Oleic acid, Palmitic acid, Dicetyl phosphate (DCP), Cetyl sulphate, Phosphatidic acid, 
Phosphatidyl serine etc, 
The charged molecule is added in niosomal formulation in an amount of 2.5–5 mol%. A 
higher concentration of charged molecules may inhibit the formation of niosomes. It is added in 
stable niosomal dispersion which exhibits a constant particle size and a constant level of 
entrapped drug. There must be no precipitation of the membrane components this treatment 
(Gopinath et al, 2004, Madhurilatha    et al, 2011).  
The inclusion of a charged molecule in the bilayer shifts the electrophoretic mobility 
making it positive or negative and prevents niosomes aggregation. 
3.4 TYPES OF NIOSOMES 
 
They are divided in to three types as follows, 
1. Multilamellar niosomes (>0.05µm)   
2. Small unilamellar niosomes (0.025-0.05µm) 
3. Large unilamellar niosomes (>0.01µm) 
39 
 
 
Figure 5. Schematic illustration of different size and number of lamellae  
SUV: Small unilamellar vesicles   LUV: Large unilamellar vesicles 
MLV: Multilamellar vesicles  MVV: Multi vesicular systems 
3.5 METHODS OF PREPARATION OF NIOSOMES 
 
1. Ether Injection Method 
2. Hand Shaking Method (Thin film hydration technique) 
3. Sonication 
4. Microfluidization 
5. Multiple Membrane Extrusion method 
6. Reverse Phase Evaporation Technique (REV) 
7. Trans membrane pH gradient Drug Uptake Process  
8. The “Bubble” method 
9. Ethanol injection method 
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10. Formation of niosomes from proniosomes 
11. Emulsion method 
12. Lipid injection method 
13. Niosome preparation using micelle 
1. Ether Injection Method  
          This method provides a means of making niosomes by slowly injecting the 
surfactant/cholesterol mixture (dissolved in diethyl ether) in to the aqueous phase maintained at 
600 through 14-gauge needle. This method produces unilamellar vesicle with highest entrapment 
efficiency. Depending upon the conditions used, the diameter of the vesicles range from             
50-1000nm (Rakesh et al, 2007, Alamayehu et al, 2010). 
2. Hand Shaking Method (Thin film hydration technique)  
The mixture of vesicle forming ingredients like surfactant and cholesterol are dissolved in 
a volatile organic solvent (diethyl ether, chloroform or methanol) in a round bottom flak. The 
solvent is evaporated at constant low temperature using a rotary evaporator, leaving behind a thin 
layer of solid mixture deposited on the wall of the flask. The dried surfactant film is rehydrated 
with aqueous phase maintained at 0-60 ºC with gentle agitation (Vyas et al, 2004, Rakesh et al, 
2007, Pranshu et al, 2011).   
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Figure 6. Thin film hydration method 
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Figure 7.  Mechanism of formation of niosomes 
 The lipids are cast as stacks of film from their organic solution in rotary flash evaporator 
under reduced pressure. The cast film is dispersed in an aqueous medium by hydration of the 
lipids (surfactants and cholesterol) which swell, peel off from the wall of the round bottom flask, 
become vesiculate and form multilamellar vesicles. The energy required for the swelling of the 
lipids and dispersion of lipid film is imparted by agitation.  
 Thermo sensitive niosomes are prepared by evaporating organic solvent there by leaving 
behind a thin film of lipid on the wall of rotary flask. The aqueous phase, containing drug is 
added slowly by shaking at room temperature followed by sonication. 
3. Sonication  
 The surfactant/cholesterol mixture in organic solvent is mixed with aqueous phase in a 
vial. Then the mixture is sonicated at 600 for 3 minutes to produce niosomes. The vesicles 
produced are unilamellar and smallest in size (Sankar et al, 2009, 2010, Subodh et al, 2010).  
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4. Micro fludization 
 
Microfludization is used for preparing unilamellar vesicles of a defined size distribution. 
This method is based on submerged jet principle in which two fluidized streams interact at ultra 
high velocities (up to 1700 ft/sec) in a precisely defined micro channels within the interaction 
chamber. The impingement of thin liquid sheet along a common front is arranged such that the 
energy supplied to the system remains within the area of niosomes formation. The result is a 
greater uniformity, smaller size and better reproducibility of niosomes formed (Pranshu  et al, 
2011, Dubey et al, 2010, Rakesh et al, 2007). 
5. Multiple Membrane Extrusion method 
  
Mixture of surfactant, cholesterol and dicetyl phosphate in chloroform is made into thin 
film by evaporation. The film is hydrated with aqueous drug solution and the resultant 
suspension is extruded through polycarbonate membranes which are placed in series up to 8 
passages. It produces niosomes of uniform size (Rakesh et al, 2007, Madhurilatha et al, 2011).   
6. Reverse Phase Evaporation Technique (REV)  
The novelty in this method is the removal of solvent from an emulsion by evaporation. 
Cholesterol and surfactant (1:1) are dissolved in a mixture of ether and chloroform. An aqueous 
phase containing drug is added to this and the resulting two phase system is sonicated at 4-5°C. 
The clear gel formed is further sonicated after the addition of a small amount of phosphate 
buffered saline (PBS). The organic phase is removed at 40°C under low pressure. The resulting 
viscous niosome suspension is diluted with PBS and heated on a water bath at 60°C for                 
10 minutes to yield niosomes (Pranshu et al, 2011, Navin et al, 2011).   
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7. Trans membrane pH gradient Drug Uptake Process      
Surfactant and cholesterol are dissolved in chloroform. The solvent is then evaporated 
under reduced pressure to get a thin film on the wall of the round bottom flask. The film is 
hydrated with 300 mM citric acid (pH 4.0) by vortex mixing. The resulting multilamellar 
vesicles are then treated to three freeze thaw cycles and sonicated. To this niosomal suspension, 
aqueous solutions containing    10 mg/ml of drug is added and vortexed. The pH of the sample is 
then raised to    7.0-7.2 with the addition of 1M disodium phosphate (this causes the drug which 
is outside the vesicle to become non-ionic and can then cross the niosomal membrane, and once 
inside it is again ionized thus not allowing it to exit the vesicle). This mixture is later heated at 
60°C for 10 minutes to give niosomes (Rakesh et al, 2007, Dubey et al 2010). 
8. The “Bubble” Method 
 
It is novel technique for the preparation of liposomes and niosomes without the use of 
organic solvents. The bubbling unit consists of round-bottomed flask with three necks positioned 
in water bath to control the temperature. Water-cooled reflux and thermometer is positioned in 
the first and second neck and nitrogen supply through the third neck. Cholesterol and surfactant 
are dispersed together in this buffer (pH 7.4) at 70°C, the dispersion is mixed for 15 seconds with 
high shear homogenizer and immediately afterwards “bubbled” at 70°C using nitrogen gas 
(Rakesh et al, 2007, Dubey et al, 2010).  
9. Ethanol injection method  
This method has been reported for the preparation of small unilamellar vesicles (SUVs) 
without sonication. In this method, an ethanol solution of surfactant is injected rapidly through a 
fine needle into excess of saline or other aqueous medium. Vaporization of ethanol leads to the 
formation of vesicles (Navin et al, 2011). 
 10. Formation of niosomes fro
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12. Lipid injection method  
 This method does not require expensive organic phase. Here, the mixture of lipids and 
surfactant is first melted and then injected into a highly agitated, heated aqueous phase 
containing dissolved drug. The drug can be dissolved in molten lipid and the mixture  injected 
into agitated, heated aqueous phase containing surfactant (Kazi et al, 2010). 
13. Niosome preparation using micelle  
 Niosomes may also be formed from a mixed micellar solution by the use of enzymes. A 
mixed micellar solution of C16G2, dicalcium hydrogen phosphate, polyoxyethylene cholesteryl 
sebacetate diester (PCSD) converts to a niosome dispersion when incubated with esterases.  
PCSD is cleared by the esterases to yield polyoxyethylene, sebacic acid and cholesterol. 
Cholesterol in combination with C16G2 and DCP then yields C16G2 niosomes (Amritha et al, 
2006) 
3.6 THE REDUCTION OF NIOSOME SIZE  
 A reduction in vesicle size may be achieved by  
• Probe sonication 
• Extrusion through 100nm nucleopore filter 
• The combination of sonication and filtration 
• Micro fluidizer 
• High pressure homogenizer. 
3.7 SEPERATION OF UNENTRAPPED DRUG 
  
In vesicular system half of the drug is encapsulated and half is external to the niosomes 
and may eventually yield systems with a beneficial biphasic bidistribution profile (Uchegbu et al, 
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1998, Rakesh et al, 2007, Kumar et al, 2011). The removal of unentrapped solute from the 
vesicles can be accomplished by  
1. Dialysis  
The aqueous niosomal dispersion is dialyzed in dialysis tubing against phosphate buffer 
or normal saline or glucose solution.  
2. Gel Filtration  
The unentrapped drug is removed by gel filtration of niosomal dispersion through a 
Sephadex-G-50 column and elution with phosphate buffered saline or normal saline.  
3. Centrifugation   
The niosomal suspension is centrifuged and the supernatant is separated. The pellet is 
washed and then resuspended to obtain a niosomal suspension free from unentrapped drug.  
3.8 CHARACTERIZATION OF NIOSOMES 
 
1. Entrapment efficiency 
          The unentrapped drug is separated by dialysis, centrifugation or gel filtration
 
as described 
above and the drug remained entrapped in niosomes is determined by complete vesicle 
disruption using 50% n-propanol or 0.1% Triton X-100 and analyzing the resultant solution by 
appropriate assay method for the drug. Where,                                    
     
                                       (Total drug – Drug in supernatant)  
  % drug entrapment =             × 100 
Total drug 
2. Vesicle diameter 
Niosomes assume spherical shape and so their diameter can be determined using light 
microscopy, photon correlation microscopy, and scanning electron microscopy and freeze 
fracture electron microscopy (Biju et al, 2006, Navin et al, 2011)  
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3. In-vitro release 
         A method of invitro release study includes the use of dialysis tubing. A dialysis sac is 
washed and soaked in distilled water. The vesicle suspension is pipetted into a bag made up of 
the tubing and sealed (Kasi et al, 2010). The bag containing the vesicles is placed in buffer 
solution in a beaker with constant shaking at 25°C or 37°C. At various time intervals, the buffer 
is analyzed for the drug content. 
3.9 ROUTES OF ADMINISTRATION
 
 Azmin et al, 1985, investigated niosomal delivery of methotrexate to mice by oral and 
intravenous administration. On oral administration absorption of methotrexate was significantly 
increased.  
           Hofland et al, 1992, studied transdermal delivery of estradiol entrapped within niosomes. 
Brewer and Alexander performed studies on adjuvant activity of niosomes on the BALB/C 
humoral response to bovine serum albumin after intraperitoneal and subcutaneous 
administration. 
3.9 In vivo BEHAVIOUR OF NIOSOMES 
 
in vivo niosomes have been found to be equiactive to liposomes in improving the 
therapeutic performance of drug   and their distribution in the body. Like liposomes, niosomes 
are taken up by the liver and break down to release the free drug which re enters the circulation 
and maintains the plasma drug level. 
            Parthasarathi et al, 1994, found niosomes to be stable in plasma. Moser et al found 
niosomes bearing hemoglobin to be physically stable and albumin, transferrin were absorbed on 
vesicles without destabilizing them. 
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3.11 CHARACTERIZATION OF NIOSOMES
 
Table I.  Analytical methods for characterizing niosomes 
S.NO. PARAMETER(S) METHOD(S) 
1. Morphology 
Transmisson Electron Microscopy, Scanning 
Electron Microscopy, Optical Microscopy (OM), 
Cryo- Scanning Electron Microscopy, Freeze 
Fracture Microscopy 
2. 
Vesicle size determination 
and Size distribution  
Dynamic Light Scattering using particle Size 
Analyzer(PSA), Malvern Master Sizer, Photon 
Correlation Spectroscopy (PCS),  
OM, SEM, Laser Diffraction PSA 
3. 
Zeta potential/ Surface 
Charge 
Micro-electrophoresis meter, High Performance 
Capillary electrophoresis and Malvern Zeta Sizer 
(Zetameter) 
4. 
Rheological Properties 
(Elasticity) 
Ostwald’s U-tube, Low shear Rheo Analyzer and 
Extrusion method 
5. Viscosity Ostwald’s viscometer 
6. Membrane micro-structure Negative Staining TEM 
7. Lamellarity  OM, TEM 
8. Bilayer spacing and thickness X-Ray Scattering Analysis 
9. 
Gel-Liquid transition 
temperature & Thermal 
Analysis 
Differential Scanning calorimetry, Differential 
Thermal Analysis and Hot Stage Microscopy 
10. Circular Dichroism Spectropolarimeter 
11. Micropolarity measurement Fluorescence Spectrophotometer 
12. Fluidity of vesicles Differential Polarized Phase Fluorimetry 
13. Turbidity measurement UV-Visible Diode Array Spectrophotometer 
14. Entrapment Efficiency 
Centrifugation method, Dialysis method, Gel 
Exclusion Chromatography 
15. In-vitro release rate Using dialysis membrane 
16. Permeation study Franz Diffusion Cell 
17. Conductivity Conductometer 
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3.12 TOXICITY AND STABILITY 
 
Non-ionic surfactants used in niosomes are non-toxic and no toxic effects have been 
reported in animal studies due to the use of niosomes as drug carriers. 
Jain et al, 1995, reported that there are no morphological changes on storage for three 
months. Baille et al, 1986, determined the stability in buffer and reported that the entrapped 
solute would be retained under long term storage conditions. 
3.13 STUDIES ON NIOSOMES AND THEIR MEDICINAL APPLICATIONS 
 
Table II 
S. NO. APPLICATIONS DRUGS STUDIED 
1. 
Cancer chemotherapy and targeted 
drug delivery 
Doxorubicin, Danorubicin Hcl, Methotrexate 
(MTX), 5-flurouracil, Adiramycin, Vincristine, 
Cytarabine Hcl 
2. Transdermal drug delivery 
Nimesulide, Lidocaine, Cyclosporine, Estradiol, 
Erythromycin, α-interferon, Indomethacin, 
Enoxacin, Finasteride 
3. Enhancement of bioavailability 
Diclofenac, Flurbiprofen, Bleomycin, 
Vincristine, Doxorubicin, Acetazolamide 
4. Ocular drug delivery Timolol maleate, Acetazolamide, Cyclopetolate 
5. Pulmonary drug delivery All trans retinoic acid (ATRA) 
6. Brain Targeted Drug Delivery VIP loaded glucose bearing niosomes 
7. 
Protein/Peptide and Hormone 
delivery 
LHRH, Insulin (oral), 9-desglycinamide         
-8-arginine vasopressin (DGAVP) 
8. Local/Intra Articular drug delivery Radiolabelled Diclofenac Na niosomal vesicles 
9. 
Enhancement of stability improved 
photo stability 
DGAVP, Haemoglobin, Dithranol,                
β-carotene 
10. 
Improved thermal and oxidative 
stability 
β-carotene 
11. Prolonged release Propranolol Hcl, Doxorubicin 
12. For improved anti-infective therapy Sodium stibogluconate, Rifampicin 
13. 
Immuno stimulatory niosomes 
(antigenic) 
Haemagglutinin, Ovalbumin, Hepatitis B DNA 
vaccine niosomes, Plasmid DNA encoding 
proteins of Hepatitis B virus, Influenza DNA 
vaccine niosomes and Tetanus Toxoid Niosomes 
14. Diagnosis Urokinase 
15. 
Radio-pharmaceutical carrier and 
imaging study. 
Iobitridol (X-ray imaging studies), and 
Iopromide (Kidney imaging studies) 
51 
 
3.14 OTHER APPLICATIONS 
(a) Sustained release 
Niosomes can provide relatively constant and sustained plasma level of drug.  Sustained 
action of niosomes could be applied to drugs with low therapeutic index.  
(b) Localized drug action 
Localization of drug action results in enhancement of efficacy or potency of the drug and 
at the same time reduces its systemic toxic effects. Niosomes are a promising vehicle for drug 
delivery and being non-ionic it is less toxic and improves the therapeutic index of drug by 
restricting its action to target cells (Alamayehu et al, 2010, Madhav et al, 2011). 
3.15 ENHANCEMENT OF BIOAVAILABILITY 
 
The lipophilic form of drug has enhanced membrane/water partition coefficient as 
compared to the hydrophilic form of the drug. A big advantage of increased bioavailability 
through increased lipophilicity is reduction in drug dose.                      
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CHAPTER-IV 
 
TRANSDERMAL DRUG DELIVERY SYSTEM 
 
 INTRODUCTION  
 Transdermal drug delivery system is one among of the various modes of drug delivery 
which facilitates passage of therapeutic quantities of drug substances through the skin and for 
systemic (or) local effects (Loyd.V et al., 2005). 
 Discovering a new medicine is a very expensive and time-consuming work. But however, 
redesigning the modules and means to transport medicine into the body is a less demanding and 
more lucrative task.  
 In the normal drug release, if the medication may not be absorbed means it will release 
too slowly (or) if it delivered too fastly means, the patient may suffer untoward effects. To 
rectify the above drawback one of the solutions developed was transdermal drug delivery 
systems. 
       Human skin is a uniquely engineered organ that permits terrestrial life by regulating heat and 
water loss from the body whilst preventing the ingress of noxious chemicals or microorganisms. 
It is also the largest organ of the human body, providing around 10% of the mass of an average 
person, and it covers an average area of 1.7m2. Whilst such a large and easily accessible organ 
apparently offers ideal and systemic actions, human skin is a highly efficient self-repairing 
barrier designed to keep the insides in and the outside out. 
            Skin membranes can be examined at various levels of complexity, the membranes can be 
regarded as a simple physical barrier more complexity can be introduced by viewing skin as 
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various barriers in series. We can then introduce barriers in parallel by considering drug transport 
through pores in the tissue.   
4.1  SKIN
 
 
Figure 9. Structure of skin 
Skin is the largest organ of 1.5 to 2 m
2
 in adult which covers the whole body.  Thickness 
of skin varies from place to place i.e. it is so thick in palm, foot and so thin in eyelid.  
 
 The skin is broadly classified into two layers. They are; A) epidermis and B) Dermis. 
A. Epidermis 
 It is the most superficial (or) outermost layer of skin. The cells in the epidermis shed 
periodically and replaced by new cells usually a complete replacement of epidermis takes about 
40 days (Vyas.S.P et al, 2005).  
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Figure 10. structure of epidermis 
Various Layers In Epidermis  
 There are about four layers. They are;  
i. Stratum corneum. 
ii. Stratum lucidum. 
iii. Stratum granulosm.  
iv. Germinative layer.  
 
Figure 11. Structure of stratum corneum 
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B. Dermis 
 
 
Figure 12. Structure of stratum corneum 
 Dermis consists of the following things in it  
- Blood vessels. 
- Lymph vessels. 
- Sensory (somatic) nerve ending. 
- Sweat glands and their ducts. 
- Hair roots, hair follicles and hairs. 
- The arrectores pilorum – involuntary muscles attached to the hair follicles. 
- Sebaceous glands. 
Heirs, secretions from sebaceous glands and ducts of sweat glands pass via the epidermis 
to reach the surface.  
4.2 FUNCTION OF SKIN  
 It does major functions to the human body. They are 
- Mechanical function  
- Protective function  
-  
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• microbiological barrier 
• Chemical  barrier 
• Radiation barrier  
• Electrical Barrier  
- Regulation of body temperature 
- Formation of vitamin D 
- Sensation  
- Absorption  
- Excretion  
4.3 RATIONAL APPROACH TO DELIVER THE DRUG VIA SKIN Fig.no:11 
 
There are three main ways to approach the problem of formulating a successful topical 
dosage form.  
1. Manipulating the barrier function of the skin  
2. Directing drugs to the viable skin tissues without using oral, systemic (or) other routes.  
3. Using skin delivery for systemic treatment.  
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Dermatologist aim five main target regions. They are skin surface, horny layer, viable 
epidermis & upper dermis, skin glands and systemic circulation.  
4.4 FACTORS AFFECTING DRUG DELIVERY  
Transdermal route should have the capability to deliver the drug, regardless of size (or) 
structure at a predetermined rate. But there are some factors which influence the rate of drug 
delivery (There are two types of factors 
They are as follows  
A. Biological factors  
• Skin condition.  
• Skin age. 
• Amount of blood flow. 
• Regional Skin sites. 
• Skin metabolism. 
• Species differences. 
B. Physiochemical Factors  
• Skin hydration. 
• Temperature and pH 
• Diffusion Coefficient 
• Drug applying surface area. 
• Drug Concentration. 
• Partition Coefficient.  
• Molecular size and shape. 
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4.5 TYPES OF TREATMENT ACHIEVED BY TOPICAL DRUG DELIVERY  
• Camouflage. 
• Protection effects,. 
• Insect repellant. 
• Antimicrobial. 
• Antifungal. 
• Emolliency.  
• Keratosis. 
• Antiperspirant. 
• Exfolient. 
• Antibiotic. 
• Depilatory. 
• Anti inflammation. 
• Anti pruritic. 
• Local anesthetic. 
• PUFA and PDT. 
• Anti histamine. 
• Anti angina. 
• Anti-ischaemic. 
4.6 VARIOUS TYPE OF DOSAGE FROM USED IN TOPICAL DRUG DELIVERY 
• Liquid preparations. 
• Gels (jellies). 
• Powders. 
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• Ointments. 
• Creams. 
• Paste. 
• Aerosols. 
• Poultice. 
• Transdermal patch. 
4.7  METHODS TO INCREASE PERCUTANEOUS ABSORPTION  
Chemical penetration enhancers such as  
• Solvents  
• Alkyl Methyl sulphoxides 
• Pyrrolidones 
• Azone and related compounds 
• Surfactants  
• Ionophoresis 
• Sonophoresis 
• Electrophoresis 
• Laser Ablation 
• Prodrugs  
4.8 ADVANTAGES OF TRANSDERMAL DRUG DELIVERY SYSTEM 
1. Avoidance of significant presystemic metabolism (degradation in GI tract (or) Liver, gut 
wall) and the daily drug dose is reduced(Vyas.S.P et al.,2002).  
2. Reduction of Inter and Intra Patient variability.  
3. Drug level can be maintained in systemic circulation within the therapeutic window.  
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4. Drug action is extended and frequency of administration is reduced.  
5. Improved patient compliance.  
6. Drug input can be easily terminated. 
7. Increased safety.  
8. Greater convenience. 
9. Drugs with short biological half lives. 
 
4.9 DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY SYSTEM  
1. Skin irritation.  
2. Skin allergy. 
3. Potent drugs cannot be given by this route. 
4.10 ROLE OF NIOSOMES IN TRANSDERMAL DRUG DELIVERY SYSTEM  
 Niosomes can be used to deliver both hydrophobic and hydrophilic drugs via transdermal 
route. Although niosomes were tried for various routes it is used in the market for transdermal 
route (Novasome Products Such as 30% Petrolatum Novasomes and 10% Salicyclic Acid 
Novasomes). Studies showed that an enhanced delivery of drugs when encapsulated in niosomes. 
Niosomes increase skin penetration of drugs and it can act as local depot for sustained release of 
dermally active compounds. When non ionic surfactants are incorporated into niosomes they are 
much better tolerated by the skin then when they are used in emulsion (Jia – Y – Fang et al, 
2001). 
4.11  VARIOUS BIO ACTIVE AGENTS WHICH ARE TRIED VIA TRANS DERMAL 
ROUTE AS NIOSOME DRUG DELIVERY SYSTEM 
• Cyclosporin – A. 
• Lidocaine. 
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• Estradiol. 
• Erythromycin. 
• Alpha – interferon. 
• Diclofenac sodium.  
• Nimesulide. 
• Enoxacin. 
• Miconazole nitrate. 
• Ketoconazole. 
• Tretionin. 
• Metronidazole.  
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CHAPTER-V 
LITERATURE REVIEW 
 
Raju Jukanti et.al., 2011, developed a oral delivery of valsartan from maltodextrin based 
proniosome powders .The proniosome powders were prepared by varying the ratio of span 60 
and cholesterol and evaluated for micromeritic properties and the results indicate acceptable flow 
properties. The formulation containing equimolar ratio of span 60 and cholesterol showed 
smaller vesicle size, high surface charge and entrapment efficiency. The formation of noisomes 
and surface morphology of optimized proniosome formulation was studied by optical and 
scanning electron microscopy, respectively. FT-IR, differential scanning calorimetry, and 
powder X-ray diffraction studies performed to understand the solid state properties of the drug 
reveal the absence of chemical interaction, drug transformation from crystalline to amorphous 
and molecular state. The invitro dissolution study carried out in both simulated gastric and 
intestinal fluid demonstrates improved dissolution characteristics compared to pure drug. The 
augment in permeation enhancement from proniosome formulation across rat intestine suggest 
the potential of proniosome carriers for improved oral delivery of valsartan.       
Phikunthong Kopermsub et al., 2011, prepared a niosome for encapsulation of nisin and EDTA 
and their antibacterial activity enhancement. Different formulations of niosomes were prepared 
using span 80 with sodium stearoyl lactate (SSL) and PEG400 as additives .The corresponding 
niosomes were used for encapsulation of antibacterial agents including nisin and EDTA 
.Characterization of unloaded and loaded niosomes was carried out by means of size, zeta 
potential, and also encapsulation efficiency and antibacterial activity specifically for loaded 
niosomes. Unloaded niosomes were stable at least 2 months when temperature challenge was 
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applied at 4
0
 C, RT, and 45
0
 C. An addition of 0.5mM SSL, both with and without PEG was 
found to enhance stability of loaded niosomes throughout 2-months of storage. Effect of niosome 
formulation to zeta potential and encapsulation efficiency of nisin and EDTA was discussed in 
this paper. A 96- well plate assay was used to assess the antibacterial activity between free and 
encapsulated forms of nisin and EDTA against Staphylococcus aureus and Escherichia coli. 
Ammar.O.H et al., 2011, formulated a proniosomes as a carrier system for transdermal delivery 
of tenoxicam. Proniosomes offer a versatile vesicle delivery concept with the potential for drug 
delivery via the transdermal route. In this study, different proniosomal gel bases were prepared, 
characterized by light microscopy, revealing vesicular structures, and assessed for their drug 
entrapment efficiency, stability, and their effect on invitro drug release and ex vivo drug 
permeation. The lecithin-free Proniosomes prepared from Tween 20: Cholesterol (9:1) proved to 
be stable with high entrapment and release efficiencies. The in vivo behavior of this formula was 
studied on male rats and compared to that of the oral market product. The investigated tenoxicam 
loaded proniosomal formula proved to be non- irritant, with significantly higher                     
anti-inflammatory and analgesic effects compared to that of the oral market tenoxicam tablets.        
Mansoor A. Khan et al., 2011, developed a process understanding of a novel pediatric anti-HIV 
tenofovir niosomes with a high-pressure homogenizer. A variety of factors were systemically 
evaluated in order to establish the characteristics of the niosomes obtained with a high-pressure 
homogenizer. The vesicular sizing parameters, electrical properties, drug entrapment data and 
drug release characteristics were investigated using two groups of factors. The first group 
presented the physical process variables such as pressure of the homogenizer and the times that 
the samples were processed (cycles). The second group encompassed the compositional variables 
such as the drug loading, surfactant chain length, cholesterol level and the level of the charge 
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imparting agent. The obtained data showed that the drug distributed within both the aqueous and 
lipid phases of the formed niosomes. Saturation-like behaviors for both the effect of 
homogenization cycles on the produced size and the effect of the pressure on the size 
homogeneity were recorded. In contrast to the drug entrapment and conductivity of the niosomal 
suspension, the vesicular size parameters as well as the zeta potential were inversely proportional 
with the homogenization parameters. Drug release was significantly affected by the 
compositional factors rather than the physical ones. The current study demonstrated the 
usefulness of the microfluidization for the production and further scale-up of anti-HIV niosomes 
with very small mean vesicular sizes. 
Raju Jukanti et al., 2011, studied the enhanced bioavailability of exemestane via proliposomes 
based transdermal delivery. The prepared proliposomes were characterized for size, zeta 
potential, and entrapment efficiency. The size of the vesicles was found to be between 440 and 
700nm with high entrapment efficiency for the formulation containing greater amounts of 
phosphatidylcholine. DSC and FTIR studies were performed to understand the phase transition 
behavior and mechanism for skin permeation, respectively. The drug release across cellophane 
membrane follows zero-order kinetics by diffusion.Ex vivo permeation enhancement assessed 
from flux, permeability coefficient, and enhancement ratio were significantly higher for 
proliposomes gels compared with control. A significant improvement in the bioavailability            
(2.4-fold). The stability data reveal that the formulations are more stable when stored at 4
0
 C.  
Tetsuo Minamino et al., 2011, development of anti-EGF immuno liposomes for the treatment of 
breast cancer. In the present study, we developed novel immuno liposomes targeting HB-EGF 
for cancer therapy. The immuno liposomes significantly associated with Vero-H cells over 
expressing HB-EGF compared with their binding to wild-type Vero cells, whereas liposomes 
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without modification by the antibody did not associate with either type of cells. Moreover, 
enhanced uptake of the immuno liposomes into Vero-H cells was observed as well as that into 
MDA-MB-231 human breast cancer cells, which are known to highly express HB-EGF. These 
results suggest that HB-EGF mediates the binding and uptake of the immune liposomes in                     
HB-EGF-expressing cells. Next, we determined the therapeutic effect of these immune 
liposomes encapsulating an anticancer drug on tumor-bearing mice. For this purpose, we 
prepared doxorubicin (DOX)-encapsulated immune liposomes and injected them intravenously 
into mice bearing MDA-MB-231 cancer cells. As a result, these DOX-encapsulated immune 
liposomes suppressed not only tumor progression but also tumor regression. In conclusion, our 
results indicate that anti-HB-EGF antibody-modified liposomes could be a useful DDS carrier 
for the treatment of HB-EGF expressing cancer. 
Nahum Allon et al., 2011, developed a new liposome-based gene delivery system targeting lung 
epithelial cells using endothelin antagonist. We formulated a new gene delivery system based on 
targeted liposomes. The efficacy of the delivery system was demonstrated in invitro and in vivo 
models. The targeting moiety consists of a high-affinity 7-aminoacid peptide, covalently and 
evenly conjugated to the liposome surface. The targeting peptide acts as an endothelin 
antagonist, and accelerates liposome binding and internalization. It is devoid of other biological 
activity. Liposomes with high phosphatidyl serine (PS) were specially formulated to help their 
fusion with the endosomal membrane at low pH and enable release of the liposome payload into 
the cytoplasm. A DNA payload, pre-compressed by protamine, was encapsulated into the 
liposomes, which directed the plasmid into the cell's nucleus. Upon exposure to epithelial cells, 
binding of the liposomes occurred within 5–10 min, followed by facilitated internalization of the 
complex. Endosomal escape was complete within 30 min, followed by DNA accumulation in the 
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nucleus 2 h post-transfection. A549 lung epithelial cells transfected with plasmid encoding for 
GFP encapsulated in targeted liposomes expressed significantly more protein than those 
transfected with plasmid complexed with Lipofectamine. The intra-tracheal instillation of 
plasmid encoding for GFP encapsulated in targeted liposomes into rat lungs resulted in the 
expression of GFP in bronchioles and alveoli within 5 days. 
Varaporn Buraphacheep Junyaprasert et al., 2011, evaluated the physiochemical properties 
and skin permeation of Span 60 / Tween 60 niosomes of ellagic acid. The aim of the present 
study was to develop niosomal formulations obtained from the mixture of Span 60 and Tween 60 
that could encapsulate EA for dermal delivery. The EA-loaded niosomes were prepared with 1:0, 
2:1, 1:1, 0:1 Span 60 and Tween 60, using polyethylene glycol 400 (PEG 400), propylene glycol 
(PG) or methanol (MeOH) as a solubilizer. The influence of formulations on vesicle size, 
entrapment efficiency and stability of EA-loaded niosomes was investigated. It was found that all 
ratios of surfactants could produce EA-loaded niosomes when using 15% (v/v) PG, 15% (v/v) 
PEG 400 or 20% (v/v) MeOH. The niosomes were spherical multilamellar vesicles showing the 
localization of EA in the vesicles. The vesicle sizes of the niosomes after extrusion were 124–
752 nm with PI less than 0.4. The percentages of entrapment efficiency (% E.E.) of all EA-
loaded niosomes varied between 1.35% and 26.75% while PEG 400 niosomes gave the highest 
% E.E. The most stable and highest entrapped formulation was 2:1 Span 60 and Tween 60 
niosomes. Additionally, the in vitro skin permeation revealed that the penetration of EA from the 
niosomes depended on vesicle size, the amount of EA entrapped and the added solubilizer which 
could act as a permeation enhancer. From skin distribution study, the EA-loaded niosomes 
showed more efficiency in the delivery of EA through human epidermis and dermis than EA 
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solution. The results indicated that the Span 60 and Tween 60 niosomes may be a potential 
carrier for dermal delivery of EA. 
Abdul Hasan Sathali et al., 2011, formulation and evaluation of in situ gelling system of 
levofloxacin. Levofloxacin is an antibacterial agent which exhibits rapid precorneal elimination 
and poor ocular bioavailability, when given in the form of conventional ophthalmic solutions. To 
overcome this, an attempt has been made to formulate pH-triggered in situ gelling system of 
levofloxacin to provide sustained release of drug based on polymeric carriers that undergo sol-to-
gel transition upon change in pH. The levofloxain in situ gelling system formulated by using 
poly acrylic acid (Carbopol 940) in combination with hydroxyl propyl methyl cellulose (HPMC) 
which acted as viscosity enhancing agent. The developed formulation was stable, non-irritant and 
provided sustained release over 8-hour period and it is a viable alternative to conventional eye 
drops.  
Ahmed S. Zidan et al., 2011, studied the characteristics of the niosomes obtained with a high-
pressure homogenizer. The vesicular sizing parameters, electrical properties, drug entrapment 
data and drug release characteristics were investigated using two groups of factors. In contrast to 
the drug entrapment and conductivity of the niosomal suspension, the vesicular size parameters 
as well as the zeta potential were inversely proportional with the homogenization parameters. 
Drug release was significantly affected by the compositional factors rather than the physical 
ones. The current study demonstrated the usefulness of the microfluidization for the production 
and further scale-up of anti-HIV niosomes with very small mean vesicular sizes. 
Ismail Mouzam et al., 2011, prepared formulations were then subjected to the drug and 
excipients used. The method adopted achieved higher entrapment efficiency of 95% with least 
concentration of span 60 and cholesterol, while vesicular diameter observed was 4.88micrometer 
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for the sane concentration. The TEM images showed the formulated niosomes were spherical 
and discrete. At equimolar concentration span 60 and cholesterol (1:1) higher invitro release of 
98.53% was observed, and was considered to be best formulation. 
Malay K Das et al., 2011, developed the +sorbitan ester niosomes for topical delivery of 
rofecoxib. Niosomes were prepared by thin film method and were analyzed for size, entrapment 
efficiency and drug retention capacity. Niosomal vesicles were then incorporated into blank 
Carbopol gel to form niosomal gel.  The size and entrapment if the niosomal vesicles increased 
with gradual increase in HLB value of non ionic surfactants used. The niosomal gel showed a 
prolong drug release behavior compared to plain drug gel.  
Mohamed Nasr et al., 2010, In Vitro and In Vivo Evaluation of Proniosomes Containing 
Celecoxib for Oral Administration. Proniosomes were prepared by sequential spraying method, 
which consisted of cholesterol, span 60, and dicetyl phosphate in a molar ratio of 1:1: 0.1, 
respectively. The average entrapment percent of celecoxib proniosome-derived niosomes was 
about 95%. The prepared proniosomes showed marked enhancement in the dissolution of 
celecoxib as compared to pure drug powder. The bioavailability of 200 mg single dose of both 
celecoxib proniosomal formulation and a conventional marketed celecoxib capsule was studied 
in human volunteers. The obtained results show that the proniosomal formulation significantly 
improved the extent of celecoxib absorption than conventional capsule. The mean relative 
bioavailability of the proniosomal formulation to the conventional capsule was172.06±0.14%. 
The mean Tmax for celecoxib was prolonged when given as proniosomal capsule. There was no 
significant difference between the values of K and t1/2 for both celecoxib preparations 
Esmaeil Moazeni et al., 2010, developed a niosome-encapsulated ciprofloxacin (CPFX) HCl 
formulation for pulmonary delivery, the feasibility of encapsulation of CPFX in niosomes, its 
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stability and nebulization capability was evaluated. Various combinations of nonionic surfactants 
with cholesterol were used to prepare the formulations. The in vitro deposition data of the 
niosomal formulations were examined using an Andersen cascade impactor. Formulations 
composed of Span 60 and Tween 60 in combination with 40 mol% of cholesterol exhibited high 
encapsulation efficacy and stability and also had fine particle fraction and nebulization efficiency 
of about 61.9%_1.0 and 77.9_2.8, respectively. Minimal inhibitory concentration of the niosomal 
CPFX against some pulmonary pathogens were lower than free CPFX. Using the MTT assay in 
human lung carcinoma cell line (A549), niosome-entrapped CPFX showed significantly lower 
cytotoxicity in comparison to the free drug. These results indicate that niosome can be used as a 
carrier for pulmonary delivery of CPFX via nebulization. 
Aarti Jagtap et al., 2010, developed the formulation and evaluation of niosome entrapped 
pentoxifylline using in vivo bronchodilatory activity in guinea pigs. The objective of this study is 
to formulate niosomes of pentoxifylline, characterize niosomes in terms of entrapment 
efficiency, particle size distribution, in vitro release and stability and investigate the 
bronchodilatory activity of plain and niosomal pentoxifylline in vivo guinea pigs. Pentoxifylline 
was entrapped in niosomes by lipid layer hydration method using span60, cholesterol and dicetyl 
phosphate. The entrapment efficiency of niosomes of pentoxifylline was determined by 
separating the entrapped drug from the free drug by centrifugation. The in vitro release profile of 
the drug from niosomes was carried out in phosphate buffer saline (pH 7.4). The stability of 
niosomes was assessed by storage at 4±1
0   
  , 25±1
0
, 37±1
0
 and 45±1
0
 for one month. The plain 
(20, 40 and 80mg/kg) and niosomal pentoxifylline (5, 10, 20 and 40 mg/kg) was injected 
intraperitoneally to guinea pigs for evaluating bronchodilatory activity. The entrapment 
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efficiency of niosomes of pentoxifylline was found to be 9.26±1.96% giving a sustained release 
of drugs over a period of 24 h and better stability over the period of storage. 
Kandasamy Rukmani et al., 2010, developed a formulation and optimization of zidovudine 
niosomes. The objective of this study was to evaluate process-related variables like hydration 
and sonication time, rotation speed of evaporation flask, and the effects of charge-inducing agent 
and centrifugation on zidovudine entrapment and release from niosomes. Formulation of 
zidovudine niosomes was optimized by altering the proportions of Tween, Span and cholesterol. 
The effect of process–related variables like hydration time, sonication time, charge-inducing 
agent, centrifugation and rotational speed of evaporation flask on zidovudine entrapment and 
release from niosomes was evaluated. The effect of changes in osmotic shock and viscosity were 
also evaluated. Non-sonicated niosomes were in the size range of 2-3.5 µm and sonicated 
niosomes formulated with Tween 80 and dicetylphosphate (DCP) had a mean diameter of 
801nm.Zidovudine niosomes formulated with Tween 80 entrapped high amounts of drug and the 
addition of DCP enhanced drug release for a longer time (88.72% over 12 h). The mechanism of 
release from Tween 80 formulation was the Fickian type and obeyed first-order release kinetics. 
Niosomes can be formulated by proper adjustment of process parameters to enhance zidovudine 
entrapment and sustainability of release.  
Kandasamy Ruckmani et al., 2010, studied the tissue distribution, pharmacokinetics and 
stability studies of zidovudine delivered by niosomes and proniosomes. Proniosomes were 
prepared in the form of a slurry using β-cyclodextrin as carrier. The effect of the surfactants 
tween and span and the negative charge inducers (DCP) on tissue distribution of niosomes and 
proniosomes was studied. The distribution of ZDV in lungs, kidney, heart, liver and spleen of 
mice after intravenous bolus injection was higher in tween 80 niosomes without DCP than either 
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niosomes with DCP or tween 80 proniosomes. The amount of ZDV in plasma was low in tween 
80 niosomes without DCP. The results of a pharmacokinetic study in rabbits confirmed that 
tween 80 formulations with DCP were cleared from the circulation within five hours. An 
increased half-life of 202 minutes and mean residence time of 212.1 minutes was observed in 
tween 80 formulation. A stability study showed that after 90 days of storage, the drug leakage 
from tween 80 formulations stored at room temperature was significant (p>0.001) compared to 
niosomes stored  at 4
0
C .  Encapsulation ZDV in proniosomes reduced drug leakage from 
vesicles stored at room temperature. 
Pavala Rani et al., 2010, developed a formulation and evaluation of rifampicin and gatifloxacin 
niosomes on logarithmic – cultures of Mycobacterium tuberculosis. Niosomes are vesicles 
mainly consisting of non-ionic surfactants that encloses and encompasses the drug molecules. 
Niosomes of rifampicin and gatifloxacin were prepared by lipid hydration technique using rotary 
flash evaporator. The prepared rifampicin and gatifloxacin niosomes showed a vesicle size in the 
range of 100-300nm, the entrapment efficiency were 73% and 70% respectively. The in vitro 
release study showed that 98.98% and 97.74% of release of rifampicin and gatifloxacin niosomes 
respectively. The bactericidal activities of the niosomal formulation were studied by BACTEC 
radiometric method using the resistant strains (RF 8554) and sensitive strains (H37Rv) of 
Mycobacterium tuberculosis which showed greater inhibition and reduced growth. 
AjayB.Solanki et al., 2010, optimized the composition of niosomes containing aceclofenac for 
transdermal application, with a view to improve permeation of drug during an extended period of 
time. Niosomes were prepared by thin film hydration technique. A 32 factorial design was 
utilized to study the effect of the molar ratio of drug to lipid (X1) and volume of hydration 
medium (X2) on percentage drug entrapment (PDE) and vesicle size. Selected batches of 
72 
 
niosomes were incorporated in to Carbopol gel matrix to prepare the niosomal gel formulations, 
which were evaluated for in-vitro release, skin permeation and in vivo studies. . Each of the 
prepared niosomal gel formulations significantly improved (P<0.05) cumulative amount of drug 
permeated, steady state transdermal flux and increase in paw thickness.  This study demonstrates 
that niosomal gel formulations may offer promise as a transdermal delivery of aceclofenac to 
improve efficiency and better patient compliance. 
 Arora Rajnish et al., 2010, evaluated the release studies of Ketoprofen niosomes formulation.  
Ketoprofen niosome were prepared by thin film hydration method technique using surfactant, 
cholesterol, dicetyl phosphate & drug mixture in different weight ratios. The prepared niosomes 
were characterized by various physicochemical parameters & evaluation of release studies of 
entrapped Ketoprofen in niosomes were carried out by UV Visible spectrophotometeric method. 
Abdul Hasan Sathali et al., 2010, studied the evaluation of transdermal targeted niosomal drug 
delivery of terbinafine hydrochloride niosomes of terbinafine hydrochloride were formulated by 
thin film hydration method using different ratios of non ionic surfactant (tween 20, 40, 60, and 
80) and cholesterol with constant drug concentration. The prepared formulations were evaluated 
for its vesicle size (by AFM), entrapment efficiency (by dialysis method) in vitro release studies 
and antifungal activities. Increase in surfactant concentration, increased the entrapment 
efficiency (up to 84.92%) and the formulation with surfactant cholesterol ratio 2:1 in each group 
of surfactant showed good entrapment.  
 Anand kumar et al., 2010, studied the developing and optimizing niosomal formulation of 
aceclofenac in order to improve its bioavailability. In evaluation study the effect of the varying 
composition of non ionic surfactant and cholesterol on the properties such as encapsulation 
efficiency, particle size and drug release were studied. Moreover, the release of the drug was also 
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modified and extended over a period of 72 h in all formulations. NSF-3 emerged as the most 
satisfactory formulation in so far as its properties were concerned. Further, release of the drug 
from the most satisfactory formulation NSF-6 was evaluated through dialysis membrane to get 
the idea of drug release. The mechanism of dug release was governed by Peppas model.  
Abdul Hasan Sathali et al., 2010, Studied the drug loaded ethosomes had been prepared using 
phospholipid and ethanol, were optimized and characterized for entrapment efficiency, vesicular 
size, shape, invitro skin permeation, skin retention, drug‐membrane component interaction and 
stability. The ethosomes formulation having 4%w/v of phospholipid and 40%v/v of ethanol 
(F16) showing the greatest entrapment efficiency (72.91±0.64%) with small particle size 
(251±23nm) was selected for further skin permeation studies. The skin permeation and skin 
retention studies were performed on ethosomes formulation, liposomal formulation (4%w/v of 
phospholipid without alcohol), hydro ethanolic drug solution and phosphate buffer saline 
(pH7.4) drug solution. Among them, ethosomal formulation showed higher cumulative 
percentage of drug permeation (60.37±5%) and more skin retention (619.60±18µg/cm2) after 12 
hours than the other formulations. The ethosomal vesicles were incorporated in Carbopol gel 
base and its anti‐inflammatory efficiency was compared with the marketed diclofenac gel. The 
pharmacodynamic studies showed the enhanced anti‐inflammatory activity of ethosomal gel than 
the marketed gel formulation. Our results suggest that the ethosomes are an efficient carrier for 
dermal and transdermal delivery of diclofenac potassium. 
Aranya Manosroi et al., 2010, developed the gallidermin (Gdm) loaded in anionic niosomes 
composed of Tween 61/CHL/DP (1:1:0.05 molar ratio) gave the highest entrapment efficiency 
(45.06%). (25.74±5.05_gcm−2 h−1) in VED to the unloaded Gdm incorporated in gel. This 
study has suggested that Gdm loaded in anionic niosomes and incorporated in gel is the superior 
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topical antibacterial formulation because of the high accumulation in the skin with no risk of 
systemic effect. 
Srikanth.K et al., 2010, developed the formulation and evaluation of topical meloxicam 
niosomal gel niosomes were prepared by thin film hydration method using non-ionic surfactants, 
cholesterol and drug in different ratios. The prepared niosomes were characterized for size, 
shape, entrapment efficiency invitro drug release and in vivo performance. The niosomes 
appeared as round in shape and size range was found to be 1.54 – 2.64 micro meter. In vivo anti 
inflammatory activity of niosomal gel prepared carrageenam induced rat paw edema method.  
The studies were demonstrated that niosomal gel was shown better pharmacological activity than 
the conventional preparations.  
Pratap S.Jadon et al., 2009, enhanced oral bioavailability of griseofulvin via niosomes. 
Niosomes were prepared by using different nonionic surfactants span 20, span 40, and span 60. 
The lipid mixture consisted of surfactant, cholesterol, and dicetyl phosphate in the molar ratio of 
125:25:1.5, 100:50:1.5, and 75:75:1.5, respectively. The niosomal formulations were prepared by 
thin film method and ether injection method. The influence of different formulation variables 
such as surfactant type, surfactant concentration, and cholesterol concentration was optimized for 
size distribution and entrapment efficiency for both methods. Result indicated that the niosomes 
prepared by thin film method with span 60 provided higher entrapment efficiency. The niosomal 
formulation exhibited significantly retarded in vitro release as compared with free drug. The in 
vivo study revealed that the niosomal dispersion significantly improved the oral bioavailability 
of griseofulvin in albino rats after a single oral dose. The maximum concentration (Cmax) 
achieved in case of niosomal formulation was approximately double (2.98 µg/ml) as compared to 
free drug (1.54 µg/ml). Plasma drug profile also suggested that the developed niosomal system 
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also has the potential of maintaining therapeutic level of griseofulvin for a longer period of time 
as compared to free griseofulvin. The niosomal formulation showed significant increase in area 
under the curve0-24 (AUC; 41.56 µg/ml h) as compared to free griseofulvin (22.36 µg/ml h) 
reflecting sustained release characteristics. In conclusion, the niosomal formulation could be one 
of the promising delivery system for griseofulvin with improved oral bioavailability and 
prolonged drug release profiles. 
Rathi Jagdish Chandra et al., 2009, developed the formulation and evaluation of maltodextrin 
based proniosomes loaded with indomethacin. Microscopy confirms that all particles are uniform 
in size and shape. The entrapment efficiency was determined by separating the unentrapped 
using dialysis. The positive values of zeta potential indicated that the indomethacin niosomes 
were stabilized by electrostatic repulsion forces..In the stability it was observed that the drug 
leakage from the vesicles was least at 4º  followed by 25ºC.     
Shyamala Bhaskaran et al., 2009, studied the comparative evaluation of niosome formulations 
prepared by different techniques. Niosomes containing salbutamol sulphate was prepared using 
Span 60 as the surfactant, by employing different techniques namely, thin film hydration, hand 
shaking, ether injection, lipid layer hydration and trans membrane pH gradient method. The drug 
encapsulation efficiency varied from 62 % to 87 %. In vitro drug release studies was carried out 
and formulation exhibited retarded release for 24 h. Transmembrane pH gradient method was 
found to be most satisfactory which released 78.4 % of drug in 24 h. This formulation was 
lyophilized and characterized by infrared spectroscopy. Tissue distribution studies in albino rats 
and bio- availability studies in rabbits were carried out. 
 Vijay Prakash pandey et al., 2009, developed the preparation and characterization non-ionic 
surfactant vesicles for ophthalmic use. In the present study, the nonionic surfactant vesicles were 
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prepared by lipid film hydration method using span 60 and cholesterol with various molar ratios 
and characterized for entrapment efficiency; in-vitro drug release, surface charge, rheological 
character, physical stability, minimum inhibitory concentration, in-vivo drug release and ocular 
irritation were conducted. The span 60: cholesterol in molar ratio of 100:60 showed higher 
entrapment of drug and released73.77 % at 10th h and the availability of drug in the aqueous 
humor was 4.373µg/ml (Cmax), confirmed by HPLC method. The histopathology study also 
confirmed the safe use of niosomes. Study may be concluded that the non-ionic surfactant 
vesicles formulated with span 60 and cholesterol in a molar ratio of 100:60 showed potential 
approach to improve the ocular bioavailability of ofloxacin for the prolonged period of time. 
Jong Soo Woo et al., 2009, studied the formulation and invitro assessment of minoxidil 
niosomes for enhanced skin delivery. Niosomes formed from polyoxyethylene alkyl ethers 
(BrijTM) or sorbitan monoesters (SpanTM) with cholesterol molar ratios of0, 1 and 1.5 were 
prepared with varying drug amount 20–50mg using thin film-hydration method. The prepared 
systems were characterized for entrapment efficiency, particle size, zeta potential and stability. 
Skin permeation studies were performed using static vertical diffusion Franz cells and hairless 
mouse skin treated with either niosomes, control minoxidil solution (propylene glycol–water–
ethanol at 20:30:50,v/v/v) or a leading topical minoxidil commercial formulation (Minoxyl). The 
results showed that the type of surfactant, cholesterol and incorporated amount of drug altered 
the entrapment efficiency of niosomes. Higher entrapment efficiency was obtained with the 
niosomes prepared from Span 60 and cholesterol at1:1 molar ratio using 25mg drug. Niosomal 
formulations have shown a fairly high retention of minoxidil inside the vesicles (80%) at 
refrigerated temperature up to a period of 3 months. It was observed that both dialyzed and      
non-dialyzed niosomal formulations (1.03±0.18 to 19.41±4.04%) enhanced the percentage of 
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dose accumulated in the skin compared to commercial and control formulations (0.11±0.03to 
0.48±0.17%) except dialyzed Span 60 niosomes. The greatest skin accumulation was always 
obtained with non-dialyzed vesicular formulations.  
`Praveen S. Hiremath et al., 2009, prepared a proliposomes of exemestane for improved oral 
delivery: Formulation and invitro evaluation using PAMPA, Caco-2 and rat intestine..The 
present study was to develop proliposomes formulations to enhance the oral bioavailability of 
exemestane by improving solubility, dissolution and / or intestinal permeability. Proliposomal 
powder formulations were prepared using different ratio of drug and lipids, cholesterol by 
solvent evaporation method. The effect of phospholipids compostion and drug: lipids ratio on 
invitro performance of proliposomes was studied. Proliposomes were characterized for the 
particle size distribution, thermal characteristics by the DSC and dissolution behaviour. Further, 
the formulated proliposomes were subjected to invitro permeation or transport studies using 
different models such as rat intestine, parallel artificial membrane permeability assay and Cac-2 
cell line. Proliposomes provided enhanced exemestane dissolution due to incorporation into the 
phospholipid bilayers and change in the physical state from crystalline to amorphous. The invitro 
transport studies in rat intestine, PAMPA and cac-2 models revealed that the proliposomes were 
successful in enhancing the permeation exemestane. 
Meenakshi Chauhan et al., 2009, developed the span-60 niosomal oral suspension of 
fluconazoloe: formulation and in vitro evaluation. Different batches of Fluconazole niosomal 
preparations were prepared by changing the surfactant concentration but keeping the cholesterol 
concentration constant. The surfactant used was Span 60 and the five batches of niosomal 
preparations prepared were in the ratios 1:1:1, 1.5:1:1, 2:1:1, 2.5:1:1 and 3:1:1 (surfactant: 
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cholesterol: drug). Furthermore, the release profile, entrapment efficiency, size distribution and 
stability of these niosomes under various temperatures were studied. 
Mahmoud Mokhtar et al., 2008, studied the proniosomal gels or solutions of flurbiprofen were 
developed based on span 20 (Sp 20), span 40 (Sp 40), span 60 (Sp 60), and span 80 (Sp 80) 
without and with cholesterol. Nonionic surfactant vesicles (niosomes) formed immediately upon 
hydrating proniosomal formulae. The entrapment efficiency (EE %) of flurbiprofen (a poorly 
soluble drug) was either determined by exhaustive dialysis of freshly prepared niosomes or 
centrifugation of freeze-thawed vesicles. Results indicated that the EE% followed the trend Sp 
60 (C18)>Sp 40 (C16)>Sp 20 (C12)>Sp 80 (C18). Cholesterol increased or decreased the EE% 
depending on either the type of the surfactant or its concentration within the formulae. The 
maximum loading efficiency was 94.61% when the hydrating medium was adjusted to pH 5.5. 
Increasing total lipid or drug concentration also increased the EE% of flurbiprofen into 
niosomes. However, incorporation of either dicetyl phosphate (DCP) which induces negative 
charge or stearyl amine (SA) which induces positive charge decreased the EE% of flurbiprofen 
into niosomal vesicles. Finally, in vitro release data for niosomes of Sp 40 and Sp 60 showed that 
the release profiles of flurbiprofen from niosomes of different cholesterol contents is an 
apparently biphasic release process.  
Varaporn Buraphacheep Junyaprasert et al., 2008, studied the effect of charged and non-
ionic membarane additives on physic chemical properties and stability of niosomes.  The 
niosomes were composed of 1:1 mole ratio of Span 60: cholesterol as vesicle forming agents. 
The results show that incorporation of salicylic acid to the niosomes did not affect zeta potential 
values; however, addition of the membrane additives changed the zeta potential depending on the 
type of the additives. Transmission electron microscopy revealed that niosomes had unilamellar 
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structure. The particle sizes of all developed niosomes were between 217 to360 nm. The 
entrapment efficiency (%E.E.) of all salicylic acid niosomes at pH 3 was higher than that of 
niosomes at pH 5, indicating that salicylic acid in unionized form was preferably incorporated in 
niosomes. Furthermore, the positively charged niosomes showed the highest %E.E. of salicylic 
acid owing to electrostatic attraction between STR and salicylic acid. After 3 months of storage 
at 4°C, the particle size of the niosomes remained in the nano size range except for DCP salicylic 
acid niosomes at pH 3 whose size increased due to an instability of DCP at low pH. In addition, 
all niosomes showed no leakage of the salicylic acid after 3 months of storage indicating the 
good stability. 
Ghada Abdelbary et al., 2008, developed a niosome- encapsulated gentamicin for ophthalmic 
controlled delivery. Niosomal formulations were prepared using various surfactants (Tween60, 
Tween 80 or Brij 35), in the presence of cholesterol and a negative charge inducer dicetyl 
phosphate (DCP) in different molar ratios and by employing a thin film hydration technique. The 
ability of these vesicles to entrap the studied drug was evaluated by determining the entrapment 
efficiency %EE after centrifugation and separation of the formed vesicles. Photomicroscopy and 
transmission electron microscopy as well as particle size analysis were used to study the 
formation, morphology and size of the drug loaded niosomes. Results showed a substantial 
change in the release rate and an alteration in the %EE of gentamicin sulphate from niosomal 
formulations upon varying type of surfactant, cholesterol content and presence or absence of 
DCP. In-vitro drug release results confirmed that niosomal formulations have exhibited a high 
retention of gentamicin sulphate inside the vesicles such that their invitro release was slower 
compared to the drug solution. A preparation with 1:1:0.1 molar ratio of Tween60, cholesterol 
and DCP gave the most advantageous entrapment (92.02%±1.43) and release results 
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(Q8h=66.29%±1.33) as compared to other compositions. Ocular irritancy test performed on 
albino 
Biswal.S  et al., 2008, studied the vesicles of non-ionic surfactants (Niosomes) and drug delivery 
potential. Niosomes exhibit more chemical stability than liposomes (a phospholipids vesicle) as 
non-ionic surfactants are more stable than phospholipids. Non-ionic surfactants used in 
formation of niosomes are polyglyceryl alkyl ether, glucosyldialkyl ether, crown ether, 
polyoxyethylenealkyl ether, ester-linked surfactants, and steroid-linked surfactants and a spans, 
and tweens series. Niosomes preparation is affected by processes variables, nature of surfactants, 
and presence of membrane additives and nature of drug to be encapsulated.  
Massimo Fresta et al., 2008, prepared a innovative bola- surfactant as topical delivery systems 
of 5- fluorouracil for the treatment of skin cancer .An innovative niosomal system made up of 
_hexadecyl-bis-(1-aza-18-crown-6) (Bola), Span 80® and cholesterol (2:5:2 molar ratio) was 
proposed as a topical delivery system for 5-fluorouracil (5-FU), largely used in the treatment of 
different forms of skin cancers. Bola-niosomes showed a mean size of 400 nm, which were 
reduced to 200 nm by a sonication procedure with a polydispersion index value of 0.1. Bola 
niosomes showed a loading capacity of 40% with respect to the amount of 5-FU added during 
the preparation. 5-FU-loaded bola-niosomes were tested on SKMEL-28 (human melanoma) and 
HaCaT (non-melanoma skin cancer with specific mutations in the p53 tumor suppressor gene) to 
assess the cytotoxic activity with respect to the free drug. 5-FU-loaded bola-niosomes showed an 
improvement of the cytotoxic effect with respect to the free drug. Confocol laser scanning 
microscopy studies were carried out to evaluate both the extent and the time-dependent bola-
niosome–cell interaction. The percutaneous permeation of 5-FU-loaded niosomes was evaluated 
by using human stratum corneum and epidermis membranes. Bola-niosomes provided an 
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increase of the drug penetration of 8- and 4-folds with respect to a drug aqueous solution and to a 
mixture of empty Bola-niosomes with a drug aqueous solution. 
Manivannan Rangasamy et al., 2008, evaluated the acyclovir entrapped niosomes were 
prepared by hand shaking and ether injection process with different ratios of (1:1, 1; 2 and 1:3) 
cholesterol (CHOL) and Span-80 (Non-ionic surfactant).The niosomes prepared were in the size 
range of 0.5- 5 microns in the case of hand shaking process and 0.5-2.5 microns in the case of 
Ether injection process. The order of encapsulation efficiency increases when span-80 
concentration was increased. In-vitro release study on acyclovir niosomes indicates 76.64% 
release for formulation prepared with CHOL: Span-80 (1:1) and it takes an extended period of          
1 day and 16 h for release. 
Ismail A.Attia et al., 2007, studied the influence of a niosomal formulation on the oral 
bioavailability of acyclovir in rabbits. The purpose of this research was to prepare acyclovir 
niosomes in a trial to improve its poor and variable oral bioavailability. The nonionic surfactant 
vesicles were prepared by the conventional thin film hydration method. The lipid mixture 
consisted of cholesterol, span 60, and dicetyl phosphate in the molar ratio of 65:60:5, 
respectively. The percentage entrapment was ~11% of acyclovir used in the hydration process. 
The vesicles have an average size of 0.95 µm, a most probable size of 0.8 µm, and a size range of 
0.4 to 2.2 µm. Most of the niosomes have unilamellar spherical shape. Invitro drug release 
profile was found to follow Higuchi’s equation for free and niosomal drug. The niosomal 
formulation exhibited significantly retarded release compared with free drug. The in vivo study 
revealed that the niosomal dispersion significantly improved the oral bioavailability of acyclovir 
in rabbits after a single oral dose of 40 mg kg−1. The average relative bioavailability of the drug 
from the niosomal dispersion in relation to the free solution was 2.55 indicating more than 2-fold 
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increase in drug bioavailability. The niosomal dispersion showed significant increase in the mean 
residence time (MRT) of acyclovir reflecting sustained release characteristics.  
Prasun Bandyopadhyay et al., 2007, evidence for vesicle formation from 1:1 non ionic 
surfactant span 60 and fatty alcohol mixtures in aqueous ethanol: potential delivery vehicle 
composition. A study of the self-organization of non ionic surfactant span 60 in presence of fatty 
alcohol (stearyl, cetyl and lauryl) is presented. When ethanolic solution of the surfactant-fatty 
alcohol (1:1) mixture is added in water spontaneous large unilamellar vesicles are formed which 
may potentially be useful vehicles for drug delivery purposes. Vesicular suspension has been 
characterized by transmission electron microscopy, dynamic light scattering, and confocol laser 
scanning microscopy, dye entrapment and release studies. Surface tension measurement indicates 
the suitability of fatty alcohols towards spontaneous vesicle formation from span 60.      
Tianqing liu et al., 2007, preparation and properties of highly stable innocuous niosome in Span 
80/PEG 400/H2O system .The highly stable innocuous niosome composed of only three 
components is successfully prepared in Span 80/PEG 400/H2O system. The niosome properties 
are studied by some means of freeze fracture replication-transmission electron microscopy, 
negative staining-transmission electron microscopy, dynamic light scattering and differential 
scanning calorimetry. The obtained results indicate that the niosome can be stable for over one 
year. The niosome diameter is between 100 and 180 nm. The compositions of the system affect 
the preparation and properties of the niosome. But the temperature and ionic intensity do not 
distinctly change the stability and the radius.  
Majid Tabbakhian et al., 2006, studied the enhancement of follicular delivery of finasteride by 
liposomes and niosomes, invitro permeation and in vivo deposition studies using hamster flank 
and ear models. Vesicles were prepared by the thin film hydration technique and characterized 
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with regard to the size, drug entrapment effiency and gel-liquid transition temperature. Invitro 
permeation of finasteride through hamster flank skin was showed that liquids . 
Anna M.Fadda et al., 2006, developed the niosomes as carriers for tretinoin III.A study into the 
in vitro cutaneous delivery of vesicle- incorporated tretinoin. Positively and negatively charged 
vesicular formulations were prepared using either stearylmine or dicetylphosphate as a charge 
inducer. Niosomes made with polyoxyethylene lauryl ether and liposomes made with soy 
phosphatidylcholine were also prepared and studied. Vesicular formulations were characterized 
by transmission electron microscopy and optical and light polarized microscopy for vesicle 
formation and morphology, and by dynamic laser light scattering for size distribution. The effect 
of the vesicular incorporation of tretinoin on its transdermal delivery through the newborn pig 
skin was also investigated invitro using Franz cells, in comparison with a commercial 
formulation of the drug. The amount of tretinoin delivered through and accumulated in the 
several skin layers was detected by HPLC. The results showed that tretinoin cutaneous delivery 
is strongly affected by vesicles composition and thermodynamic activity of the drug. Negatively 
charged niosomal formulations, which are saturated with tretinoin, have shown to give higher 
cutaneous drug retention than both liposomes and commercial formulation 
Vyas.S.P et al., 2006, developed the niosomal system for delivery of rifampicin to lymphatics. 
Niosomes containing rifampicin were prepared using various non ionic surfactants of sorbitan 
ester class and cholesterol in 50:50 percent mole fraction ratio. The drug- entrapment vesicles 
were characterized for their shape, size, drug entrapment efficiency and in vitro release rare. On 
the basis of in vitro characterization, the niosomes showing maximum entrapment and minimum 
release rate were selected for in vivo evaluation.    
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Behrooz Nasseri et al., 2005, studied the effect of cholesterol and temperature on the elastic 
properties of niosomal membranes. The mechanical characteristics of non-ionic bilayer 
membranes composed of sorbitan monostearate, cholesterol and poly-24-oxyethylene cholesteryl 
were studied by measuring the modulus of surface elasticity (µ), a measure of membrane 
strength, as a function of cholesterol content and temperature. The modulus of surface elasticity 
increased slowly with increasing cholesterol concentration, with a sharp increase around 40 
mol% cholesterol (on average an increment of 0.43×106 Nm−2 per molar percentage), and 
displayed a maximum of 6.5×106 Nm−2 around 47.5 mol% cholesterol. Further cholesterol 
resulted in a decrease in µ. Generally the interaction of cholesterol with the sorbitan 
monostearate should increase the rigidity of the membrane. However, the latter effect may be 
due to the formation of cholesterol clusters at high cholesterol content where excess amounts of 
cholesterol cannot interact with the sorbitan monostearate, and deposits on the bilayers 
compromising their uniformity, strength and permeability. This behaviour was evident when 
measurements were carried out above and below 25 ◦C. 
Vyas.S.P et al., 2005, developed the non ionic surfactant based vesicles (niosomes) for non- 
invasive topical genetic immunization against hepatitis B. Niosomes composed of span 85 and 
cholesterol as constitute lipids were prepared by reverse phase evaporation method. Prepared 
niosomes were characterized for their size, shape and entrapment efficiency. The immune 
stimulating activity was studied by measuring serum anti-HBs Ag titer and cytokines level 
following topical application of niosomes in Balb/c mice and results were compared with naked 
DNA and liposomes encapsulated DNA applied topically as well as naked DNA and pure 
recombinant HBsAg administered intramuscularly. It was observed that topical niosomes elicited 
a comparable serum antibody titer and endogenous cytokines levels as compared to 
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intramuscular recombinant HBsAg and topical liposomes. The study signifies the potential of 
niosomes as DNA vaccine carriers for effective topical immunization.  
Samar Mansour et al., 2005, studied the preparation and evaluation of reverse – phase 
evaporation and multilayer niosomes as ophthalmic carriers of acetazolamide. Niosomes formed 
from span 40 and span 60 and cholesterol in the molar ratio of 7:4, 7:6 and 7:7 were prepared 
using reverse-phase evaporation and thin film hydration methods. The prepared systems were 
characterized for entrapment efficiency, size, shape and in vitro release. Stability studies were 
carried out to investigate the leaching of drug from niosomes during storage. The intraocular 
pressure lowering activity of acetazolamide niosomal formulations in rabbits was measured 
using tonometer. The results showed that the type of surfactant, cholesterol content and the 
method of preparation altered the entrapment efficiency and drug release rate from niosomes. 
Higher entrapment efficiency was obtained with multilayer niosomes prepared from Span60 and 
cholesterol in a 7:6 molar ratio. Niosomal formulations have shown a fairly high retension of 
acetazolamide inside the vesicles at a refrigerated temperature up to period of 3 months. 
Multilamellar acetazolamide niosomes formulated with Span 60 and cholesterol in a 7:4 molar 
ratio were found to be most effective and showed prolonged decrease in IOP.      
Suresh P.Vyas et al., 2005, developed the non-invasive vaccine delivery in transfersomes, 
niosomes and liposomes: a comparative study. Niosomes and liposomes were prepared and 
characterized for shape, shape and entrapment efficiency. These vesicles were extruded through 
polycarbonate filter to assess the elasticity of the vesicles. The stimulating activity of 
transfersomes, niosomes and liposomes were studied by measuring the serum anti-TT IgG titre 
following topical immunization. The immune response elicited by topical immunization was 
compared with that elicited by same dose of alum-adsorbed tetanus toxoid given intramuscularly. 
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The results indicate that optimal formulations of transfersomes, niosomes and liposomes could 
entrap 72.7±3.4, 42.5±2.4 and 41.3±22% of antigen and their elasticity values were 
124.4±4.2,29.3±2.4 and 21.7±1.9, respectively.      
Mullaicharam.A.R et al., 2004, developed the formulation, optimization and stability of 
rifampicin niosomes. A niosomal drug delivery system of rifampicin was developed using 
factorial design and the niosomes were optimized. The effects of alteration of process variables 
like volume of solvent, hydration time, volume of hydration medium and sonication time were 
studied. The prepared niosomes were characterized for size, shape and lamellarity. The stability 
of niosomes in terms of retention of drug was measured at refrigerated temperature and ambient 
temperature (25-35oC) for the period of 60 days.     
Ibrahim A.Alsarra et al., 2005, niosomes have been utilized as carriers to enhance Atenolol 
absorption from the gastrointestinal tract. The prepared niosomes were evaluated for 
enhancement effect on drug permeation across the intestinal membranes using an everted sac 
technique. Permeation through an everted intestinal sac showed a significant enhancement effect 
(more than 4 fold). 
Ambikanandan Misra et al., 2002, niosomes were prepared by lipid film hydration method 
using tweens and spans. Preparation of niosomes was optimized for highest percent drug 
entrapment. The prepared niosomes were incorporated into 1 percent Carbopol gel base 
evaluated for drug diffusion across human cadaver skin using modified validated diffusion cell. 
The drug retension studies in niosomes were performed at refrigerated temperature and at room 
temperature for the period of 2 months. Invivo performance of plain drug gel, niosomal 
entrapped drug in Carbopol gel base and marketed formulation were evaluated using acute rat 
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paw edema mehod. High mean percentage edema inhibition was observed for niosomal 
nimesulide gel after 24 hours.   
PATENTS ON NIOSOMES IN VARIOUS UNIVERSITIES 
• Albert Einstein College of Medicine, New Hyde Park. Ain Shams University, Cairo 
Centre  for Drug Delivery Research Drug Delivery Research.  
• The School of Pharmacy, university of London. 
• St.johns university and Dept. of pharmaceutical Sciences. 
• Vicks Research Center, Richardson, Vicks Inc., Shelton. 
• University of Strath Clatde. 
• University of Wro Claw.  
• 7. University of Witten Germany, School of   Medicine. 
• University of California. 
• University of Pittspurgh. 
• Department of Chemistry, University of Oxford. 
• Department of Pharmaceutical Engineering, Koyang University, Nonsan. Korea. 
• Technical University, Clausthal. Russia. 
• Institute for Nuclear Research, Dubna, Russia. 
• Australia national University, Canberra ACT, Australia. 
• University of Kentucky Medical Center, Lexington. 
• University of Waterloo, Waterloo.    
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Patent Status 
1. US Patent Number: 6576254 
   Ucheghu IF, Department of Pharmaceutical Sciences. 
   The School of Pharmacy. University of London.  
2. US Patent Number: 5910488 
    Alejandro Madrigal, Stand ford University. 
3. US Patent application: 0040115278 
   Oxford University, Newyork. 
4. US Patent application: 2695331996 
   Ucheghu IF, Department of Pharmaceutical Sciences. 
5. US Patent application: 2106913146 
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CHAPTER-VI 
SCOPE OF WORK 
 
Nonsteroidal anti-inflammatory agents (NSAIDs) are class of drugs which budded from 
the bark of willow in the mid-eighteenth century. Now a day, there has been a rapid increase in 
the number of products that have been designed to deliver NSAIDs. These include creams, gels, 
ointment, and more complex transdermal systems. A number of approaches have been 
continuously investigated so as to enhance dermal delivery by use of prodrugs, ultrasound, 
ionotophorosis and microneedles. But the choice of the most appropriate drug depends on a 
number of factors which includes its potency, its ability to permeate the stratum corneum, its 
lack of local skin toxicity and stability towards metabolizing enzymes present on the skin 
surface. 
Etoricoxib is one of the NSAID widely used for musculoskeletal complaints especially 
arthritis, rheumatoid arthritis, Osteo arthritis, dental pain and gouty attacks. 
           Oral dose of etoricoxib can causes an increased risk of serious gastrointestinal adverse 
events including bleeding, ulceration and perforation of the stomach or intestines which can be 
fatal. These events can occur at any time during use and without warning symptoms. This drug 
may also cause an increased risk of serious cardiovascular thrombotic events, myocardial 
infarction and stroke.  
Due to presence of these oral adverse effects, necessitates the need for investigating other 
routes of drug delivery of Etoricoxib. Transdermal delivery of the drug can improve its bio 
activity and transdermal effect, reduce the side effects, sustained effect and enhance therapeutic 
efficacy. This can be achieved  only when the drug has entered the lower layers of the skin, then 
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only it can be absorbed by blood and transported to the site of action, or penetrate deeper in to 
areas where inflammation occurs. Pure drug or liposomal formulations not reach the lower layers 
of the skin. 
Niosomes a novel liposome, is especially suitable for topical and transdermal 
administration carrier. Compared to other liposomes, the physical and chemical properties of 
niosomes make the delivery of the drug through the stratum corneum in to a deeper layer 
efficiently or even into the blood circulation. Etoricoxib is a hydrophobic drug generally the 
entrapment efficiency of the niosomes of a water insoluble drug is higher than that of the other 
vesicle formulation. So the etoricoxib niosomal gel formulation may be better than other 
transdermal or topical formulation of NSAIDS. 
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CHAPTER-VII 
PLAN OF WORK 
 
1. Standard Curve for Etoricoxib 
   2. Pre Formulation Studies 
               FT-IR Studies 
               DSC Studies 
3. Formulation of Etoricoxib Niosomes 
  Drug Content 
  Entrapment Efficiency 
  invitro Release Studies 
  invitro Release Kinetics 
     4. Formulation of Etoricoxib niosomal gel 
     5. Evaluation of the Prepared Etoricoxib Niosomal Gel 
       Drug Content 
      pH Measurements 
       Rheology Studies 
       Particle Size 
         Zeta Potential 
        Transmission Electron Microscopy 
    invitro Release Studies 
.   invitro Release Kinetics 
   invivo-Anti-Inflammatory Studies 
    Stability Studies 
  Analysis of variance 
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CHAPTER-VIII 
 
MATERIALS  
 
 
• Drug      : Etoricoxib 
• Cholesterol     : S.D.Fine Chem. Ltd., India 
• Sorbiton manolaurate                : Loba Chemie, India 
• Sorbiton monopalmitate   : Loba Chemie, India 
• Sorbiton monostearate   : Loba Chemie, India 
• Sorbiton monooleate                : Loba Chemie, India  
• Tween 60     : Loba Chemie, India 
• Tween 80     : Loba Chemie,India 
• Brij-52       : Loba Chemie,India 
• Chloroform     : Rankem, India 
• Methanol     :      Rankem, India 
• n-propanol     : Nice Chemicals, India 
• Sodium chloride        : Central Drug House, India                    
• Potassium dihydrogen ortho phosphate : Nice Chemicals, India 
• Disodium hydrogen ortho phosphate      : Qualigens, India 
• Dialysis membrane    : Himedia, India 
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EQUIPMENT USED 
 
• Rotary Flash Evaporator  :  Super fit rotary flash evaporator, India  
• Ultra Sonicator :  Vibronic’s Ultrasonic Processor, India 
• Electronic Balance :  A&D Company, Japan 
• Magnetic Stirrer :  MC Dalal & Co, India 
• UV Visible Spectrophotometer :  UV Pharma Spec 1700,   
  Shimadzu, Japan 
• Cooling Centrifuge Apparatus      :  Eppendorf Centrifuge 5417R,  
  Germany 
• Malvern zeta analyzer :  Malvern Instruments, Uk 
• FT-IR Spectrophotometer :  Shimadzu, Japan 
• Differential Scanning Calorimeter :  Perkin Elmer STA 6000 Thermal  
  Analyzer,USA 
• Refrigerator :  Kelvinator, India 
• Environmental chamber :  Inlab Equipments (Madras) Pvt. Ltd, India. 
• Transmission electron microscopy : Technai Sprit, FEI, Netherlands 
• Digital Pletheesmometer : Ugobasile, Italy 
 
 
 
  
 DRUG NAME 
SYNONYMS 
CHEMICAL STRUTURE  
CHEMICAL FORMULA 
IUPAC NAME 
 
PHYSICAL CHEMICAL PR
• Molecular weight 
• Physical state 
• Solubility 
• Log p value 
• Refractivity 
• Polarizability 
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CHAPTER-IX 
DRUG PROFILE 
 
:  ETORICOXIB 
:  MK-663 
 
:  C18 H15 CLN2O2S 
: 5- chloro-3- (4- methane sufo
 2-   6- methyl pyridin-3-yl) py
OPERTIES: 
: 358.842 
: SOLID 
: 3.28 e-0.3g/l 
: 3.70 
: 95.04 
: 36.42         
nyl phenyl)  
ridine. 
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CATEGORIES 
 Cyclo-oxignenase inhibitors 
CLASSES 
• Bipyridines 
• Phenyl propenes 
• Pyridines & Derivatives 
• Sulfonyls 
• Benzene Derivatives. 
PHARMACODYNAMICS; 
  Etoricoxib selectively inhibits isoform 2 of cyclo-oxignenase enzyme (COX-2). This 
reduces prosta glanding (PGs) generation from arachidonic acid, there by decrease the 
inflammation (www.drugbank.com). 
PHARMACOKINETICS; 
• Absorbtion 
 Oral absorption 
• Metabolism 
 Cytochrome P450 
• Bioavailability 
 100% -ORALY 
• Protein binding 
 92% 
• Half-life 
 22 HOURS 
96 
 
THERAPEUTIC USES 
• Acute gout 
• Rheumatoid arthritis 
• Osteo arthritis 
• Chronic low back pain 
• Ankylosing Spondylitis   
SIDE EFFECTS 
Very common side effects 
• Ulceration, bleeding or perforation of the stomach or intestinal lining 
• Increased risk of heart attacks and stroke. 
Common side effects (affect between 1 in 10 & 1 in 100 people) 
• Dizziness 
• Head ache 
•  High blood pressure 
•  Cold or flu- like syndrome 
Un common side effects (affect 1 in 100 and 1 in 1000 people) 
• Change in appetite 
• Anxiety or depression  
• Change in taste 
• Blurred vision 
• Nose bleeds 
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USE WITH CAUTION IN  
• Elderly people 
• History of disorders affecting the Stomach or intestines. 
• Decreased liver function 
• Liver cirrhosis 
• Dehydration 
• History of heart failure 
• Hypertension 
• Diabetes 
• Smokers 
NOT BE USED IN 
• Children and adolescent under 16 years of age. 
• Severely decreased liver function  
• Moderate to severely decreased kidney function 
• Active peptic ulcer or bleeding from the gut. 
• Heart failure  
• Pregnancy 
• Breast feeding  
Available brands of Etoricoxib 
• Coxet (Anthus) 
• Ebov (Glenmark (Integrace)) 
• Erofica (Micro HC) 
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• Eteron (CFL) 
• Eticox (East West) 
• Etody (AHPL) 
• Etofan (Emar) 
• Etom (Intra Labs) 
• Etorica (Micro Eros) 
• Etoshine (Sun) 
• Etoxib (Unichem) 
• Etozox (Cipla) 
• ETRO (Allenge) 
• Etrobax (Ranbaxy) 
• Hicox (Systopic) 
• Hireto (Aamorb (St.Morison)) 
• Ifydrox (Sanify (Syntonic)) 
• Kingcox (Cadila HC) 
• Kretos (Glenmark (Majesta)) 
• L-KON (Laksun) 
• M-KON (Madhav Biotech) 
• Nucoxia (Zy. Cadila) 
• Nucoxia -P (Zy. Cadila) 
• Nucoxia -SP (Zy. Cadila) 
• Retoz (Dr. Reddy's) 
• Torcoxia (Torrent) 
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• Torcoxia BCD (Etoricoxib (with Betacyclodextrin) (Torrent) 
• Xibra (Khandelwal) 
DOSAGE 
• Osteoarthritis – 60mg – once daily 
• Rheumatoid – 90 mg – once daily 
• Acute gout – 120mg – once daily 
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CHAPTER-X 
EXCIPIENTS PROFILE 
CHOLESTEROL
 
SYNONYM 
Cholesterin, Cholesterolum 
CHEMICAL NAME 
Cholest -5- en-3β -ol. 
EMPIRICAL FORMULA 
C17 H46 O 
MOLECULAR WEIGHT 
386.67 
FUNCTIONAL CATEGORY 
• Emollient 
• Emulsifying agent 
DESCRIPTION 
• Cholesterol occurs as white or faintly yellow, almost odourless, pearly leaflets, needles, 
powder or granules. 
• On prolonged exposure to light and air, it acquires a yellow to tan color. 
PROPERTIES 
 Boiling Point - 360 o C 
 Density - 1.052g/cm
3
 for anhydrous form  
 Melting Point - 147-150
o
C 
 Solubility - Soluble in acetone and vegetable oils. 
   Practically insoluble in water and chloroform                                                       
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STABILITY AND STORAGE CONDITIONS 
It is stable, and should be stored in a well-closed container and protected from light. 
SAFETY 
It is generally regarded as an essentially non-toxic and non-irritant material at the levels 
employed as an excipients. 
HANDLING PRECAUTIONS 
Rubber or plastic gloves, eye protection and a respirator are recommended. 
METHOD OF MANUFACTURE 
 The commercial material is normally obtained from the spinal cord of cattle by extraction 
with petroleum ether, but it may also be obtained from wool fat. Purification is normally 
accomplished by repeated bromination. Cholesterol may also be produced by entirely synthetic 
means. 
REGULATORY STATUS 
 Induced in the FDA inactive ingredients. 
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SORBITAN MONOLAURATE 
SYNONYM 
Arlacel 20; Crill 1; Liposorb L;  Montane 20; Sorbitan laurate; Span 20. 
CHEMICAL NAME 
Sorbitan mono dodecanoate. 
EMPIRICAL FORMULA 
C18 H34 O6 
MOLECULAR WEIGHT 
346 
DESCRIPTION 
Yellow viscous liquid.  
METHOD OF MANUFACTURE 
 Sorbitol is dehydrated to form a hexitan (1,4-sorbitan), which is then esterified with the 
desired fatty acid. 
PROPERTIES 
 Acid value : ≤7 
 Hydroxyl value : 159-169 
 Saponification value : 159-169 
 Density : 1.01g/cm
3
 
 HLB Value  : 8.6   
FUNCTIONAL CATEGORY 
• Emulsifying agent 
• Nonionic surfactant 
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• Solubilizing agent 
• Wetting agent 
• Dispersing / suspending agent. 
STABILITY 
• Gradual soap formation occurs with strong acids or bases 
• Stable in weak acids or bases. 
STORAGE 
 It should be stored in a well-closed container in a cool, dry place. 
SAFETY 
 Daily intake according to the WHO limit is about 25mg/Kg body weight. 
HANDLING PRECAUTIONS 
 Eye protection and Gloves are recommended. 
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SORBITAN MONOPALMITATE 
SYNONYMS 
 Ablunol S-40, Armotan  MP, Liposorb P, Span 40,  Arlacel 40,  Montane 40,  Sorbitan Palmitate. 
CHEMICAL NAME 
Sorbitan monohexa decanoate. 
EMPIRICAL FORMULA 
             C22H42 O6 
MOLECULAR WEIGHT 
 403 
DESCRIPTION 
 It occurs as cream solid with a distinctive odour and taste. 
METHOD OF MANUFACTURE 
 Sorbitol is dehydrated to form a hexitan (1, 4 Sorbitan) which is then esterified with the 
desired fatty acid. 
PROPERTIES 
Acid value 3 to 7 
Hydroxyl value  270 to 303 
Iodine valure ≤ 1 
Density (g/cm
3
)  1.0 
HLB Value 6.7 
Melting point 430C - 48oC 
Solubility Soluble in oils and in most organic 
solvents. Insouble but dispersible in 
water. 
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FUNCTIONAL CATEGORY 
• Emulsifying agent. 
• Non ionic Surfactant. 
• Solubilizing agent. 
• Wetting agent. 
STABILITY 
 It should be stored in a well-closed container in a cool, dry place. 
SAFETY 
 It is generally regarded as non-toxic and non-irritant material. 
HANDLING PRECAUTIONS 
Eye protection and Gloves are recommended.
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SORBITAN MONOSTEARATE 
SYNONYMS 
 Ablunol S-60, Alkamuls SMS, Sorgen 50, Tego SMS, Span 60, Arlacel 60, Durtan 60, 
Montane 60, Sorbitan Stearate. 
CHEMICAL NAME 
 Sorbitan mono – Octadecanoate. 
EMPIRICAL FORMULA 
 C24 H46 O6 
MOLECULAR WEIGHT  
          431 
DESCRIPTION 
 It occurs as a cream solid with a distinctive odour and taste. 
METHOD OF MANUFACTURE 
 Sorbitol is dehydrated to form a hexiton (1,4 Sorbitan) which is then esterified with the 
desired fatty acid. 
PROPERTIES 
Acid value  5 to 10 
Hydroxyl value  235 to 260 
Iodine value  ≤ 1 
HLB Value 4.7 
Melting Point  530C – 57oC 
Solubility Soluble in oils and in most organic solvents.  
Insoluble but dispersible In water. 
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FUNCTIONAL CATEGORY 
• Emulsifying agent. 
• Nonionic Surfactant. 
• Solubilizing agent. 
• Wetting agent. 
STABILITY 
• Gradual Soap formation occurs with strong acids or bases. 
• Stable in weak acids or bases. 
STORAGE 
 It should be stored in a well-closed container in a cool, dry place. 
SAFETY 
• It is generally regarded as non-toxic and non-irritant material. 
• Very mildly toxic by ingestion. 
HANDLING PRECAUTIONS 
 Eye protection and Gloves are recommended. 
 
 
 
  
108 
 
POLYSORBATE 60
 
SYNONYM 
 Atlas 70k, Atlas armotan PMS 20, Glycosporse s-20, Tween 60, Tween 60k, Tween 60VS. 
CHEMICAL NAME 
Sorbitanmono Octadecanoate. 
EMPIRICAL FORMULA 
 C64 H126 O26 
MOLECULAR WEIGHT 
 1312 
DESCRIPTION 
 Yellow oily liquid.  
MEYHOD OF MANUFACTURE 
Polysorbate are prepared from sorbitol in a three-step process. Water is initially removed 
from the sorbitol to form a sorbitan (a cyclic sorbitol anhydride). The sorbitan is then partially 
esterified with a fatty acid such as oleic acid (or) stearic acid to yield a hexiton ester. Finally, 
ethylene oxide is chemically added in the presence of a catalyst to yield the polysorbates. 
PROPERTIES 
Acid value - 2.0 
 Hydroxyl value -  81 – 96 
 Saponification value - 45 - 55 
 Density (g/cm
3
) - 1.1g/cm
3
 
 HLB Value - 14.9 
 Solubility - Soluble in ethanol and water. Insoluble in   
   Mineral oil and vegetable oil.    
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FUNCTIONAL CATEGORY 
• Emulsifying agent 
• Nonionic surfactant 
• Solubilizing agent 
• Wetting agent 
• Dispersing / suspending agent. 
STABILITY 
• Gradual soap formation occurs with strong acids or bases 
• Stable in weak acids or bases. 
STORAGE 
 It should be stored in a well-closed container in a cool, dry place. 
SAFETY 
 Daily intake according to the WHO limit is about 25mg/Kg body weight and moderately 
toxic by IV route. 
HANDLING PRECAUTIONS 
 Eye protection and Gloves are recommended. 
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POLYSORBATE 80
 
SYNONYM 
 Atlas E, Capmul POE-o, Glycospere o-20,Tego SMO 80,Tego SMO 80 x, Tween 80. 
CHEMICAL NAME 
(Z) Sorbitan mono-9- Octadecanoate poly (oxy 1,2, ethanediyl) derivatives. 
EMPIRICAL FORMULA 
 C64 H124 O26 
MOLECULAR WEIGHT 
 1310 
DESCRIPTION 
 Yellow oily liquid. 
MEYHOD OF MANUFACTURE 
 Polysorbate are prepared from sorbitol in a three-step process. Water is initially removed 
from the sorbitol to form a sorbitan (a cyclic sorbital anhydride). The sorbitan is then partially 
esterified with a fatty acid such as oleic acid (or) stearic acid to yield a hexiton ester. Finally, 
ethylene oxide is chemically added in the presence of a catalyst to yield the polysorbates  
PROPERTIES 
Acid value - 2.0 
 Hydroxyl value - 65 – 80 
 Saponification value - 45 - 55 
 Density (g/cm
3
) - 1.08g/cm
3
 
 HLB Value - 15 
 Solubility - Soluble in ethanol and water. Insoluble in                  
   mineral oil and vegetable oil.    
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FUNCTIONAL CATEGORY 
• Emulsifying agent 
• Nonionic surfactant 
• Solubilizing agent 
• Wetting agent 
• Dispersing / Suspending agent. 
STABILITY 
• Gradual soap formation occurs with strong acids or bases 
• Stable in weak acids or bases. 
STORAGE 
 It should be stored in a well-closed container in a cool, dry place. 
SAFETY 
• Daily intake according to the WHO limit is about 25mg/Kg body weight  
• LD50 (Mouse, oral)-25g/Kg. 
HANDLING PRECAUTIONS: 
 Eye protection and Gloves are recommended. 
REGULATORY STATUS: 
 Polysorbates 20,40,60,65 and 80 are accepted as food additives in Europe. Polysorbates 
20, 40, 60, and 80 are included in the FDA inactive ingredients guide (IM, IV, Oral, rectal, 
topical and vaginal preparations). Polysorbates are included in parenteral and non-parenteral 
medicines licensed in the UK.  
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CARBOPOL 940 
Structure: 
 
 Synonyms 
Acritamer acrylic acid polymer; Carbopol; carboxypolymethylene, polyacrylic acid; 
carboxyvinyl polymer; Pemulen;Ultrez. Chemical Name and CAS Registry Number 
Carbomer 
Empirical Formula and Molecular Weight 
Carbomers are synthetic high-molecular-weight polymers of acrylic acid that are 
crosslinked with either allyl sucrose or allyl ethers of pentaerythritol. They contain between 56% 
and 68% of carboxylic acid (COOH) groups 104 400 g/mol for Carbopol 940 have been reported 
Structural Formula 
Carbomer polymers are formed from repeating units of acrylic acid. The monomer unit is 
shown above. The polymer chains are crosslinked with allyl sucrose or allylpentaerythritol. 
Functional Category 
Bioadhesive; emulsifying agent; release-modifying agent; suspending agent; tablet 
binder; viscosity-increasing agent. 
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Applications in Pharmaceutical Formulation or Technology 
Carbomers are mainly used in liquid or semisolid pharmaceutical formulations as 
suspending or viscosity-increasing agents.Formulations include creams, gels, and ointments for 
use in ophthalmic,(5–7) rectal,(8–10) and topical preparations. 
Emulsifying agent  
          0.1–0.5 
Gelling agent  
          0.5–2.0 
Suspending agent 
          0.5–1.0 
Tablet binder 
          5.0–10.0 
Description 
Carbomers are white-colored, ‘fluffy’, acidic, hygroscopic powders with a slight 
characteristic odor. 
Pharmacopeial Specifications 
Carbomer 940 (0.5 w/v) — 40 000–60 000(a) 
Typical Properties 
Acidity/alkalinity 
pH = 2.7–3.5 for a 0.5% w/v aqueous dispersion; 
pH = 2.5–3.0 for a 1% w/v aqueous dispersion. 
Density (bulk) 
1,.76–2.08 g/cm3 
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Density (tapped):  
1.4 g/cm3 
Glass transition temperature:  
100–1058C 
Melting point 
Decomposition occurs within 30 minutes at 2608C. 
Moisture content 
Normal water content is up to 2% w/w. However,   carbomers are hygroscopic and a 
typical equilibrium moisture content at 258C and 50% relative humidityis 8–10% w/w. The 
moisture content of a carbomer does not affect its thickening efficiency, 
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CHAPTER - XI 
EXPERIMENTAL PROTOCOL 
 
11.1  STANDARD CURVE FOR ETORICOXIB 
Dissolve 2.38 g of disodium hydrogen phosphate, 0.19 g of potassium dihydrogen 
phosphate and 8.0 g of sodium chloride in sufficient quantity of distilled water and the volume 
made up to 1000(I.P 2007). 
100mg of Etoricoxib is accurately weighed and dissolved in a small quantity of methanol 
and made up to 100ml with the buffer phosphate buffered saline pH 7.4. From this primary 
solution 10ml is pipetted out and made up to 100ml with phosphate buffered saline pH 7.4. From 
this secondary solution aliquots are taken to produce 1, 2, 3, 4, 5, 6, 7, 8, 9, 10µg/ml. 
The absorbance of the resulting solution is measured at 235nm in the UV-Visible 
Spectrophotometer (Shimadzu UV-1700 Pharma spec Japan) using phosphate buffered saline  
pH 7.4 as blank. The standard curve is plotted by taking concentration in X-axis and Absorbance 
in Y-axis. (Sridhar et al, 2008). 
11.2  PREFORMULATION STUDIES 
11.2.1    FT-IR studies  
The possibility of drug-excipients (cholesterol, nonionic surfactants) interactions are 
further investigated by FT-IR spectrum study. The FT-IR spectrum of pure drug and combination 
of drug with excipient are obtained by using Perkin FT-IR Spectrophotometer (Ismail Mouzam 
et al, 2011, Gurrapu.A et al, 2011). The scanning range is 450-4000 cm
-1 
and the resolution is 
4cm
-1
. Samples are prepared in KBr pellets 
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11.2.2 Differential scanning calorimetry 
Differential Scanning Calorimetry is performed using Perkin Elmer STA 6000 Thermal 
Analyzer. The instrument is calibrated with indium standard. Accurately weighed (it varies from 
3mg-25mg) samples are placed in an open type ceramic sample pans. Thermo grams are 
obtained by heating the sample at a constant heating rate of 8ºC/minute. A dry purge of Argon 
gas (60ml/min) is used for all runs. Samples heated from 37ºC-400ºC (Malay K Das et al, 2011, 
Indu Pal Kaur et al, 2011, Gurrapu .A et al, 2011). 
11.3  FORMULATION OF ETORICOXIB NIOSOMES 
Different ratios of surfactant and cholesterol are used to prepare niosomes with the 
concentration of the drug being the same. 
The niosome formulations are prepared by thin film hydration technique. The weighed 
amount of cholesterol, non-ionic surfactant (cholesterol: non-ionic surfactant in micromoles) 
dissolved in 5ml of solvent mixture (Chloroform: Methanol 2:1 ratio). It is then transferred to a 
100ml round bottom flask. A thin film is formed under reduced pressure in a rotary flash 
evaporator rotated at 100rpm at 55ºC. 
The organic solvent is evaporated to form a dry film on the walls of the flask. An 
appropriate amount of Etoricoxib dissolved in methanol and add 10 ml phosphate buffered saline 
pH 7.4 and this is added slowly to the round bottom flask having thin film of surfactant and 
cholesterol and vortexed continuously for a period of 45 minutes at 55ºC, until a good dispersion 
of the mixture is obtained (Pratap S. Jadon et al, 2009, Vijay Prakash pandey et al, 2009, Malay 
K Das et al, 2011, Jong Soo Woo et al, 2009). The niosomal dispersion is collected and stored at 
4ºC for maturation.  
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 The empty niosomes also prepared by the same method without the drug for further 
evaluation. 
11.3.1 Drug content  
 
The amount of drug in the formulation is determined after lysing the niosomes using 50% 
n- propanol. 
Niosomes preparation equivalent to 200µg of Etoricoxib (0.1ml) is pipetted out in 100ml 
standard flask. To this sufficient quantity of 50% n- propanol is added and shaken well for the 
complete lysis of the vesicles. The volume is made up to 100 ml with the buffer phosphate 
buffered saline pH 7.4. 
The absorbance is measured at 235nm in the UV-Visible Spectrophotometer (Shimadzu 
UV-1700 Pharma spec Japan) using empty niosomes as blank. 
The drug content is calculated from the standard curve, by using the following formula, 
                                          Sample Absorbance   
            Drug content = × 100. 
                                         Standard Absorbance 
 
11.3.2 Entrapment Efficiency 
 
 Etoricoxib niosome preparations (1 ml) are centrifuged at 14,000 rpm for 120 
minutes at 4ºC using a refrigerated centrifuge (Eppendorf, 5417R, Germany) in order to separate 
niosomes from unentrapped drug. The free drug concentration in supernatant layer after 
centrifugation is determined at 235 nm using UV-Visible Spectrophotometer (Shimadzu              
UV-1700 Pharma spec Japan). The percentage of drug entrapment in niosomes is calculated 
using the following formula. (Vijay Prakash Pandey et al, 2009, Maly K Das et al, 2011, 
Gyanendra Singh et al, 2010). 
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                               (Total drug – Drug in supernatant)  
   % drug entrapment =                      × 100. 
                                                           Total drug 
 
11.3.3 Invitro release studies  
Invitro release pattern of niosomes suspension is carried out by dialysis bag (Himedia 
dialysis membrane (mw 12,000) method. The niosomal preparation of Etoricoxib is placed in a 
dialysis bag with an effective length of 5 cm which acts as a donor compartment. Dialysis bag is 
placed in a beaker containing 250 ml of buffer phosphate buffered saline pH 7.4, which acts as 
receptor compartment. The temperature of receptor medium maintained at 37±1ºC and the 
medium is agitated at 50 rpm speed using magnetic stirrer. Aliquots of 5 ml samples are 
collected at predetermined time and replenished immediately with the same volume of fresh 
buffer phosphate buffered saline pH 7.4 (Pavala Rani et al,2010, Ghada Abdelbary et al,2008, 
Ajay B.Solanki et al,2010, Florence A.T et al, 1994). The sink condition is maintained 
throughout the experiment. The collected samples are analyzed spectrophotometrically at 235 nm 
using UV-Visible Spectrophotometer (Shimadzu UV-1700 Pharma spec Japan). Each study is 
performed in triplicate (Prasun Bandyopadhyay et al, 2007, Manivannan Rangasamy et al, 
2010). 
 
The invitro release studies are also carried out for the pure drug by same method. 
 11.3.4 Invitro release kinetics  
 In general drug release from vesicular system is controlled by various factors such as 
type of non-ionic surfactant, cholesterol content, membrane rigidity and lamellarity. 
To understand the pharmacokinetics and mechanism of drug release, the result of in-vitro 
drug release study of niosomes were fit with various pharmacokinetic equations like zero order 
(cumulative % release vs time), first order (log % drug remaining vs. time), Higuchi's model 
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(cumulative % drug release vs. square root of time), and the Korsmeyer-Peppas (log cumulative 
% drug release vs log time) and Hixson-Crowel models (cubic root of drug remaining vs time). 
The r 2 and k values were calculated for the linear curve obtained by regression analysis of the 
above plots. (Ismail Mouzam et al, 2011, Gyanendra Singh et al, 2010,Abul Kalam Lutful Kabir 
et al.,2009, Harris Shoaib. M et al,2006). 
The data are evaluated according to the following equation.  
• Zero order  - Q = KOt 
• First Order – Log Q = LogQ0-kt / 2.303 
• Higuchi – Qt = KH t½  
• Korsmeyer-Peppas -  Mt M=Kt ∞ / Ktn 
• Hixson – Crowell – Q 1/3 – Qt 1/3 =  
11.4  FORMULATION OF ETORICOXIB NIOSOMAL GEL 
 
On the basis of entrapment efficiency and in-vitro release studies, maximum entrapment 
and sustained release niosomal dispersion is selected for the preparation of topical gel system.   
Carbopol 934, (as a gelling agent in 0.9% w/w concentration) is dispersed in to distilled 
water. The dispersion is allowed to hydrate for 4-5 hours. Niosomes equivalent to 1% w/v of 
Etoricoxib is incorporated in to aqueous dispersion of polymers. The resultant dispersion after 
uniform mixing is neutralized and made viscous by the addition of tri ethanolamine (5% w/v) to 
obtain a translucent gel. (Ajay B.Solanki et al, 2010, Abdul Hasan Sathali et al, 2010). Niosomal 
gels are evaluated for Drug content, pH, Rheological behaviors, Particle size, Zeta potential, 
Transmission electron microscopy, Invitro release, In vivo studies, Stability studies and 
Statistical analysis. 
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11.5 EVALUATION OF THE PREPARED ETORICOXIB NIOSOMAL GEL 
11.5.1 Drug content  
Etoricoxib is extracted from 1gm of each gel formulations with methanol and diluted 
with phosphate buffer saline pH 7.4. The resultant mixture is filtered through membrane filter 
(pore size 0.45 mm). The absorbance of the sample solution is determined by using                   
uv-spectrophotometer at 235 nm (Shimadzu UV‐VIS spectrophotometer) after appropriate 
dilution with phosphate buffer saline (pH 7.4) (Patel R.P et al, 2009). 
11.5.2 pH measurements 
The pH of the gel formulations is determined using a pH meter. This is calibrated before 
each use with buffered solutions at pH 4, 7 and 10.Measurement is performed at1st, 15th and 30th 
day after preparation to detect any pH fluctuations (Abdul Hasan Sathali et al, 2011, Patel R.P            
et al, 2009). 
11.5.3 Rheology studies 
The viscosity of topical niosomal gel formulation is an important factor in determining 
residence time of drug in the skin. The viscosity determinations of prepared formulations are 
carried out using Brookfield DV-111+ Rheometer with spindle LV-3. The prepared system is 
allowed to gel in the STF and then viscosity is measured. The viscosity of samples is measured at 
different angular velocities. A typical run comprised changing angular velocity from 10 to 100 
rpm with equal wait for each rpm. The hierarchy of angular velocity is reversed (100 to 10 rpm) 
with similar wait. The averages of two readings are used to calculate the viscosities of 
formulations (Kapadia et al, 2009, Abdul Hasan Sathali et al, 2010).   
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11.5.4 Particle size 
The vesicle sizes of prepared niosomal formulation composed of Span 60 and Tween 80 
and cholesterol in a 6:1 and 3:1 micro molar ratio were determined by light scattering based on 
laser diffraction using the Malvern master-sizer (Malvern Instrument Ltd, Worcestershire, UK). 
All measurement was conducted at 25ºC (Arunothayam et al, 2000, Zidan.A.S et al, 2011, Xu.X 
et al, 2011). 
11.5.5 Zeta potential  
Zeta potential is measured by using a Malvern ZS 90 zeta-sizer and a folded capillary 
cell. The tests are conducted at 25ºC (Xu.X et al, 2011). The time dependent correlation function 
on the scattered light intensity is measured at a scattering angle of 90ºC (Manosroi.A et al, 2010, 
Phikunthong Kopermsub et al, 2011, Ahmed S. Zidan et al, 2011). 
11.5.6 Transmission electron microscopy  
The prepared niosomal gel formulation is characterized for their morphology using 
transmission electron microscopy (TEM). Briefly, to an small amount of prepared niosomal gel 
formulation, sufficient quantity of 1% phosphotungstic acid is added and mixed gently. A small 
amount of the gel is placed on the carbon coated grid and drained off the excess. The grid was 
allowed to dry and it is observed under transmission electron microscopy. (Hitachi model H-T 
100, Japan) (Pratap S. Jadon et al, 2009, Ammar.O.A et al, 2011, Varaporn Buraphacheep 
Junyaprasert et al, 2008).       
11.5.7 Invitro release studies
 
In-vitro release study is carried out by taking 1 g of gel formulations into dialysis bag and 
placed beaker containing 250 ml PBS pH 7.4 at 37 ± 10˚C. The beaker is placed over a magnetic 
stirrer and stirred at constant speed. Aliquots of samples are withdrawn at specified time 
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intervals and analyzed at 235 nm by using an UV spectrophotometer to determine the percentage 
drug released and replaced with equal volume of fresh PBS pH7.4 (Ajay B Solanki et al, 2010). 
11.5.8 Invitro release kinetics  
To understand the pharmacokinetics and mechanism of drug release, the result of in-vitro 
drug release study of niosomes were fit with various pharmacokinetic equations like zero order 
(cumulative % release vs time), first order (log % drug remaining vs. time), Higuchi's model 
(cumulative % drug release vs. square root of time), and the Korsmeyer-Peppas (log cumulative 
% drug release vs log time) and Hixson-Crowel models (cubic root of drug remaining vs time). 
The r
 2 
and k values were calculated for the linear curve obtained by regression analysis of the 
above plots. 
The data are evaluated according to the following equation.  
• Zero order  - Q = KOt 
• First Order – Log Q = LogQ0-kt / 2.303 
• Higuchi – Qt = KH t½  
• Korsmeyer-Peppas -  Mt M=Kt ∞ / Ktn 
• Hixson – Crowell – Q 1/3 – Qt 1/3   
11.5.9 In vivo anti-inflammatory studies
 
The in-vitro and in vivo studies are carried out and all the study protocols are approved by 
the local institutional Animal Ethical Committee. The anti-inflammatory activity is compared by 
the carrageenam induced rat paw edema method. The studies are conducted on albino rats of 
either sex, weighing 200 ± 20 g. The animals in each group (n = 3) are selected so that the 
average body weight among the groups is as close as possible. Inflammation is produced in the 
rats by injecting 0.1 ml of 1% w/v carrageenam suspension in saline, into the sub-plantar surface 
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of the rats’ left hind paw. Thirty minutes later, 0.5 g niosomal gel formulations and plain gel 
(Drug dispersion in polymers) are applied topically on the edematous paw by gently rubbing 
with an index finger. Topical activity of the various formulations is evaluated by measuring an 
increase in the hind paw thickness with the help of digital calipers before (time 0) and 1, 2, 3, 4, 
5, 6, and 24 h after carrageenam administration. The percentage of paw thickness increase from 
time 0 is calculated and compared with control group (Srikanth.K et al, 2010, Ajay B. Solanki et 
al, 2010, Ambikanandan Misra et al, 2002, Alok Namdeo et al,1999). 
GROUP-1(STANDARD GROUP) 
            Animal were treated with carrageenan 
GROUP-2(STANDARD GROUP) 
Animals were treated with Etoricoxib plain gel 
GROUP-3(TEST GROUP) 
            Animals were treated with Etoricoxib niosomal gel (High entrapment). 
GROUP-4(TEST GROUP) 
           Animals were treated with Etoricoxib niosomal gel (Low entrapment).      
The inhibition percentage of the edema formulation of the test samples were calculated 
and statistically evaluated (p<0.05) according to the following equation 
(Manosroi .A et al, 2008, Eros.I et al, 2005). 
Percentage of edema inhibition=Tc-Tt/Tc×100 
Where  
Tc is the mean edema thickness of rat paw edema control group 
Tt is the mean edema thickness of rat paw in the test sample. 
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11.5.10 Stability studies       
The best formulation of etoricoxib loaded niosomal gel is subjected to stability studies. 
The formulation is stored in two different temperatures, 4
0
C (Refrigerator), 25±2
0
C/60% 
RH±5% RH in an environmental chamber [In lab equipments (Madras) Pvt. Ltd] for the period 
of 3 months ( Indu Pal Kaur et al,2011, Raju Jukanti et al,2011, Abdul Hasan Sathali et al,2010, 
Rathi Jagdish Chandra et al, 2009). The drug content of the formulation is estimated every 
months 
Analysis of variance 
The data are expressed as the mean ± standard deviation are subjected to student t-test 
and one way analysis of variance (ANOVA)  and the significance of difference between 
formulation is calculated by student- newman-keuls ( compare all pairs) with       ( Insat Grap 
pad prism soft ware). The level of statistical significance is chosen as less than p<0.05 (Gurrapu 
et al, 2011, Shyh Darli et al, 2011).   
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CHAPTER- XII 
RESULTS AND DISCUSSION 
 
12.1  STANDARD CURVE FOR ETORICOXIB  
 The λmax of Etoricoxib was determined by scanning the 10µg/ml of drug solution in 
phosphate buffer saline (PBS) pH7.4 and it showed the λmax at 235nm. The λmax of etoricoxib is 
showed as UV graph in Figure 13  
 Calibration curve of Etoricoxib was plotted by measuring the absorbance of different 
concentrations of the drug in phosphate buffer saline (PBS) pH 7.4 at 235 nm. The linear 
correlation co-efficient was obtained for calibration of Etoricoxib in phosphate buffer saline 
(PBS) pH7.4. (K.Srithar et al, 2005). Etoricoxib obeys the beer's law within the concentration 
range of 1 to 10µg/ml. Calibration readings were shown in Table III and the calibration plot of 
etoricoxib were shown in Figure14 
12.2 PREFORMULATION STUDIES 
12.2.1 FT-IR studies 
 FT-IR infra red (FT – IR) spectroscopy was carried out separately to check the 
compatibility between drug, surfactant (Span 20,Span 40,Span 60,Span 80, Tween 60,Tween 80 
and Brij-52) cholesterol  and physical mixture used for the preparation of niosomes.  
 The spectra studied at 4000cm
-1 
 to 400 cm
-1
 were shown in Figure 15 and Table IV. It 
was found from the spectra that there was no major shifting as well as any loss of functional 
peaks in the spectra of drug, surfactant, cholesterol and physical mixture of drug, surfactants and 
cholesterol The results indicated that the selected surfactants and cholesterol were found to be 
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compatible with the selected drug (Gurrapu et al, 2011, Ismail Mouzam et al, 2011, Pandey 
Shivanand et al, 2010). 
12.2.2 Differential scanning calorimetry 
 DSC is a fast and reliable method to screen drug- excipients interactions as indicated by 
appearance of a new peak, change in the peak shape and its onset, peak temperature/melting 
point and relative peak area or enthalpy Figure 16 depicts various DSC thermograms such as 
pure drug, span20, span40, span60, span80, tween60, brij52 and cholesterol obtained during the 
study. Pure etoricoxib showed a sharp endothermic peak at 153º.09ºC.Thermogram of 
span20,span40,span60,tween60,brij52 exhibits an endothermic peak with onset at 160º.51ºC, 
48ºC, 58ºC, 6.33ºC, 172ºC respectively. Tween 80 is reported to show an exothermal peak              
at -43ºC and endothermal peaks were observed at -14ºC (Hillgren et al, 2002, Indu Pal Kaur et 
al, 2011). 
 Further, DSC thermogram suggests that the formulation components Span 20, Span 40 
Span 60, Tween 60, brij-52, cholesterol and the drug etoricoxib do not interact to form any 
additional chemical entity but remain as mixture. 
12.3  FORMULATION OF ETORICOXIB NIOSOMES 
Niosome formulations were formulated by thin film hydration method using different 
surfactants (Span 20, Span 40, Span 60, Span 80, Tween 60, Tween 80, and Brij 52) and 
Cholesterol with different ratios as per the formula given in Table V resulted a stable, uniform 
dispersion of niosomal vesicles (Pratap S. Jadon et al, 2009, Vijay Prakash pandey et al, 2009, 
Malay K Das et al, 2011, Jong Soo Woo et al, 2009). The formation of niosomal vesicle was 
confirmed by Transmission electron microscopy (TEM)  
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        12.3.1 Drug content 
The drug content of the niosomes was determined after lysing the vesicles with 50%             
n-propanol and measured at 235 nm in UV-Visible spectrophotometer 1700, Pharma spec, Japan. 
The drug content was found to be in the range of 97.23% to 99.46%. The results were indicated 
that the uniform distribution of drug in prepared niosomal formulations. The observed results 
were shown in Table VI. 
12.3.2 Entrapment efficiency  
 In niosomal formulations, the impact of surfactant and cholesterol concentration on 
entrapment efficiency was considerably significant. The ranges of entrapment efficiency of 
twenty eight niosomal formulations were observed about 71.6% to 96.9% and are shown in 
Table VI and Figure 17. The highest entrapment efficiency obtained for the formulation prepared 
with F12 Span60 (6:1) (300µmol surfactant and 50µmol cholesterol) was found to be 96.9% may 
be due to surfactant chemical structure (Span series) and having highest phase transition 
temperature.  
Effect of surfactant on entrapment efficiency  
 Formulations F1-F4 were prepared with different ratios of surfactant (Span 20) and 
cholesterol( 3:1,4:1,5:1 and 6:1) showed the entrapment efficiency of 82.7%, 84.9%, 85.8% and 
87.3% respectively. 
 Formulations F5-F8 were prepared with different ratios of surfactant(Span 40)  and 
cholesterol(3:1,4:1,5:1 and 6:1) showed the entrapment efficiency of 86.5%, 87.9%, 88.1% and 
89.2% respectively. 
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Formulations F9-F12 were prepared with different ratios of surfactant (Span 60) and 
cholesterol(3:1,4:1,5:1 and 6:1) showed the entrapment efficiency of 94.6%,95.8%,96.3% and 
96.9% respectively. 
 Formulations F13- F16 were prepared with different ratios of surfactant (Span 80) and 
cholesterol(3:1,4:1,5:1 and 6:1) showed the entrapment efficiency of 77.5%,78.2%,80.8% and 
81.6 % respectively.              
Formulations F17- F20 were prepared with different ratios of surfactant  (Tween 60) and 
cholesterol (3:1, 4:1, 5:1 and 6:1) showed the entrapment efficiency of 75.6%, 77.6%, 78.7% and 
80.9 % respectively.  
Formulations F21- F24 were prepared with different ratios of surfactant (Tween 80) and 
cholesterol (3:1, 4:1, 5:1 and 6:1) showed the entrapment efficiency of 71.4%, 72.9%, 74.1% and 
76.6 % respectively.  
            Formulations F25- F28 were prepared with different ratios of surfactant (Brij-52) and 
cholesterol (3:1,4:1,5:1 and 6:1) showed the entrapment efficiency of 83.6%,85.9%,87.7% and 
89.9 % respectively.   
The entrapment efficiency of various nonionic surfactants increases in the order of  Span 
60 > Span 40 >Span 20 > Brij 52 > Span 80>Tween60 >Tween 80.  
These results explained that the Span 60 has higher entrapment efficiency than other 
Span types and Tween 60, Tween 80 and Brij 52. This can be explained by many facts: a) Span 
60 has the highest phase transition temperature (Yoshioka et al., 1994). (b) The length of alkyl 
chain of surfactant is a crucial factor in permeability. Long Chain surfactant produces high 
entrapment (Hao et al., 2002). Span 60 has a longer saturated alkyl chain (C16) compared to 
Span40 and Span20, so it produces niosomes with higher entrapment efficiency but Span80 has 
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unsaturated alkyl chain (C18) produces less entrapment. c) The longer alkyl chain influences the 
HLB value of the surfactant mixture which by its turn directly influences the drug entrapment 
efficiency (Raja Naresh et al., 1994). The lower the HLB of the surfactant the higher will be drug 
entrapment efficiency. (Guinedi.A.S et al, 2005). 
          In addition, entrapment efficiency for niosomes prepared with Tween 60 was higher than 
that of Tween 80 .This shows that the longer the alkyl chain of the surfactant, the less  drug will 
be entrapped. Tween 80 has a longer saturated alkyl chain than tween 60 and lower entrapment 
efficiency. The length of the alkyl chain influences the hydrophilic- lipophilic balance (HLB) 
value of the surfactant, the lower will be the entrapment efficiency (Ruckmani et al, 2009, Ghada 
Abdelbary et al, 2008, Srikanth.K et al, 2010).  
12.3.3 In vitro Release Studies 
 The in vitro drug release studies of etoricoxib from niosomes were carried out by dialysis 
bag diffusion technique in phosphate buffer saline of pH7.4. 
 The cumulative % drug release at 12 hours was 92.9% for formulation F1 whereas it was 
90 %, 86.4 % and 83.5 %, for formulations F2, F3 and F4, respectively.  
          The cumulative % drug release at 12 hours was 85.3% for formulation F5 whereas it was 
83.6 %, 77.6 %and 74.2 %, for formulations F6, F7 and F8, respectively.  
           The cumulative % drug release at 12 hours was 78.5% for formulation F9 whereas it was 
69.8 %, 62.2 % and 55.3 % for formulations F10, F11 and F12, respectively.  
          The cumulative % drug release at 12 hours was 96.1% for formulation F13 whereas it was 
89.9 %, 87.3 % and 86.0 % for formulations F14, F15 and F16, respectively. 
          The cumulative % drug release at 12 hours was 94.0% for formulation F17 where as it was 
87.5%, 82.7% and 76.4% for formulations F18, F19, and F20 respectively.  
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         The cumulative % drug release at 12 hours was 96.05% for formulation F21 where as it 
was 90.4%, 83.6% and 76.1% for formulations F22, F23 and F24 respectively. 
        The cumulative % drug release at 12 hours was 81.3% for formulation F25 where as it was 
75.3%, 74.1% and 66.7% for formulations F26, F27 and F28 respectively.  
        Significant changes in release were observed upon changing the type of surfactant used in 
the bilayer of etoricoxib niosomes. The results were shown in Table VII a, b, c, d, e, f, g and  
Figure 18 a, b, c, d, e, f, g. 
       The experimental studies showed that the rate of drug release depends on the percentage of 
drug entrapment efficiency. This result was in conformity with the report of (Anand Kumar.A et 
al, 2010, Samar Mansour et al, 2005, Arora Rajnish et al, 2010, Ghada Abdelbary et al, 2008). 
 All niosome formulations showed significant slower release than etoricoxib solution 
(10mg/0.5ml) which showed a release of about 96.6 % within 7 hours. This confirmed that a sink 
condition for etoricoxib release was accomplished and the dialysis bag used in the dissolution 
procedure did not limit etoricoxib release.  Niosomal etoricoxib formulations with Span 60, Span 
40, Brij52, Span 20 Span 80, Tween60 and Tween80 showed significant reduction in in vitro 
drug release in 12hours compared with pure drug in solution. 
Effect of surfactants on the release rate of etoricoxib from niosomes: 
 From the release studies F12 (span 60 6:1) showed   slower and prolonged drug release 
than the other formulations. This can be explained by higher entrapment efficiency (Ruckmani et 
al, 2009) and the fact that niosomes exhibit an alkyl chain length-dependent release (Guinedi. 
A.S et al, 2005). Further the release studies of the prepared formulations containing Span 20, 40, 
80, Tween60, Tween80 and Brij52 were compared.  
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Among the four formulations from F1 to F4 prepared from span 20 at different ratios 
(3:1, 4:1, 5:1, and 6:4) F1 shows maximum drug release in 12 hours. The order of decreasing 
percentage drug release in 12th hour were F1 > F2> F3 > F4. 
Among the four formulations from F5 to F8 prepared from span 40 at different ratios 
(3:1, 4:1, 5:1, and 6:4) F5 shows maximum drug release in 12 hours. The order of decreasing 
percentage drug release in 12
th
 hour were F5 > F6> F7 > F8. 
Among the four formulations from F9 to F12 prepared from span 60 at different ratios 
(3:1, 4:1, 5:1, and 6:1) F9 shows maximum drug release in 12 hours. The order of decreasing 
percentage drug release in 12
th
 hour were F9 > F10> F11 > F12. 
Among the four formulations from F13 to F16 prepared from span 80 at different ratios 
(3:1, 4:1, 5:1, and 6:1) F13 shows maximum drug release in 12 hours. The order of decreasing 
percentage drug release in 12
th
 hour were F13 > F14> F15 > F16. 
Among the four formulations from F17 to F20 prepared from Tween60 at different ratios 
(3:1, 4:1, 5:1, and 6:1) F17 shows maximum drug release in 12 hours. The order of decreasing 
percentage drug release in 12
th
 hour were F17 > F18> F19 > F20. 
Among the four formulations from F21 to F24 prepared from Tween80 at different ratios 
(3:1, 4:1, 5:1, and 6:1) F17 shows maximum drug release in 12 hours. The order of decreasing 
percentage drug release in 12th hour were F21 > F22> F23 > F24. 
Among the four formulations from F25 to F28 prepared from Brij52 at different ratios 
(3:1, 4:1, 5:1, and 6:1) F25 shows maximum drug release in 12 hours. The order of decreasing 
percentage drug release in 12
th
 hour were F25 > F26> F27 > F28. 
The entire amount of loaded drug was not released from the niosomes. This may be due 
to entrapment of the drug in the lipophilic region (Uchebhu.I.F et al, 1998). 
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The comparative release data indicate that, by encapsulation of drug into niosomes, it is 
possible to sustain and control the release of drug for longer duration (Ruckmani et al, 2000, 
Samar Mansour et al, 2005).  
12.3.4 Invitro release kinetics 
          The release constant was calculated from the slope of the appropriate plots and the 
regression coefficient (r
2
) were extrapolated by zero order, first order, Higuchi, Korsmeyer- 
peppas and Hixson- Crowell equations to know the mechanism of drug release from these 
formulations ( F1 to F28).  In this study , the invitro release profiles of drug from the all 
formulations could be best expressed by zero order and Higuchi equation, as the plots showed 
highest linearity (r2=0.977 to =0.998) and (r2=0.896 to=0.978).To confirm the diffusion 
mechanism, the data  were fitted into Korsmeyer-peppas equation. All the formulations showed 
good linearity (r
2
=0.954 to 0.994), with slope (n) values ranging from 0.693 to 0.1.061 indicating 
that diffusion was the predominant mechanism of drug release from these formulations. The 
release profile of etoricoxib from all these formulations displayed very poor fitting with Hixson 
Crowell cube root model drug release ((Kabir et al, 2009, Almira et al, 2001).  The results were 
shown in Figure 19 a, b, c, d, e, f, g and Table VIII a, b, c, d, e, f, g. 
           Among the all formulations was found, that the invitro release of F12 – Span60 (6:1) was 
best explained by higuchi equation, as the plots showed the highest linearity (r2 =0.978), 
followed by zero order (r
2
 =0.989) and first order   (r
2
 =0.958). The Korsmeyer-peppas equation 
indicated good linearity (r
2
 =0.996).The release exponent n was 0.778 which appears to indicate 
a coupling of the diffusion and erosion mechanism-so-called anomalous diffusion and may 
indicate that the drug release is controlled by more than one process. Thus F12 was selected as 
the best for niosomal release of etoricoxib (Gyanendra Singh et al, 2010). 
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           These results pointed to sustained release characteristics with a higuchi pattern of the drug 
release, where niosomes act as reservoir system for continuous delivery of drug. This slow 
release pattern of entrapped drug may indicate the stability of the niosomal formulations (Ismail. 
A. Attia et al, 2007).   
12.4 FORMULATION OF ETORICOXIB NIOSOMAL GEL 
The selected best niosomal formulation (on the basis of highest (F12Span 60, - 6:1) and 
lowest (F21 Tween 80, 3:1) entrapment efficiency among the all formulations) was incorporated 
into suitable gel base (Carbopol 940 as gelling agent 0.9%) to obtain 1% of the drug and plain 
etoricoxib gel was prepared by incorporating the drug into suitable gel base to obtain same 1% of 
the drug. Both the formulas were showed in Table IX a   and IX b. 
12.5 EVALUATION OF THE PREPARED ETORICOXIB NIOSOMAL GEL 
12.5.1 Drug Content 
 The drug content of the prepared gels was determined after lysing the vesicles with 50% 
n- propanol. It was measured at 235 nm at UV-visible spectrophotometer, 1700-pharma spec, 
Japan. The drug content was to be 98.7% for FG12 (span60 6:1) and 99.02% for FG21 (Tween 
80 3:1) respectively. This indicated that the uniform distribution of drug in prepared gel 
formulations. The results were in shown Table X.  
12.5.2 pH measurement 
         The result of pH measurement showed that all  niosomal gel formulations which were 
prepared have the pH range in between 6.9 to 7.0 at  intervals of 0 
 
, 15 ,30 th day respectively 
(Patel. R.P et al, 2009). This is considered acceptable to avoid the risk of irritation upon 
application to the skin (Japan Patel et al, 2011). The results were shown in Table XI.   
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12.5.3 Rheological Studies 
           The viscosity of the selected formulations based on entrapment efficiency and in vitro 
release. The viscosity of all these formulations decreased as the shear rate increased, which 
showed the character of pseudoplastic fluid. 
              Formulation FG-12 showed better pseudoplastic behavior compared to FG-21 
formulations. The formulation FG-12 selected as best formulation compared to that of FG-21 
formulations based on clarity, pH, in vitro release and viscosity. The pseudoplastic behaviors of 
formulations were showed in Table XII. (Abdul Hasan Sathali et al, 2010, Kapadia et al, 2009)  
12.5.4 Particle size  
           The mean particle diameters of topical niosomal gel  composed of Span 60 and 
cholesterol  in a 6:1(FG12) micro molar ratio were 1368nm, while the mean particle diameters of 
topical niosomal  gel  composed of Tween 80 and cholesterol in a 3:1(FG21) micro molar ratio 
were 1206nm. The results reveal that the niosomes prepared using Span 60 was larger in size 
than niosomes prepared using Tween80 due to Span 60 has a longer saturated alkyl chain 
compared to Tween 80 having unsaturated alkyl chain. And it was reported that surfactants with 
longer alkyl chains generally gave larger vesicles. This would account for the higher entrapment 
efficiencies obtained with Span 60 topical niosomal gel. This suggests that when the 
hydrophobicity of the surfactant increases, the vesicle size increases. Similar results were 
observed in (Agarwal et al, 2001, Manosroi.A et al, 2003, Guinedi A.S et al, 2005, Sankar et al, 
2009).The  results were shown Figure 20. 
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12.5.5 Zeta potential studies  
The zeta potential was used to study the surface charge analysis of formulation (FG 12) 
Surfactant and cholesterol in a 6:1 micro molar ratio were found to be-76mV and formulation 
(FG 21) Surfactant and cholesterol in a 3:1 micro molar ratio were found to be-89mV 
respectively. (Vijay Prakash Pandey et al., 2009). Zeta potential values increased with the 
hydrophilicity of the surfactants increased. This could be due to the fact that the surface free 
energy of the span surfactants increases with increased HLB value (Uchegbu et al, 1995). On the 
other hand, increasing the hydrophilicity of the surfactant was associated with a decrease of the 
niosomal size (Zidan A.S et al, 2011).     
12.5.6 Transmission electron microscopy 
         Transmission electron microscopy was performed to study vesicle morphology that 
revealed that niosomes gel were discrete, and had spherical in shape as showed in Figure 21a 
&21b (Pratap S. Jadon et al, 2009, Ammar.O.H et al, 2011, Ismail Mouzam et al, 2011). 
12.5.7 Invitro release studies  
 The in vitro drug release study of etoricoxib niosomal gel was carried out by dialysis bag 
diffusion technique in phosphate buffer saline of pH7.4.   
           The cumulative % drug release at 12 hours was 58.8% for  etoricoxib niosomal gel  
containing (GF12- Span 60 (6:1) , highest entrapment 96.9%) whereas it was 95.1 %, for 
etoricoxib  niosomal gel  containing (GF21- Tween 80 3:1 lowest entrapment 71.46%)  
respectively. The results were shown in Table XIII and Figure 22.  
           The cumulative % drug release at 7 hours was 98.8% for plain etoricoxib gel, when 
compared to niosomal gel GF-12 (58.8%) and GF-21 (95.1%) respectively.   
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              From the results, it was concluded that (GF-12)  etoricoxib niosomal gel showed 
prolong drug release due to the highest entrapment efficiency when compared to that of F-21  
and plain etoricoxib gel (Aliasgar Shahiwala et al, 2002, Malay K. Das et al, 2010, Mahmoud 
Mokhtar et al, 2008, Ajay B. Solanki et al, 2010). 
12.5.8 Invitro release kinetics  
 The amount of drug release from different etoricoxib niosomal gel formulations (GF12 
and GF21)   shows a linear relationship with square root of time. Hence, the drug release rate can 
be expressed by higuchi diffusion model (r
2
=0.979 to 0.944). The high correlation coefficients 
were obtained for the zero order drug release kinetics for etoricoxib niosomal gel was found to 
be (r2=0.990 to 0.991).  The results were shown in Table XIV and Figure23. (Ajay B. Solanki et 
al, 2010). 
 The n value obtained from Korsmeyer – peppas equation found to be 0.634 to 1.309 
which indicate that the formulation GF12 and GF21 showed drug release by Non-Fickian and 
case 2 transport diffusion mechanisms. (Abdul Hasan Sathali et al, 2011).  
12.5.9 Invivo-anti inflammatory studies 
           In vivo anti-inflammatory study was used to evaluate the therapeutic efficacy of a 
niosomal gel formulation. The study was carried out by albino rat using rat paw edema method. 
Niosomal topical gel formulation FG 12 (span60 6:1)23.9% showed sustained reduction in the 
paw thickness for all points of time when compared to that of FG21 (Tween 80 3:1)46.0% and 
59.6% for plain gel. The results were shown in Table XV and Figure 24. Significant differences 
in the decrease in paw thickness among all formulations showed (p<0.05). This result suggested 
that prolonged reduction in the paw thickness due to high drug entrapment and controlled invitro 
drug release (Ajay B. Solanki et al, 2010, Eros I et al, 2005, Abdul Hasan Sathali et al, 2010).     
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12.5.10 Stability studies 
 The percentage drug content of was monitored for etoricoxib niosomal gel formulation 
(FG12) upon storage at refrigerated temperature 4o±2oC and 25oC±60% RH  at accelerated 
stability chamber for a period of 3 months (Abdul Hasan Sathali et al, 2011).  
           The stability studies suggest that the etoricoxib niosomal gel formulations were 
comparatively more stable at refrigerated conditions compared to accelerated temperature. The 
results were shown in Table XV a   and XV b (Gurrapu.A et al., 2011).   
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TABLE III   CALIBRATION OF ETORICOXIB AT 235nm (PBS OF  pH 7.4) 
 
 
S.NO 
 
CONC(µg/ml) 
ABSORBANCE AT 235nm (PBS PH 7.4) AVERAGE 
AND 
STANDARD 
DEVIATION 
 TRIAL-1  TRIAL-2  TRIAL-2 
    1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
1 
  2 
3 
4 
5 
6 
7 
8 
9 
10 
0.073 
0.158 
0.234 
0.293 
O.367 
0.437 
0.498 
0.562 
0.645 
0.718 
0.078 
0.144 
0.236 
0.290 
0.368 
0.438 
0.502 
0.586 
0.650 
0.717 
0.082 
0.166 
0.233 
0.292 
0.370 
0.440 
0.504 
0.581 
0.657 
0.721 
0.077±0.004 
0.156±0.009 
0.234±0.001 
0.291±0.001 
0.368±0.001 
0.438±0.001 
0.501±0.001 
O.576±0.010 
0.650±0.004 
0.718±0.001 
 
n=3* 
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TABLE IV IR PEAKS OF DRUGS, SURFACTANTS, CHOLESTEROL AND PHYSICAL 
MIXTURE OF DRUG, SURFACTANTS AND CHOLESTEROL 
 
S. 
No 
Description Characteristic peaks (cm
-1
) obtained 
1 Etoricoxib 3753.57 , 3438.85, 3057.58 , 2923.70 , 2855.50,2368.48, 1599.25, 
1497.80 , 1431.88  1403.78 ,1299.11, 1144.12 , 1085.54 ,1014.26  
959.44,840.10, 777.91 , 736.14, 636.37 , 582.83,543.67, 492.83, 
464.80  
2 Cholesterol 3402.2,2933.53,2900.74,2867.95,1670.24, 1620.09, 1465.8, 
1440.73, 1375. 15,1274.86, 1236.29, 1191.29, 1164.92, 1134.07, 
1107.06, 1054.99,1022.2,985.56,956.63,927.7,883.34, 838.98, 
800.4,736.76,597.89,501.41. 
3 Span 20 3396.41,2923.88,2852.52,1741.6,1461.94,1375.15,1172.64, 
1110.92, 1076.21,981.7,923.84,881.41,838.98,773.4,723.26,609. 
46.372.24. 
4 Span 40 3379.05,2918.1,2850.59,1735.81,1465.8,1382.87,1288.36, 
1267.74,1245.93,1224.71,1176.5,1091.63, 1056.92, 979.77,883.34, 
811.98, 777.26,721.36. 
5 Span 60 3407.98,2918.1,2850.59,1735.81,1467.65,1380.94, 1265.22, 1244, 
1220.86, 1176.5,1097.5,1056.92, 885.27,721.33. 
6 Span 80 3396.41,2923.88,2854.45,1739.67,1652.88,1461.94,1415.65, 
1377.08,1238.21,1174.57,1110.92,881.41,723.26, 609.26, 376.09. 
7 Physical mixture of 
Drug,  Span 20 and 
Cholesterol 
3754.33, 3400.44, 2926.88 , 2857.09, 2372.15, 1741.85 , 1655.67, 
1023.89 , 458.52  
 
8 Physical mixture of 
Drug,  Span 40 and 
Cholesterol 
3753.76, 3431.95, 2927.29, 2368.35 , 1599.38, 1432.03, 1298.98, 
1144.00, 1020.32, 839.83, 777.96, 582.93, 543.93, 464.19 ,400 
9 Physical mixture of 
Drug,  Span 60 and 
Cholesterol 
3753.84, 3422.05, 2925.65, 2369.42, 1741.78 , 1599.75 , 1431.83, 
1299.50, 1144.57, 1056.22, 839.51, 777.49, 544.10 , 
10 Physical mixture of 
Drug,  Span 80 and 
Cholesterol 
3753.76, 3401.13, 2926.33, 2372.17, 1655.31,  1459.12, 1023.93, 
456.17,400 
11 Physical mixture of 
Drug,  Tween 60 and 
Cholesterol 
3404.46, 2924.91, 2367.85, 1738.42, 1655.09, 1459.65, 1108.39, 
400 
12 Physical mixture of 
Drug,  Tween 80 and 
Cholesterol 
3753.91, 3402.90, 2926.93, 2369.10, 1737.08, 1655.66, 1459.43, 
1351.58, 1107.58,400 
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TABLE V  FORMULATION OF ETORICOXIB NIOSOMES 
 
S.NO FORMULATION SURFACTANT 
RATIO 
SURFACTANT CHOLESTEROL 
1 F1 SPAN 20 3 1 
2 F2 SPAN 20 4 1 
3 F3 SPAN 20 5 1 
4 F4 SPAN 20 6 1 
5 F5 SPAN 40 3 1 
6 F6 SPAN 40 4 1 
7 F7 SPAN 40 5 1 
8 F8 SPAN 40 6 1 
9 F9 SPAN 60 3 1 
10 F10 SPAN 60 4 1 
11 F11 SPAN 60 5 1 
12 F12 SPAN 60 6 1 
13 F13 SPAN 80 3 1 
14 F14 SPAN 80 4 1 
15 F15 SPAN 80 5 1 
16 F16 SPAN 80 6 1 
17 F17 TWEEN 60 3 1 
18 F18 TWEEN 60 4 1 
19 F19 TWEEN 60 5 1 
20 F20 TWEEN 60 6 1 
21 F21 TWEEN 80 3 1 
22 F22 TWEEN 80 4 1 
23 F23 TWEEN 80 5 1 
24 F24 TWEEN 80 6 1 
25 F25 BRIJ-52 3 1 
26 F26 BRIJ-52 4 1 
27 F27 BRIJ-52 5 1 
28 F28 BRIJ-52 6 1 
 
Drug concentration used in each formulation kept as constant 200mg/10ml. 
n=3* 
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TABLEVI  % ENTRAPMENT EFFICIENCY OF DIFFERENT FORMULATIONS 
S.NO FORMULATION SURFACTANT 
RATIO % DRUG 
CONTENT 
% 
ENTRAPMENT SURFACTANT CHOLESTEROL 
1 F1 SPAN 20 3 1 97.54 82.7±0.98 
2 F2 SPAN 20 4 1 99.43 84.9±0.87 
3 F3 SPAN 20 5 1 98.41 85.8±0.12 
4 F4 SPAN 20 6 1 97.86 87.3±0.76. 
5 F5 SPAN 40 3 1 97.65 86.5±0.87 
6 F6 SPAN 40 4 1 98.76 87.9±0.65 
7 F7 SPAN 40 5 1 98.97 88.1±0.88 
8 F8 SPAN 40 6 1 99.09 89.2±0.98 
9 F9 SPAN 60 3 1 99.34 94.6±0.76 
10 F10 SPAN 60 4 1 97.54 95.8±1.09 
11 F11 SPAN 60 5 1 97.86 96.3±0.98 
12 F12 SPAN 60 6 1 99.12 96.9±0.76 
13 F13 SPAN 80 3 1 99.43 77.5±0.56 
14 F14 SPAN 80 4 1 97.56 78.2±0.77 
15 F15 SPAN 80 5 1 98.33 80.8±0.68 
16 F16 SPAN 80 6 1 98.57 81.4±0.99 
17 F17 TWEEN 60 3 1 99.07 75.6±0.56 
18 F18 TWEEN 60 4 1 99.32 77.6±0.99 
19 F19 TWEEN 60 5 1 98.45 78.7±0.68 
20 F20 TWEEN 60 6 1 98.77 80.9±0.95 
21 F21 TWEEN 80 3 1 97.98 71.4±0.56 
22 F22 TWEEN 80 4 1 99.70 72.9±0.54 
23 F23 TWEEN 80 5 1 99.56 74.1±0.44 
24 F24 TWEEN 80 6 1 98.65 76.6±0.76 
25 F25 BRIJ-52 3 1 98.79 83.6±0.87 
26 F26 BRIJ-52 4 1 99.43 85.9±0.88 
27 F27 BRIJ-52 5 1 99.54 87.7±0.99 
28 F28 BRIJ-52 6 1 98.37 89.8±0.77 
n=3* 
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TABLE VIIa   invitro CUMULATIVE % DRUG RELEASE PROFILE OF NIOSOME 
CONTAINING SPAN-20 IN DIFFERENT RATIO 
invitro 
RELEASE 
MEDIUM 
TIME IN 
HOURS 
BATCH CODE(SURFACTANT:CHOLESTEROL RATIO) 
F1(3:1) F2(4:1) F3(5:1) F4(6:1) 
MEAN±SD MEAN±SD MEAN±SD MEAN±SD 
 
 
 
 
 
 
 
 
 
PBS pH 7.4 
0.25 6.0±0.26 3.5±0.41 2.4±0.24 1.8±0.44 
0.50 8.5±0.28 6.5±0.28 5.1±0.46 3.7±0.45 
0.75 10.8±0.36 7.5±0.29 6.9±0.40 5.7±0.32 
1 12.8±0.33 11.7±0.16 9.2±0.36 8.1±0.45 
1.5 16.0±0.49 14.4±0.32 11.2±0.32 10.2±0.28 
2 18.8±0.49 17.3±0.36 13.7±0.36 12.3±0.53 
2.5 22.4±0.40 19.7±0.30 16.3±0.41 14.4±0.40 
3 25.1±0.48 21.9±0.40 18.7±0.41 16.7±0.38 
3.5 28.8±0.40 24.7±0.37 21.5±0.40 19.2±0.24 
4 31.8±0.35 27.4±0.24 24.5±0.49 20.9±0.67 
4.5 34.9±0.35 30.7±0.28 28.4±0.53 23.0±0.53 
5 38.3±0.44 33.2±0.45 31.5±0.73 26.3±0.57 
5.5 41.8±0.45 36.4±0.32 35.2±0.69 29±0.49 
6 45.6±0.52 41.8±0.21 39.6±0.37 33.6±0.28 
6.5 48.9±0.48 44.7±0.37 42.9±0.37 37.3±0.45 
7 52.5±0.41 49.0±0.29 46.4±0.37 40±0.45 
7.5 56.5±0.53 53.0±0.29 49.2±0.58 43.5±1.11 
8 60.3±0.44 56.4±0.29 52.1±0.38 46.9±1.75 
8.5 64.6±0.49 59.7±0.43 55.3±0.57 52.8±1.46 
9 68.8±0.32 63.2±0.28 58.1±0.41 56.4±0.58 
9.5 72.8±0.67 67.2±0.37 61.1±0.21 60.5±0.80 
10 76.9±0.79 70.8±0.37 65.9±0.63 63.9±0.49 
10.5 80.9±0.57 74.7±0.32 71.3±0.49 68.1±0.36 
11 84.8±0.77 79.3±0.49 75.2±0.69 72.9±0.61 
11.5 88.6±0.61 84.3±0.38 80.9±0.41 78.3±0.32 
12 92.9±1.17 90±0.58 86.4±0.62 83.5±1.02 
n=3* 
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TABLE VIIb   invitro CUMULATIVE % DRUG RELEASE PROFILE OF NIOSOME 
CONTAINING SPAN-40 IN DIFFERENT RATIO 
invitro 
RELEASE 
MEDIUM 
TIME IN 
HOURS 
BATCH CODE(SURFACTANT:CHOLESTEROL) 
F5(3:1) F6(4:1) F7(5:1) F8(6:1) 
MEAN±SD MEAN±SD MEAN±SD MEAN±SD 
 
 
 
 
 
 
 
 
 
 
 
 
PBS pH 7.4 
0.25 3.0±0.65 1.9±0.44 1.1±0.16 1.2±0.21 
0.50 5.5±0.43 3.2±0.20 3.1±0.20 2.4±0.24 
0.75 7.8±0.37 4.3±0.41 4.5±0.24 3.4±0.16 
1 9.7±0.33 6.4±0.41 5.8±0.29 5.1±0.24 
1.5 11.9±0.66 8.5±0.21 8.1±0.20 6.4±0.24 
2 14.4±0.50 11.0±0.12 10.4±0.37 8.1±0.46 
2.5 16.7±0.54 13.5±0.40 12.0±0.20 10.2±0.67 
3 18.8±0.55 16.2±0.16 15.1±1.13 12.4±0.38 
3.5 21.6±0.08 19.0±0.24 18.1±0.24 15.0±0.35 
4 24.2±0.43 22.0±0.04 21.1±0.25 17.0±0.36 
4.5 27.1±0.35 24.6±0.32 24.2±0.33 19.7±0.37 
5 30.5±0.62 28.3±0.55 27.9±1.32 22.4±0.40 
5.5 34.5±0.26 30.6±0.33 29.9±0.33 25.5±0.57 
6 39.0±0.72 34.1±0.32 32.2±0.33 28.0±0.16 
6.5 42.3±0.73 37.7±0.50 35.5±0.32 31.6±0.16 
7 45.6±0.67 41.3±0.62 38.4±0.44 35.6±0.16 
7.5 48.7±0.69 45.0±0.45 41.4±0.32 38.1±0.53 
8 51.9±0.44 48.7±0.14 44.4±0.26 41.2±0.28 
8.5 55.3±0.23 52.9±0.42 47.3±0.49 44.7±0.57 
9 58.6±0.16 56.4±0.37 51.3±0.36 47.8±0.57 
9.5 62.4±0.33 60.4±0.32 55.2±0.49 51.8±0.49 
10 67.4±0.47 64.5±0.20 58.9±0.28 55.5±0.42 
10.5 71.5±0.68 68.2±0.86 62.6±1.66 59.5±0.40 
11 76.3±0.37 73.4±0.71 67.4±0.95 64.2±0.28 
11.5 81.7±0.36 76.4±0.71 71.9±0.68 68.8±0.59 
12 85.3±0.46 83.6±0.82 77.6±0.82 74.2±0.75 
 
n=3* 
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TABLE VIIc   invitro CUMULATIVE % DRUG RELEASE PROFILE OF NIOSOME 
CONTAINING SPAN-60 IN DIFFERENT RATIO 
invitro 
RELEASE 
MEDIUM 
 BATCH CODE(SURFACTANT:CHOLESTEROL) 
TIME IN 
HOURS 
 
F9(3:1) F10(4:1) F11(5:1) F12(6:1) 
MEAN±SD MEAN±SD MEAN±SD MEAN±SD 
 
 
 
 
 
 
 
 
 
 
 
 
PBS pH 7.4 
0.25 2.6±0.20 1.7±0.20 1.1±0.21 0.76±0.12 
0.50 4.5±0.16 3.4±0.16 2.1±0.16 1.6±0.24 
0.75 6.7±0.24 5.5±0.29 3.0±0.09 2.4±0.20 
1 9.0±0.36 7.7±0.45 4.7±0.16 3.3±0.24 
1.5 11.4±0.20 9.5±0.14 6.6±0.12 4.6±0.24 
2 13.9±0.20 11.4±0.21 8.4±0.28 6.4±0.16 
2.5 16.5±0.32 13.6±0.21 10.1±0.44 7.7±0.28 
3 19.3±0.37 16.4±0.24 12.1±0.37 9.7±0.28 
3.5 22.8±0.26 18.3±0.12 14.3±0.16 11.6±0.32 
4 26.1±0.26 20.4±0.36 16.7±0.18 13.6±0.35 
4.5 29.5±0.20 23.3±0.28 18.9±0.26 15.8±0.49 
5 32.7±0.24 26.0±0.26 21.3±0.21 18.1±0.40 
5.5 35.5±0.12 28.9±0.33 24.0±0.16 20.5±0.21 
6 39.2±0.63 31.7±0.20 26.3±0.20 22.7±0.32 
6.5 41.6±0.44 34.5±0.21 28.8±0.32 25.0±0.24 
7 44.3±0.41 37.3±0.33 31.5±0.26 27.2±0.24 
7.5 47.6±0.14 40.2±0.46 33.9±0.98 29.9±0.63 
8 51.1±0.24 43.1±0.41 36.4±0.33 32.5±0.54 
8.5 54.9±0.44 45.8±0.24 39.1±0.26 34.8±0.62 
9 58.2±0.64 49.0±0.16 41.6±0.26 37.6±0.49 
9.5 61.7±0.70 52.3±0.28 44.6±0.36 41.0±0.30 
10 66.0±0.94 55.3±0.20 47.2±0.16 43.7±0.45 
10.5 69.5±1.06 58.9±0.20 50.7±0.20 46.2±0.44 
11 72.9±1.20 62.8±0.31 54.5±0.12 49.5±0.45 
11.5 75.9±1.26 66.2±0.42 57.4±0.97 53.0±0.32 
12 78.5±1.16 69.8±0.21 62.2±0.41 55.3±1.02 
 
n=3* 
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TABLE VIId   invitro CUMULATIVE % DRUG RELEASE PROFILE OF NIOSOME 
CONTAINING SPAN-80 IN DIFFERENT RATO 
invitro 
RELEASE 
MEDIUM 
 BATCH CODE(SURFACTANT:CHOLESTEROL) 
TIME IN 
HOURS 
F13(3:1) F14(4:1) F15(5:1) F16(6:1) 
MEAN±SD MEAN±SD MEAN±SD MEAN±SD 
 
 
 
 
 
 
 
 
 
 
 
 
PBS pH 7.4 
0.25 6.0±0.33 4.8±0.26 4.1±0.24 2.3±0.75 
0.50 9.3±0.32 6.8±0.30 5.7±0.32 4.6±0.20 
0.75 12.1±0.14 9.2±0.21 8.0±0.08 7.8±0.35 
1 15.2±0.35 11.1±0.20 9.9±0.36 9.3±0.16 
1.5 18.1±0.16 13.7±0.24 13.0±0.09 12.0±0.28 
2 21.0±0.32 13.7±0.24 15.5±0.21 14.7±0.20 
2.5 23.9±0.37 16.2±0.16 17.0±0.35 16.7±0.63 
3 27.1±0.28 17.7±0.43 20.1±0.28 19.1±0.58 
3.5 29.9±0.32 21.2±0.21 23.0±0.36 22.0±0.38 
4 32.8±0.36 23.8±0.12 25.3±0.37 24.0±0.23 
4.5 35.8±0.12 26.3±0.16 28.0±0.28 27.0±0.44 
5 39.0±0.16 28.9±0.12 30.8±0.18 29.4±0.57 
5.5 42.2±0.50 33.9±0.29 33.4±0.09 32.5±0.69 
6 46.2±0.37 34.7±0.83 35.8±0.21 35.3±0.37 
6.5 50.1±0.26 36.6±0.29 38.9±0.20 37.5±0.28 
7 54.3±0.26 40.3±0.24 42.1±0.85 40.3±0.17 
7.5 57.9±0.16 43.9±0.20 46.0±0.87 43.6±0.23 
8 64.4±0.28 47.1±0.35 50.5±1.40 48.5±0.19 
8.5 68.1±0.36 51.0±0.14 55.0±1.06 52.4±0.16 
9 71.9±0.16 55.4±0.16 60.2±0.69 57.1±0.41 
9.5 76.0±0.21 59.9±0.46 64.0±0.92 61.0±0.47 
10 80.4±0.16 64.5±0.24 68.2±0.67 66.2±0.48 
10.5 84.6±0.18 69.7±0.33 73.8±1.24 70.9±0.69 
11 89.0±0.04 74.1±0.12 78.2±1.20 75.7±0.36 
11.5 92.2±0.24 83.8±0.38 83.0±0.61 80.4±0.20 
12 96.1±0.35 89.9±0.26 87.3±0.94 86.0±0.37 
 
n=3* 
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TABLE VIIe    invitro CUMULATIVE % DRUG RELEASE PROFILE OF NIOSOME 
CONTAINING TWEEN-60 IN DIFFERENT RATIO 
invitro 
RELEASE 
MEDIUM 
 BATCH CODE(SURFACTANT:CHOLESTEROL) 
TIME IN 
HOURS 
F17(3:1) F18(4:1) F19(5:1) F20(6:1) 
MEAN±SD MEAN±SD MEAN±SD MEAN±SD 
 
 
 
 
 
 
 
 
 
 
 
 
PBS pH 7.4 
0.25 6.1±0.28 5.2±0.24 5.0±0.12 3.9±0.16 
0.50 8.3±0.21 6.0±0.16 6.1±0.12 5.1±0.16 
0.75 10.2±0.12 8.4±0.24 7.8±0.24 6.8±0.73 
1 12.4±0.08 10.4±0.16 9.8±0.08 8.7±0.12 
1.5 15.0±0.16 11.4±0.69 11.3±0.01 10.3±0.12 
2 17.5±0.16 14.3±0.16 13.9±.16 12.1±0.12 
2.5 20.0±0.28 16.4±0.16 15.8±0.08 14.1±0.20 
3 23.2±0.28 18.7±0.26 17.9±0.29 16.5±0.24 
3.5 27.0±0.16 21.3±0.17 20.4±0.16 18.3±0.16 
4 29.9±0.32 23.9±0.21 22.5±0.12 20.5±0.16 
4.5 33.7±0.28 26.6±0.94 24.7±0.12 22.8±0.20 
5 36.1±0.24 29.1±0.09 26.8±0.21 25.0±0.16 
5.5 39.8±0.29 32.4±0.16 29.4±0.16 27.2±0.16 
6 42.0±0.41 35.6±0.18 32.7±0.18 29.7±0.12 
6.5 46.0±0.32 38.8±0.29 36.1±0.21 32.8±0.41 
7 49.6±0.44 42.2±0.36 38.2±0.16 35.5±0.26 
7.5 53.6±0.41 46.8±0.16 41.5±0.08 38.6±0.29 
8 57.4±0.15 51.5±0.08 44.5±0.24 41.4±0.169 
8.5 61.4±0.24 56.8±0.20 48.3±0.24 44.8±0.12 
9 65.9±0.38 61.1±0.23 52.5±0.14 48.4±0.28 
9.5 70.4±0.16 65.3±0.30 56.5±0.04 52.0±0.08 
10 75.5±0.67 70.5±0.14 61.5±0.28 55.9±0.16 
10.5 80.3±0.47 75.6±0.09 66.5±0.28 60.9±0.16 
11 85.03±0.47 78.7±.30 71.6±0.29 65.3±0.29 
11.5 87.1±0.74 83.2±0.16 76.5±0.53 70.2±0.70 
12 94.0±0.41 87.5±0.04 82.7±1.11 76.4±0.16 
 
n=3* 
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TABLE VIIf    invitro CUMULATIVE % DRUG RELEASE PROFILE OF NIOSOME 
CONTAINING TWEEN-80 IN DIFFERENT RATIO 
invitro 
RELEASE 
MEDIUM 
 BATCH CODE(SURFACTANT:CHOLESTEROL) 
TIME IN 
HOURS 
F21(3:1) F22(4:1) F23(5:1) F24(6:1) 
MEAN±SD MEAN±SD MEAN±SD MEAN±SD 
 
 
 
 
 
 
 
 
 
 
 
 
PBS pH 7.4 
0.25 6.8±0.24 5.9±0.32 4.5±0.24 3.8±0.16 
0.50 8.9±0.24 8.2±0.20 6.3±0.20 5.4±0.12 
0.75 12.5±0.47 10.2±0.29 8.0±0.12 7.0±0.32 
1 14.8±0.61 11.4±0.24 10.0±0.16 8.7±0.24 
1.5 17.8±0.54 14.1±0.28 12.2±0.20 10.4±0.32 
2 21.0v0.83 15.8±0.18 14.1±0.20 12.4±0.16 
2.5 24.1±0.73 17.9±0.30 16.3±0.14 14.2±0.16 
3 27.3±0.53 20.9±0.86 18.5±0.14 16.0±0.12 
3.5 29.9±0.49 23.9±0.53 21.0±0.12 18.6±0.21 
4 32.2±1.02 26.7±0.46 23.4±0.21 21.1±0.23 
4.5 35.1±0.52 29.6±0.49 25.8±0.16 23.3±0.21 
5 38.7±0.57 32.5±0.91 29.0±0.20 25.9±0.16 
5.5 41.6±0.54 35.4±0.30 31.4±0.11 28.5±0.30 
6 44.9±0.49 39.8±0.73 34.1±0.12 31.2±0.16 
6.5 48.1±0.50 43.2±0.89 38.0±0.20 33.5±0.12 
7 51.2±0.63 46.4±0.74 41.5±0.16 36.4±0.12 
7.5 54.7±0.57 50.2±1.06 46.2±0.16 39.3±0.32 
8 58.3±0.89 54.8±1.06 50.4±0.11 42.5±0.29 
8.5 62.5±0.97 57.8±0.61 54.8±0.26 45.8±0.21 
9 66.8±1.11 61.7±0.83 59.2±0.28 48.7±0.32 
9.5 72.0±0.61 66.7±0.63 64.1±0.32 52.7±0.98 
10 77.6±0.81 70.80.55 68.3±0.32 58.6±0.18 
10.5 82.2±0.50 76.0±0.92 73.1±0.08 62.7±0.30 
11 88.3±0.50 79.5±0.50 76.5±0.16 66.9±0.36 
11.5 92.4±0.36 85.2±0.95 80.2±0.20 71.9±0.36 
12 96.0±0.42 90.4±1.09 83.6±0.57 76.1±0.23 
 
n=3* 
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TABLE VIIg    invitro CUMULATIVE% DRUG RELEASE PROFILE OF NIOSOME 
CONTAINING BRIJ-52 IN DIFFERENT RATIO 
invitro 
RELEASE 
MEDIUM 
 BATCH CODE(SURFACTANT:CHOLESTEROL) 
TIME IN 
HOURS 
F25(3:1) F26(4:1) F27(5:1) F28(6:1) 
MEAN±SD MEAN±SD MEAN±SD MEAN±SD 
 
 
 
 
 
 
 
 
 
 
 
 
PBS PH 7.4 
0.25 5.1±0.04 4.1±0.24 3.4±0.46 2.9±0.17 
0.50 7.0±0.16 6.0±0.16 4.0±0.24 4.2±0.28 
0.75 8.7±0.24 7.6±0.16 6.3±0.31 5.8±0.37 
1 10.9±0.12 9.6±0.24 7.9±0.46 7.5±0.36 
1.5 13.4±0.16 11.3±0.62 9.9±0.52 8.9±0.66 
2 15.5±0.08 13.6±0.32 11.9±0.60 10.8±0.33 
2.5 17.5±0.21 16.0±0.36 13.9±0.46 12.2±0.06 
3 20.8±0.20 17.7±0.44 15.8±0.36 14.5±0.07 
3.5 23.3±0.16 19.4±0.33 17.8±0.42 16.4±0.15 
4 26.1±0.23 22.8±0.20 19.8±0.56 18.4±0.46 
4.5 29.0±0.16 25.8±0.20 22.1±0.71 20.0±0.39 
5 32.3±0.18 27.0±0.16 24.3±0.33 22.4±0.99 
5.5 34.6±0.29 30.2±0.14 27.6±0.48 24.7±0.16 
6 37.4±0.17 32.4±0.14 31.06±0.42 27.7±0.16 
6.5 40.2±0.36 35.8±0.17 35.3±0.51 29.2±0.12 
7 43.3±0.272 38.7±0.46 37.7±0.66 31.2±0.18 
7.5 47.4±0.96 41.4±0.17 40.0±0.43 34.0±0.19 
8 50.4±0.26 44.7±0.26 43.3±0.51 36.0±0.09 
8.5 53.9±0.47 48.9±0.21 46.6±0.28 39.6±0.10 
9 56.2±0.16 51.5±0.12 49.8±0.33 42.0±0.10 
9.5 61.0±0.65 55.2±0.02 53.4±0.16 44.0±0.24 
10 65.7±0.72 59.2±0.12 57.4±0.06 49.3±0.51 
10.5 68.3±0.16 62.0±0.17 61.3±0.06 53.4±0.21 
11 72.3±0.12 66.9±0.27 64.5±0.16 57.9±0.36 
11.5 76.4±0.17 71.2±0.16 68.8±0.19 62.3±0.52 
12 81.3±0.16 75.3±0.14 74.1±0.86 66.7±0.12 
 
n=3* 
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TABLE V111a  invitro RELEASE KINETICS OF ETORICOXIB NIOSOMES CONTAINING SPAN-20 IN DIFFERENT 
RATIO 
FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGUCHI MODEL 
KORSMEYER-
PEPPAS 
HIXSON-
CROWELL 
SPAN-20 R
2
 KO
(h-1)
 R
2
 K1
(h-1)
 R
2
 KH 
h(-1/2)
 R
2
 n value R
2
 KHC
(h-1/3)
 
F1 (3:1) 0.991 6.741 0.896 -0.058 0.928 27.29 0.980 0.929 0.921 -0.161 
F2 (4:1) 0.994 6.965 0.880 -0.064 0.942 27.39 0.978 0.860 0.939 -0.174 
F3 (5:1) 0.993 6.749 0.891 -0.057 0.947 27.41 0.986 0.949 0.942 -0.160 
F4 (6:1) 0.983 6.612 0.885 -0.053 0.911 26.59 0.973 0.990 0.929 -0.152 
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TABLE VIIIb  invitro RELEASE KINETICS OF ETORICOXIB NIOSOMES CONTAINING SPAN-40 IN DIFFERENT 
RATIO 
 
FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGUCHI MODEL 
KORSMEYER-
PEPPAS 
HIXSON-
CROWELL 
SPAN-40 R
2
 KO
(h-1)
 R
2
 K1
(h-1)
 R
2
 KH 
h(-1/2)
 R
2
 n value R
2
 KHC
(h-1/3)
 
F5 (3:1) 0.991 6.741 0.896 -0.058 0.949 27.17 0.985 0.849 0.941 -0.161 
F6 (4:1) 0.989 6.695 0.899 -0.053 0.921 27.06 0.991 1.068 0.941 -0.153 
F7 (5:1) 0.991 6.156 0.917 -0.045 0.933 24.92 0.994 1.061 0.951 -0.134 
F8 (6:1) 0.983 5.970 0.913 -0.042 0.905 23.98 0.987 1.140 0.943 -0.126 
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Table VIII c   invitro RELEASE KINETICS OF ETORICOXIB NIOSOMES CONTAINING SPAN-60 AT DIFFERENT 
RATIO 
FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGUCHI MODEL 
KORSMEYER-
PEPPAS 
HIXSON-
CROWELL 
SPAN-60 R
2
 KO
(h-1)
 R
2
 K1
(h-1)
 R
2
 KH 
h(-1/2)
 R
2
 n value R
2
 KHC
(h-1/3)
 
F9 (3:1) 0.998 6.426 0.949 -0.051 0.953 26.27 0.992 0.922 0.974 -0.147 
F10 (4:1) 0.995 5.581 0.951 -0.039 0.938 22.69 0.986 0.938 0.971 -0.117 
F11 (5:1) 0.992 4.984 0.955 -0.031 0.929 20.19 0.994 0.961 0.971 -0.099 
F12 (6:1) 0.989 4.622 0.958 -0.027 0.998 26.23 0.996 0.878 0.971 -0.088 
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TABLE VIII d  invitro RELEASE KINETICS OF ETORICOXIB NIOSOMES CONTAINING SPAN-80 AT DIFFERENT 
RATIO 
 
FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGUCHI MODEL 
KORSMEYER-
PEPPAS 
HIXSON-
CROWELL 
SPAN-80 R
2
 KO
(h-1)
 R
2
 K1
(h-1)
 R
2
 KH 
h(-1/2)
 R
2
 n value R
2
 KHC
(h-1/3)
 
F13 (3:1) 0.994 7.476 0.834 -0.088 0.941 30.43 0.974 0.795 0.922 -0.214 
F14 (4:1) 0.982 6.781 0.843 -0.062 0.909 27.31 0.970 0.872 0.908 -0.169 
F15 (5:1) 0.982 6.771 0.865 -0.060 0.910 27.27 0.973 0.902 0.919 -0.165 
F16 (6:1) 0.981 6.602 0.865 -0.056 0.910 27.12 0.975 0.913 0.918 -0.157 
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TABLE VIII e  invitro RELEASE KINETICS OF ETORICOXIB NIOSOMES CONTAINING TWEEN-60 AT 
DIFFERENT RATIO 
FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGUCHI MODEL 
KORSMEYER-
PEPPAS 
HIXSON-
CROWELL 
TWEEN-60 R
2
 KO
(h-1)
 R
2
 K1
(h-1)
 R
2
 KH 
h(-1/2)
 R
2
 n value R
2
 KHC
(h-1/3)
 
F17 (3:1) 0.992 7.200 0.837 -0.074 0.929 27.31 0.979 0.859 0.917 -0.192 
F18 (4:1) 0.980 6.920 0.870 -0.062 0.900 27.75 0.954 0.783 0.920 -0.169 
F19 (5:1) 0.973 6.128 0.862 -0.049 0.899 23.34 0.956 0.752 0.910 -0.141 
F20 (6:1) 0.975 5.678 0.889 -0.041 0.896 22.77 0.966 0.784 0.926 -0.123 
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TABLE VIII f  invitro RELEASE KINETICS OF ETORICOXIB NIOSOMES CONTAINING TWEEN-80 AT 
 DIFFERENT RATIO 
FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGUCHI MODEL 
KORSMEYER-
PEPPAS 
HIXSON-
CROWELL 
SPAN-80 R
2
 KO
(h-1)
 R
2
 K1
(h-1)
 R
2
 KH 
h(-1/2)
 R
2
 n value R
2
 KHC
(h-1/3)
 
F21 (3:1) 0.988 7.201 0.791 -0.088 0.929 29.21 0.976 0.693 0.892 -0.204 
F22 (4:1) 0.982 6.677 0.893 -0.056 0.934 26.82 0.963 0.786 0.932 -0.159 
F23 (5:1) 0.982 6.677 0.893 -0.054 0.904 26.89 0.959 0.792 0.941 -0.147 
F24 (6:1) 0.978 5.797 0.896 -0.043 0.900 23.27 0.967 0.788 0.931 -0.127 
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TABLE VIIIg   invitro RELEASE KINETICS OF ETORICOXIB NIOSOMES CONTAINING BRIJ-52 IN DIFFERENT 
RATIO 
FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGUCHI MODEL 
KORSMEYER-
PEPPAS 
HIXSON-
CROWELL 
BRIJ-52 R
2
 KO
(h-1)
 R
2
 K1
(h-1)
 R
2
 KH 
h(-1/2)
 R
2
 n value R
2
 KHC
(h-1/3)
 
F25 (3:1) 0.993 6.212 0.935 -0.045 0.935 25.22 0.976 0.740 0.955 -0.144 
F26 (4:1) 0.988 5.763 0.923 -0.043 0.904 26.82 0.963 0.786 0.932 -0.159 
F27 (5:1) 0.986 5.761 0.924 -0.041 0.914 23.21 0.973 0.825 0.951 -0.124 
F28 (6:1) 0.977 5.000 0.915 -0.033 0.901 20.10 0.975 0.810 0.941 -0.102 
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TABLE IX a  COMPOSITION OF ETORICOXIB PLAIN GEL 
 
SL. NO INGREDIENTS FOR 50 G 
1. Carbopol 934 0.9g 
2. Triethanolamine 0.5 ml 
3. Water 50 ml 
4. Drug (ETORICOXIB) 500 mg 
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TABLE IX b  COMPOSITION OF ETORICOXIB NIOSOMAL GEL  
 
SL. NO INGREDIENTS FOR 50 G 
1. Carbopol 934 0.9g 
2. Triethanolamine  0.5 ml 
3. Water  50 ml 
4. Etoricoxib Niosomes 25 ml 
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TABLE X DRUG CONTENT OF ETORICOXIB NIOSOMAL GEL 
 
S.NO FORMULATION % DRUG CONTENT 
1 FG12(SPAN 60) 6:1 98.70 
2 FG21(TWEEN80) 3:1 99.02 
3 PLAIN ETORICOXIB GEL 98.88 
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TABLE XI   APPEARANCE, CLARITY AND pH OF FORMULATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FORMULATIONS 
 
 
APPEARANCE 
 
CLARITY 
 
pH 
at 0 day 
 
pH 
at 15 th 
day 
 
pH 
at 30 th 
day 
Plain gel Colourless Clear 7.0 6.9 6.9 
FG12 SPAN60 
(6:1) 
Colourless Clear 6.9 6.9 6.9 
FG21 TWEEN 80 
(3:1) 
Colourless Clear 7.0 7.0 7.0 
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TABLE XII RHEOLOGICAL EVALUATION OF NIOSOMAL GEL 
FORMULATIONS 
S.NO RPM VISCOSITY IN CPS 
FG12 FG21 
1 0.1 54888 44091 
2 0.5 11937 9178 
3 1.0 5699 4499 
4 5.0 1188 935 
5 10.0 666 542 
6 20.0 415 325 
7 50.0 202 172 
8 100 132 114 
 
n=3* 
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TABLE XIII    COMPARISON OF invitro CUMULATIVE % DRUG RELEASE 
PROFILE OF PLAIN GEL AND NIOSOMEL GEL CONTAINING 
HIGH ENTRAPMENT AND LOW ENTRAPMENT  
invitro 
RELEASE 
MEDIUM 
 BATCH CODE(SURFACTANT:CHOLESTEROL) 
TIME IN 
HOURS 
FG12 (6:1):( H.E) FG21 (3:1):( L.E) PLAIN GE;L 
MEAN±SD MEAN±SD MEAN±SD 
 
 
 
 
 
 
 
 
 
 
 
 
PBS pH 7.4 
0.25 0.89±0.36 7.0±0.41 9.2±0.16 
0.50 1.58±0.42 8.8±0.28 17.6±0.16 
0.75 2.7±0.51 11.9±0.28 22.9±0.46 
1 3.5±0.65 15.6±0.36 30.4±0.32 
1.5 4.4±0.73 19.5±0.41 36.1±0.28 
2 5.8±0.21 23.4±0.57 41.2±0.73 
2.5 7.1±0.33 26.1±0.72 45.0±0.87 
3 8.9±0.49 29.4±0.86 51.9±0.96 
3.5 12.7±0.51 31.5±0.73 57.1±0.21 
4 14.5±0.21 34.8±0.16 62.5±0.16 
4.5 16.9±0.38 39.4±0.28 69.1±0.71 
5 17.8±0.16 42.6±0.63 76.7±0.71 
5.5 23.7±0.29 45.4±0.45 80.5±0.86 
6 28.5±0.38 47.9±0.41 90.9±0.93 
6.5 30.9±0.45 49.2±0.67 95.1±0.16 
7 32.2±0.21 52.4±0.17 98.8±0.58 
7.5 35.5±0.16 55.8±0.46  
8 36.7±0.43 59.3±0.71  
8.5 39.3±0.26 62.8±0.21  
9 42.2±0.21 66.5±0.48  
9.5 45.1±0.86 71.2±0.51  
10 48.4±0.21 76.1±0.49  
10.5 49.7±0.86 83.1±0.53  
11 53.1±0.16 88.9±0.51  
11.5 55.4±0.93 92.1±0.48  
12 58.8±0.86 95.1±0.37  
 
n=3*  
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TABLE XIV  invitro RELEASE KINETICS OF ETORICOXIB NIOSOMAL GEL CONTAININ FG12, FG21 AND PURE 
DRUG AT DIFFERENT RATIO 
 
FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGUCHI MODEL 
KORSMEYER-
PEPPAS 
HIXSON-
CROWELL 
BRIJ-52 R
2
 KO
(h-1)
 R
2
 K1
(h-1)
 R
2
 KH 
h(-1/2)
 R
2
 n value R
2
 KHC
(h-1/3)
 
FG12(6:1) 0.991 5.080 0.971 -0.031 0.979 20.59 0.992 1.309 0.971 -0.099 
FG21(3;1) 0.990 7.035 0.813 -0.813 0.944 28.85 0.979 0.765 0.904 -0.200 
PURE DRUG 0.990 12.53 0.794 -0.204 0.980 40.65 0.977 0.634 0.929 -0.428 
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TABLE XV  COMPARISON OF % INHIBITION OF RAT PAW EDEMA USING 
PLAIN ETORICOXIB GEL, NIOSOMAL GEL CONTAINING FG12 
AND FG21 
S.NO 
TIME IN 
HOURS 
STANDARD 
MEAN±SD 
TEST-1 HIGH 
ENTRAPMENT(FG12) 
MEAN±SD 
TEST-2 LOW 
ENTRAPMENT(FG21) 
MEAN±SD 
1 1 28.2±0.72 16.9±0.82 27.7±0.70 
2 2 28.9±0.82 19.9±0.98 28.4±0.78 
3 3 34.8±0.52 18.1±0.68 31.2±0.70 
4 4 39.8±0.50 19.1±0.46 37.3±0.56 
5 5 49.0±0.52 19.4±0.69 38.9±0.48 
6 6 51.7±0.44 21.2±0.62 44.5±0.32 
7 24 59.6±0.30 23.9±0.46 46.0±0.52 
 
n=3* 
ONE WAY ANALYSIS OF VARIANCE (ANOVA) 
COMPARSION 
GROUP 
TIME INTERVALS 
1
st
  HOUR 3
th
HOUR 6
th
 HOUR 24
th
HOUR 
STD vs FG12  *** P<0.001 *** P<0.001 *** P<0.001 *   P<0.05 
STD vs FG21 *** P<0.001 *** P<0.001 *** P<0.001 *** P<0.001 
FG12 vs FG12 *** P<0.001 *** P<0.001 *** P<0.001 *** P<0.001   
 
n=3*  
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TABLE XVI a  STABILITY STUDY ON ETORICOXIB CONTENT IN NIOSOMAL 
FORMULATION (FG12) FOR 3 MONTHS OF STORAGE PERIOD  
REFRIGERATOR 
TEMPERATURE 
TIME OF STORAGE 
IN MONTHS 
DRUG CONTENT* 
 
4
0
C 
0 98.62±0.23 
1 98.57±0.66 
2 98.23±0.25 
3 98.08±0.22 
 
                        n=3*
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TABLE 16 b  STABILITY STUDY ON ETORICOXIB CONTENT IN NIOSOMAL 
FORMULATION (FG12) FOR 3 MONTHS OF STORAGE PERIOD 
REFRIGERATOR 
TEMPERATURE 
TIME OF STORAGE 
IN MONTHS 
DRUG CONTENT* 
 
4
0
C 
0 98.62±0.23 
1 94.57±0.66 
2 89.23±0.25 
3 86.08±0.22 
 
n=3* 
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Figure 13 Determination of λmax of Etoricoxib 
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Figure 14 Calibration of Etoricoxib at Pbs of  pH7.4 
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15(a) Etoricoxib 
 
15(b) CHOLESTEROL 
 
 
Figure 15a   FT-IR spectra are as follows-(a) Etoricoxib (b) cholesterol 
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15(c) SPAN 20 
 
15(d) SPAN 40 
 
 
Figure 15b   FT-IR spectra are as follows-(c) Span20, (d) Span40 
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15(e) SPAN 60 
 
15(f) SPAN 80 
 
Figure 15c   FT-IR spectra are as follows-(e) Span60, (f) Span80 
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15(g) SPAN 20 + DRUG + CHOLESTEROL 
 
15(h) SPAN 40 + DRUG + CHOLESTEROL  
 
Figure 15d    FT-IR spectra are as follows (g) Span 20 + Drug + Cholesterol, (h) Span     
 40 + Drug + Cholesterol  
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15(i) SPAN 60 +DRUG + CHOLESTEROL 
 
15(j) SPAN 80 + DRUG + CHOLESTEROL 
 
Figure 15e    FT-IR spectra are as follows (i) Span 60 + Drug + Cholesterol, (j) Span80 
+ Drug + Cholesterol  
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15(k) TWEEN 60 + DRUG + CHOLESTEROL 
 
15(l) TWEEN 80 + DRUG + CHOLESTEROL 
 
Figure 15f    FT-IR spectra are as follows (k) Tween 60 + Drug + Cholesterol, (l) 
Tween80 + Drug + Cholesterol  
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16(a) ETORICOXIB 
 
16(b) CHOLESTEROL 
 
Figure 16a DSC Thermogram is as follows-(a) Etoricoxib (b) Cholesterol 
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16(c) SPAN 20 
 
16(d) SPAN 40 
 
 
Figure 16b DSC Thermogram is as follows-(c) Span20 (d) Span40 
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16(e) SPAN 60 
 
16(f) TWEEN 60 
 
 
Figure 16c DSC Thermogram is as follows-(e) Span60 (f)Tween60 
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16(g) BRIJ-52 
 
16(h) SPAN 20+ DRUG+CHOLESTEROL 
 
 
Figure 16d DSC Thermogram is as follows-(g) Brij-52(h) Span 20+ Drug +Cholesterol 
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16(i) SPAN 40 +DRUG+CHOLESTEROL 
 
 
16(j) SPAN 60+DRUG+CHOLESTEROL
 
Figure 16 e DSC Thermogram are as follows-(I) Span 40 +Drug+ Cholesterol (J) Span 
60+Drug+Cholesterol 
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16(k) BRIJ-52+ DRUG+ CHOLESTEROL 
 
 Figure 16f   DSC Thermogram are as follows- (K) Brij-52+ Drug+ Cholesterol 
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Figure 17 Comparison of Percentage Entrapment Efficiency of Different Surfactant in Different Ratios 
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Figure 18a Comparison of Invitro Release of Niosomes Containing Span20 in Different Ratio 
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Figure 18b Comparison of invitro release of niosomes containing span40 in different ratio 
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Figure 18 c Comparison of Invitro Release of Niosomes Containing Span60 In Different Ratio 
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Figure18d Comparison of Invitro Release of Niosomes Containing Span80 in Different Ratio 
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Figure 18 e Comparison of Invitro Release of Niosomes Containing Tween60 in Different Ratio 
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Figure18f   Comparison of Invitro Release of Niosomes Containing Tween80 inDifferent Ratio 
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Figure 18g Comparison of Invitro Release of Niosomes Containing Brij-52 in Different Ratio 
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COMPARISION OF INVITRO ZERO ORDER RELEASE KINETICS OF SPAN-20 AT DIFFERENT RATIO
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COMPARISION OF INVITRO FIRST ORDER RELEASE KINETICS OF SPAN-20 AT DIFFERENT
RATIO
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COMPARISION OF INVITRO HIGUCHI MODEL RELEASE KINETICS OF SPAN-20 AT
DIFFERENT RATIO
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COMPARISION OF INVITRO KORSMEYER&PEPPAS MODEL RELEASE KINETICS OF
SPAN-20 AT DIFFERENT RATIO
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COMPARISION OF INVITRO HIXSON-CROWELLMODEL RELEASE KINETICS OF SPAN-20
AT DIFFERENT RATIO
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Figure 19a   invitro Release Kinetics of Niosomal Formulation Containing Span20 in 
Different Ratio 
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COMPARISION OF INVITRO ZERO ORDER RELEASE KINETICS OF SPAN-40 AT DIFFERENT
RATIO
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COMPARISION OF INVITRO FIRST ORDER RELEASE KINETICS OF SPAN-40 AT DIFFERENT
RATIO
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COMPARISION OF INVITRO HIGUCHI MODEL RELEASE KINETICS OF SPAN-40 AT
DIFFERENT RATIO
SQUARE ROOT OF TIME
C
U
M
U
L
A
T
IV
E
 %
D
R
U
G
 R
E
L
E
A
S
E
0 1 2 3 4
0
20
40
60
80
100
F5(3:1)
F6(4:1)
F7(5:1)
F8(6:1)
 
COMPARISION OF INVITRO KORSMEYER&PEPPAS MODEL RELEASE KINETICS OF
SPAN-40 AT DIFFERENT RATIO
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COMPARISION OF INVITRO HIXSON-CROWELL MODEL RELEASE KINETICS OF SPAN-40
AT DIFFERENT RATIO
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Figure 19b  invitro Release Kinetics of Niosomal Formulation Containing Span40 in 
Different Ratio 
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COMPARISION OF INVITRO ZERO ORDER RELEASE KINETICS OF SPAN-60 AT DIFFERENT RATIO
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COMPARISION OF INVITRO FIRST ORDER RELEASE KINETICS OF SPAN-60 AT DIFFERENT
RATIO
TIME IN HOURS
L
O
G
 C
U
M
U
L
A
T
IV
E
 %
 D
R
U
G
 R
E
M
A
IN
IN
G
0 1 2 3 4 5 6 7 8 9 10 11 12
1.2
1.4
1.6
1.8
2.0
2.2
F9(3:1)
F10(4:1)
F11(5:1)
F12(6:1)
196 
 
COMPARISION OF INVITRO HIGUCHI MODEL RELEASE KINETICS OF SPAN-60 AT
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COMPARISION OF INVITRO KORSMEYER&PEPPAS MODEL RELEASE KINETICS OF
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COMPARISION OF INVITRO HIXSON-CROWELL MODEL RELEASE KINETICS OF SPAN-60
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Figure 19c  invitro Release Kinetics of Niosomal Formulation Containing Span60 in 
Different Ratio 
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Figure 19d  invitro Release Kinetics of Niosomal Formulation Containing Span80 in 
Different Ratio 
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Figure 19e   invitro Release Kinetics of Niosomal Formulation Containing Tween60 in 
Different Ratio 
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COMPARISION OF INVITRO HIXSON-CROWELL MODEL RELEASE KINETICS OF
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Figure 19f  invitro Release Kinetics of Niosomal Formulation Containing Tween80 in 
Different Ratio 
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Figure 19g    invitro Release Kinetics of Niosomal Formulation Containing Brij-52 in 
Different Ratio 
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20(a) FG12 (SPAN60 6:1)  
 
 
20(b) FG21 (TWEEN80 3:1)
 
Figure 20  Particle Size Determination of Niosomal Gel Formulation Containing (A) 
Fg12 (Span60 6:1) (B) Fg21 (Tween80 3:1)  
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21a (a) FG12-(Span 60 6:1) 
 
 
21a (b) FG12-(Span 60 6:1) 
 
Figure 21 a  Transmission Electron Microscopy  Images of Niosomal Gel Containing (A)               
Fg12-(Span 60 6:1), (B) Fg12-(Span 60 6:1) 
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21b (a) FG21 (TWEEN 80 3:1)  
 
21b (b) FG21 (TWEEN 80 3:1)  
 
Figure 21 b  Transmission Electron Microscopy   Images Of Niosomal Gel Containing (A) 
Fg21 (Tween 80 3:1) 21b (B) Fg21 (Tween 80 3:1)  
 
213 
 
0 1 2 3 4 5 6 7 8 9 10 11 12
0
10
20
30
40
50
60
70
80
90
100
F12(6:1) F21(3:1) PLAIN GEL
TIME IN HOURS
C
U
M
U
L
A
T
I
V
E
 
%
D
R
U
G
 
R
E
L
E
A
S
E
 
Figure 22 Comparison of Invitro Release of Plain Gel, Niosomel Gel with Highest and Lowest Entrapment Efficiency 
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Figure 23   invitro Release Kinetics of Niosomal Gel Containing F12 (6:1), F214:1) in 
Different Ratio 
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Figure 24  Comparison of Percentage Inhibition of Rat Hind Paw Edema Method using Plain Etoricoxib Gel and Niosomal Gel 
Containing FG12 and FG21
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CHAPTER-XIII 
 SUMMARY AND CONCLUSION 
• The niosomal formulations were successfully prepared by thin film hydration technique 
using cholesterol and Span20, 40, 60, 80 Tween 60, 80 and Brij-52 as non-ionic 
surfactant. The presence of cholesterol made the niosomes more stable with high 
entrapment efficiency and retention properties. The highest entrapment efficiency was 
observed with span60 and it may be concluded that the entrapment efficiency may be 
improved using surfactant with decrease HLB value and highest phase transition 
temperature.  
• FT-IR and DSC investigations confirmed that there was no interaction of cholesterol 
and surfactant towards the drug. 
• Brook field viscometer confirmed the Pseudoplastic behaviour of prepared niosomal 
gel. 
• TEM image showed spherical vesicles 
• Malvern zeta sizer used to confirmed the vesicle size of niosomal dispersion 
• Release kinetics showed sustained release and anomalous diffusion indicated that 
niosomes of etoricoxib can deliver significant levels of drug.   
• The invitro release and invivo anti-inflammatory studies of niosomal gel as compared to 
plain gel indicated that the prolonged drug release behavior with sustained therapeutic 
action. 
• The result indicates that the niosomal gel can be used as novel drug delivery carrier for 
skin targeting of etoricoxib for its anti-inflammatory action. 
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